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Introduction: The existence of a bi-directional relationship between tuberculosis (TB) and insulin 
resistance (IR)/diabetes has been alluded to in literature. Although diabetes has been linked to 
increased TB risk, the relationship between TB as a causative factor for IR remains unclear. The 
study aimed to determine if an association existed between TB and IR development in adults with 
newly diagnosed pulmonary tuberculosis (PTB) at baseline. It was additionally aimed to document 
changes in IR status during follow-up.   
 
Methods: This observational, cross-sectional study evaluated ambulatory participants at baseline 
for IR prevalence via anthropometrical and biochemical measures, together with diagnostic IR tests 
[homeostasis model assessment–IR (HOMA-IR) and quantitative insulin sensitivity check index 
(QUICKI)]. In addition, a prospective cohort sub-section study was performed on approximately half 
of the baseline study population (n=29), who were followed-up at two and five months whilst on TB 
treatment. Summary statistics, correlation co-efficients and appropriate analysis of variance were 
used to describe and analyse data. Participants were excluded if they presented with other forms of 
TB, were HIV-positive, obese or had any pre-disposing IR conditions such as diabetes or metabolic 
syndrome.    
 
Results: A total of 59 participants were included from August 2013 until December 2014. The 
majority of participants were male (81.4%) and the mean age was 33.95 ±12.02 years. The 
prevalence of IR was 25.4% at baseline, determined by using a calculated HOMA-IR cut-off point of 
2.477. Patients with IR were shown to be younger (p=0.04) and had a higher fasting insulin level 
(p<0.01). Although the difference between IR levels in participants between baseline and follow-up 
was not significant, a decrease was experienced over time.  
 
Most participants (61.0%) presented with a normal BMI at baseline and the majority of 
anthropometrical measurements showed a significant increase over the follow-up period, mainly in 
the first two months of treatment.  
 
The majority of participants (84.7%) had an increased mean CRP (60.18 ±50.92 mg/L) and 
decreased mean HDL-cholesterol level [69.5% (males: 0.94 ±0.88 mmol/L; females: 1.14 ±0.88 
mmol/L)] at baseline. Mean baseline values of fasting glucose and albumin were within normal 
ranges (4.82 ±0.80 mmol/L and 39.32 ±4.35 g/L respectively). According to fasting glucose levels at 
baseline, 1.7% and 3.4% of participants presented with impaired fasting glucose and diabetes  
 
 






mellitus respectively. Several biochemical markers (CRP, albumin and white cell count) showed an 
improvement during the follow-up period.  
 
Conclusion: The study found an association between TB and IR development in newly diagnosed 
PTB patients. Many anthropometrical and biochemical measures showed improvements with time, 
especially during the intensive phase of treatment. Although not significant, IR levels decreased over 
time, which could be indicative of a clinical improvement. IR participants were shown to be younger 
and had a higher fasting insulin measurement. A high prevalence of IR among TB patients therefore 
highlights the need for early identification in order to facilitate a reversal of IR and prevent possible 



































ABSTRAK / OPSOMMING 
 
Inleiding: Die tweerigtingverhouding tussen tuberkulose (TB) en insulienweerstandigheid 
(IW)/diabetes is al in literatuur beskryf. Diabetes hou wel verband met ’n verhoogde risiko vir TB, 
maar die rol van TB as oorsakende faktor vir IW bly onduidelik. Die doel van hierdie studie was om 
te bepaal of daar wel ’n verband bestaan tussen TB en die ontwikkeling van IW onder volwassenes 
met nuut gediagnoseerde pulmonale tuberkulose (PTB). ’n Addisionele doel was om enige 
veranderinge in die IW status, tydens opvolg ondersoeke, te dokumenteer.  
 
Metodes: Die waarneming, deursnee-studie het ambulante deelnemers tydens die basislyn periode 
geëvalueer vir IW d.m.v antropometriese en biochemiese bepalings, asook diagnostiese IW toetse 
[“homeostasis model assessment–insulin resistance” (HOMA-IR) en die “quantitative insulin 
sensitivity check index” (QUICKI)]. ‘n Prospektiewe kohort sub-gedeelte studie is ook uitgevoer op 
ongeveer die helfte van die basislyn studiepopulasie (n=29), wat op twee en vyf maande opgevolg 
was tydens TB behandeling. Beskrywende statistiek, korrelasie koeffisiënte en toepaslike analises 
van variansie is gebruik om data te beskryf en analiseer.Deelnemers is uitgesluit indien hulle met 
enige ander vorm van TB gediagnoseer is, MIV-positief of vetsugtig was of presenteer het met enige 
predisponerende IW toestande, soos diabetes of metaboliese sindroom.  
 
Resultate: Nege en vyftig deelnemers is ingesluit tussen Augustus 2013 en Desember 2014. Die 
meerderheid was manlik (81.4%) met ’n gemiddelde ouderdom van 33.95 ±12.02 jaar. Die basislyn 
prevalense van IW was 25.4%, bepaal deur ’n berekende HOMA-IR afsnypunt van 2.477. IW 
pasiënte was jonger (p=0.04) en besit ’n hoër vastende insulienvlak (p<0.01). Alhoewel daar geen 
beduidende verskil in die IW vlakke tussen basislyn en opvolg periodes was nie, was daar wel ’n 
afname waargeneem oor tyd.  
 
Die meeste deelnemers (61.0%) het ’n normale LMI by basislyn gehad. Die meerderheid 
antropometriese metings het ’n beduidende toename getoon tydens die opvolg periode, hoofsaaklik 
in die eerste twee maande van behandeling.  
 
Die meerderheid deelnemers (84.7%) het ’n verhoogde gemiddelde CRP (60.18 ±50.92 mg/L) en ’n 
verlaagde gemiddelde HDL-cholesterolvlak [69.5% (mans: 0.94 ±0.88 mmol/L; vrouens: 1.14 ±0.88 
mmol/L)] by basislyn getoon. Die gemiddelde basislyn waardes van vastende glukose en albumien 
was binne normale perke (4.82 ±0.80 mmol/L en 39.32 ±4.35 g/L onderskeidelik). Volgens die 
basislyn vastende glukosevlakke, is 1.7% met ingekorte vastende glukose en 3.4% met diabetes  
 
 






mellitus geklassifiseer. Verskeie biochemiese aanduiders (CRP, albumien en witsel-telling) het ’n 
verbetering tydens die opvolg periode getoon.  
 
Gevolgtrekking: Hierdie studie het ‘n assosiasie tussen TB en IW-ontwikkeling, in nuut 
gediagnosserde PTB pasiënte, getoon. Verskeie antropometriese en biochemiese metings het 
verbeter met tyd, veral tydens die intensiewe fase van behandeling. Alhoewel nie beduidend, het IW 
vlakke met tyd afgeneem, wat moontlik ’n kliniese verbetering aandui. Deelnemers met IW was 
jonger en het hoër vastende insulien vlakke getoon. Hoë voorkoms van IW onder TB pasiënte 
beklemton die behoefte vir vroeë identifisering, om sodoende, ’n omkering in IW te fasiliteer en IW-
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DEFINITION OF TERMS 
Acute phase response  A number of changes (including behavioural, physiological, 
biochemical and nutritional) occurring during the first days 
following an insult to the body.1  
Anthropometry  The science of measuring the size, weight and proportions of the 
human body.2 
Biochemistry  Tests available for assessing the nutritional status of an 
individual. These tests can be either static or functional.2 Static 
tests (undertaken in this study) relate to the measurement of a 
specific nutrient (or its metabolite) in blood, urine or bodily 
tissues.2  
Diabetes mellitus  A metabolic disorder with varying aetiologies, which is recognised 
for its long-term hyperglycaemia and alterations in macronutrient 
(carbohydrate, fat and protein) metabolism, which are mainly 
resultant from defective insulin secretion, action or a combination 
of the two.3   
Extra-pulmonary 
tuberculosis 
Forms of tuberculosis occurring when mycobacteria migrate from 
the lungs to other organs and joints or central nervous system 
and cause disease. Usually these bacilli will be controlled by the 
body’s immune system and disease will not arise.4,5 
Fasting insulin resistance 
tests 
Tests that are based on fasting blood values.  
Group 1 Participants in the total study population that were seen only at 
baseline  
Group 2 Participants in the total study population that were seen for a total 
of three visits (namely baseline, 2 and five months) 
 



























HOMA-IR A fasting index used in the determination of basal insulin 
resistance,6 using only the fasting insulin and glucose values.7  
Insulin resistance A state in the body whereby cells become increasingly resistant to 
insulin, in which increased insulin levels are necessary to elicit a 
normal physiological response.8-12 
Intensive phase The initial two months after treatment commencement, when a 
more aggressive regimen of TB drugs is prescribed, namely 
isoniazid, rifampicin, ethambutol and pyrazinamide.5 
Invasive insulin resistance 
tests 
Tests that require intravenous insulin/glucose infusions.13 
Metabolic syndrome  A condition encompassing the following occurrences: abdominal 
obesity, atherogenic dyslipidaemia, elevated blood pressure, 
insulin resistance, and/or a pro-inflammatory/thrombotic state.14-17  
Non-invasive insulin 
resistance tests 
Measurements that do not require the administration of either 
exogenous insulin or glucose via the intravenous route.13 
Primary infection Time of first exposure to bacilli in a previously unexposed 
individual.5 
Pulmonary tuberculosis Mycobacterium tuberculosis infection occurring in the lungs, which 
is also the most infectious and widely recognised form.8 
Tuberculosis (general term) is regarded as a significant airborne-
transmitted bacterial infection, resulting from infection with M 
tuberculosis bacilli.18,19 
QUICKI  Another example of a fasting index for IR. Inverse logarithm of the 
HOMA-IR, also utilizing fasting insulin and glucose 
measurements.20  
Secondary infection Period of disease occurring after the primary infection.21 
 











































1.1    INTRODUCTION  
 
The aim of this study is to generate new information regarding tuberculosis (TB) and the possible 
development of insulin resistance (IR) in a typical South African setting, which is a subject that has 
not received much attention thus far. This literature review describes the current TB epidemic, on 
both a global and national scale, and attempts to explore the important facets of TB transmission, 
infection, clinical presentation and diagnosis, among others. An important component of the literature 
review is also dedicated to the impact of TB on nutritional status, where aspects such as malnutrition 
among TB patients, changes in anthropometrics and micronutrient status, as well as various 
biochemical changes occurring during the course of the disease, are analysed.  
 
The concept of IR is examined, and this includes the aetiology, prevalence rate, as well as a 
discussion on the metabolic syndrome that often follows an insulin resistant diagnosis. A crucial 
section on the current methods available for measuring IR is also included, detailing known strengths 
and limitations of each method. The review concludes with an up-to-date presentation of current 
evidence regarding the bi-directional relationship between IR and/or diabetes mellitus (DM) and TB 
and provides information on the possible mechanisms of action.  
 
Since the subject matter on hand encompasses such a broad spectrum, it must be noted that the 
literature review is selective in terms of discussion points, because many of the aspects, although of 
interest, are beyond the scope of this particular review.  
 
 
1.2       TUBERCULOSIS 
 
1.2.1     Background – A Problem on a Global and National Scale   
 
1.2.1.1  Global overview  
 
Tuberculosis is commonly regarded as an extremely significant bacterial infection, affecting a large 
proportion of the global population.19 It is reported to be the second leading cause of mortality due 
to infectious disease worldwide, following the Human Immunodeficiency Virus (HIV) / Acquired 
Immune Deficiency Syndrome (AIDS).18,22 This led the World Health Organization (WHO) to declare 
TB a global public health emergency in 1993. Statistics released by the WHO in 2014, show that 
there were an estimated nine million cases of TB diagnosed globally in 2013.18  
 






Demographic data shows that men are more likely to be infected with TB than women.18,23 Global 
reports indicate approximately 60% of infections and deaths are found among male patients. 
Furthermore, two-thirds of infections are found to occur in the 15 to 59-year-old age group,18 although 
the young adult group seems to be the most affected.23 It is thus evident that the nature of the disease 
is such that it strikes at the heart of the economic work force, most often in developing, third-world 
countries, of which South Africa (SA) is one.  
 
Of the 9 million individuals who developed TB in the past year, approximately 1.1 million were found 
to be HIV-positive.18 If one considers statistics from South Africa regarding the HIV-positive rate 
among TB patients, it ranks significantly higher than the global percentage.24 This is in line with the 
findings that show South Africa to have a very high disease burden of both HIV and TB.  
 
When comparing statistics of incident TB cases, between the six WHO global regions (African 
Region, Region of the America’s, Eastern Mediterranean Region, European Region, South-East 
Asia Region and Western Pacific Region), the majority (56%) were found in the South-East Asia and 
the Western Pacific regions. The African Region was responsible for 25% of cases, and was also 
found to have the highest rate of cases and mortality in relation to population size.18,23 It has also 
been shown that the African Region is responsible for approximately 80% of HIV-positive TB cases 
among HIV-infected individuals.18 If one considers the rates of infection in the African Region, there 
is an improvement, but this is unfortunately still slower than what is required for successful TB 
control. 
 
Global mortality rates as a result of TB disease indicate that approximately 1.5 million people died 
from the condition in 2013.18 Of these 1.5 million deaths, 360 000 were found to be living with HIV 
(24%), which is line with TB being a common opportunistic infection associated with HIV/AIDS. 
Tuberculosis has been recognised as the principal cause of HIV-related mortality despite being a 
treatable condition.25 Another disillusioning statistic shows that approximately 78% of the total TB 
deaths occurred in the African and South-East Asian regions, again showing the vulnerability of the 
African Region.18   
 
Despite these dire statistics, it was found that global TB rates are on the decline (the prevalence rate 
has decreased globally by 41% since 1990),18 which is partly due to the efficacious diagnosis and 
treatment of infectious individuals. This may not seem accurate if one considers the higher number 
of recorded incident cases and mortalities compared with previous years, but this is in fact 
attributable to improved recording and reporting methods and not to a greater number of TB cases. 
Furthermore, promising global treatment success rates in 2013 showed as many as 86% of cases 
being effectively treated.18 Another promising factor is that, despite Africa’s high percentage of HIV-






infected individuals, 76% of these persons had been tested for HIV and were aware of their status 
in 2013.18 
 
Tuberculosis and its subsequent eradication remains one of the key priorities for global health 
organisations. The Global Plan to Stop TB 2006–2015 was initiated in 2005 by the Stop TB 
Partnership, an organisational network that hopes to both curb the spread of and eliminate TB as a 
public health problem.22,26 This target and concomitant timeline tie in closely with the Millennium 
Development Goals (MDGs), specifically MDG 6, “Combat HIV/AIDS, malaria and other diseases” 
by the year 2015,27,28 which also aims to reduce global TB incidence rates.18  Since this target date 
has already transpired, a new set of attainable targets has been devised and is being considered for 
approval. The new goals, aptly named the Sustainable Development Goals (SDGs),29,30 are a list of 
17 objectives with a target deadline of 2030. These goals have not formally been accepted as a 
framework but are expected to be finalised towards the end of 2015. One of these new goals relates 
specifically to the issue of TB, namely, “to ensure healthy lives and promote well-being for all at all 
ages.” 29 This is similar to the previous MDG; the new goals include a target to “end the epidemics 
of AIDS, TB, malaria and neglected tropical diseases and combat hepatitis, waterborne diseases 
and other communicable diseases”.18 
 
1.2.1.2   National overview 
 
2013 statistics show that South Africa is considered by the WHO to be one of twenty-two “high 
burden countries” (HBC’s).18,31,32 These HBC’s are duly named because they house approximately 
80% of the world’s TB cases. Other African HBC’s include the Democratic Republic of the Congo, 
Ethiopia, Kenya, Mozambique, Nigeria, Uganda, the United Republic of Tanzania and Zimbabwe. It 
was largely due to this non-prestigious classification that the South African Department of Health 
(DoH) declared TB to be at an official crisis-level, and this resulted in the compilation of a TB national 
crisis management plan, which was released in 2006.33 
 
Assessment of South Africa’s progress in relation to achieving the targets set out by the MDGs 
indicate that whilst SA has achieved a declining TB incidence rate, other markers have not been so 
readily achieved. These include halving the TB mortality rate, halving the 1990 TB prevalence level 
and meeting the 2015 targets for lowering TB cases and mortality rates. South Africa is by far not 











1.2.1.3   Provincial overview 
 
According to 2013 statistics specific to the Western Cape, there were 183 628 suspected TB cases 
identified in 2013 for the entire province. Of these, 183 512 persons were tested (99.93%), which is 
a promising screening rate. A total of 19 893 individuals were identified as being sputum smear-
positive with TB (10.8%). The total number of outpatients in attendance for more than five years at 
various facilities around the province amounted to 12 157 911 individuals.34 
 
Data extrapolated from the Cape Metropole of the Western Cape show the following statistics for the 
Western Sub-District of the region. Data gathered in the first three-quarters of 2014 show an average 
of 624 TB suspects per month (a suspect is an individual who is suspected of having active TB 
disease on the grounds of physical signs or symptoms that are synonymous with TB, such as a 
persistent cough).4,35 Of these suspects, 52.9% were male and 47.1% were female. Of the number 
of individuals actively diagnosed with TB disease, approximately 216 new cases per month in the 
Western Sub-District were identified, with pulmonary tuberculosis (PTB) accounting for 88.1% of 
cases. Of these newly identified TB cases, 51.0% (n=991) were shown to be HIV-negative, whilst 
HIV-positive and those with unknown status accounted for the remainder of the population.36 
 
Upon examining data generated from the Albow Gardens clinic (the recruitment site for this study), 
the following data for the first three-quarters of 2014 was noted. Newly diagnosed and registered TB 
patients accounted for an average of 28 new patients per month, of which the majority (79.7%) were 
diagnosed with PTB. The majority (52.5%) of cases treated by the clinic were also HIV-positive. Of 
the newly registered patients, 80.1% were cases of first-time TB and 19.9% were re-treatments.36 
 
It is, therefore, evident that the population of the Western Cape is extremely susceptible to the effects 
of TB, and the area is thus one of priority.   
 
1.2.2     Transmission of TB  
 
Tuberculosis results from infection with the bacillus M tuberculosis, of which the primary target site 
of the bacteria is the lungs.18 This is typically referred to as PTB, but the infection can also occur in 
other areas of the body such as the abdominal cavity and brain.8 The spread of the disease is classed 
as airborne and is distributed when infectious persons release infectious droplets containing a small 
amount of M tuberculosis bacilli into the air, via coughing, spitting, sneezing, singing or talking.18,37 
The transmission of TB is dependent upon three factors, namely the number of organisms released 
into the air, the concentration of said organisms and the length of time an exposed person is in 






contact with the contaminated air.5 These bacteria fare better in dark areas because exposure to 
direct sunlight results in quick death of the bacilli.  
 
The majority of people who are infected with the TB bacilli remain asymptomatic, and the estimation 
by the WHO is that although approximately one-third of the population are latent carriers, only 10% 
will progress to clinical TB, with 50% of these individuals developing active disease at the time of 
infection and 50% at a later stage.5,18,19,37 This estimation is, however, based on healthy individuals, 
whereas there is an increased risk of developing active TB if an individual becomes immuno-
compromised.22 In addition, other vulnerable groups for infection include children, HIV-infected 
individuals and the elderly.5 Immune-compromised conditions such as diabetes mellitus, silicosis 
and prolonged use of corticosteroid agents and other immune-suppressants have also been linked 
to faster progression to active TB.5 
 
Part of the problem experienced through the global TB epidemic is the slow progression of the 
disease, which allows persons to present asymptomatically and not seek treatment. This delay in 
commencing suitable medication places others in the population at risk because an untreated person 
with active TB disease can infect as many as 15 unsuspecting persons.38  
 
A systematic review conducted in 2014 concluded that aspects placing an individual at risk of TB 
included low-income households, poor educational opportunities, sub-optimal living conditions 
(overcrowding), substance abuse (alcohol, drugs and smoking), pre-existing conditions such as 
malnutrition and diabetes, indigenous communities and migration, lack of accessibility to appropriate 
health care and inadequate knowledge regarding TB. The majority of these are rife in a developing 
country such as South Africa.39 In addition, HIV infection and indoor air pollution were also identified 
to be prominent risk factors in the spread of the disease.38 
 
1.2.3     Primary and Secondary Infection  
 
1.2.3.1  Primary infection 
 
The infection occurs at the time of first exposure to TB bacilli of a previously unexposed individual.5 
The infectious droplets are inhaled into an alveolus and the bacilli are phagocytosed by alveolar 
macrophages. 21,40 Bacterial multiplication and growth within the macrophage then occurs, and this 
consequently generates an inflammatory response in the carrier. This stage of infection is not usually 
accompanied by any symptoms and is thus difficult to diagnose, apart from a positive tuberculin skin 
test 4 - 6 weeks after the infection occurred.5,21 The risk of developing active disease is highest 
during the first two years after primary infection.21 






1.2.3.2   Secondary (or post-primary) infection  
 
This refers to the period of the disease occurring after the primary infection, i.e. in a previously 
infected human host and is often known as ‘reactivation’.21 There is no pre-determined time period 
for the development of active disease because progression can be attributed either to re-infection 
with M tuberculosis or to reactivation of previously dormant bacteria.5 This post infection commonly 
affects the lungs, but the infection can spread to other parts of the body and may cause disease. 
This occurs most commonly after a primary infection, but may also be seen in HIV-infected 
individuals.  
 
1.2.4   Different Types of TB  
 
Pulmonary tuberculosis is the most common and widely recognised form of TB disease. It is also the 
most infectious and represents the majority (80%) of cases among TB-infected persons.5 However, 
HIV-infected individuals can often exhibit extra-pulmonary forms of the disease.21 Other forms of TB 
commonly occur when mycobacteria migrate from the lungs to other organs, and this is commonly 
referred to as extra-pulmonary tuberculosis (EPTB). Extra-pulmonary tuberculosis occurs in many 
forms, of which the most common types include TB lymphadenitis, TB of the bones and joints, TB of 
the spine or central nervous system, TB meningitis, disseminated/miliary TB effusion (pleural, 
pericardial and peritoneal) and tuberculous empyema.4,5 The miliary form of the disease often 
presents concomitantly with severe symptoms such as septic shock and acute respiratory distress 
syndrome (ARDS), which can increase mortality rates.41-43 
 
1.2.5     Clinical Presentation of PTB  
 
Symptoms associated with PTB are very often wide-ranging and are not always indicative of TB 
since they could be caused by other co-morbidities or infections. Symptoms include: 
 Chronic, persistent cough for two weeks or more  
o HIV-positive patients presenting with a cough (even if less than two weeks) should be identified 
o Occasionally blood-stained sputum  
 Fever of more than two weeks duration  
 Drenching night sweats  
 Unintentional/unexplained weight loss  
o Usually more than 1.5 kg in a month 
 Chest pains / breathlessness / localised wheeze  
 Fatigue  
 Anorexia5,21,44,45 






A patient with TB is therefore classified as bacteriologically confirmed TB or as having commenced 
TB treatment by a health care worker based on the patient’s clinical presentation, X-ray findings or 
other diagnostic tests.5 
 
1.2.6     Diagnosis of TB – Different Methods/Tools  
 
1.2.6.1  General  
 
As mentioned previously, a worldwide decline in incident TB rates has largely been due to effective 
diagnosis and treatment of the disease and improved socio-economic conditions. However, 
diagnosis still poses problems that need to be carefully managed by health workers in contact with 
suspected individuals. Furthermore, effective diagnosis and management is directly related to 
persons with TB-like symptoms going for check-ups at their closest health facility, the screening for 
TB in health care facilities and the wider community, the reliability and validity of diagnostic tests, 
the turnaround time for laboratory testing, as well as the notification of individuals of their positive 
status and the commencement of suitable treatment without delay.5 Table 1.1 highlights the current 
diagnostic tests available in South Africa.  
 
Table 1.1: Diagnostic tests available for TB in South Africa5 
 





 High specificity  
 Short TAT 
 Low sensitivity in people 
with low bacillary load (i.e. 





 High sensitivity   Long TAT 








Line Probe Assay  Short TAT 
 Detects RIF and INH 
resistance 
 High sensitivity for MDR-
TB 
 Reduced sensitivity in 
smear negative   
Gene Xpert or 
MTB/RIF 
 Short TAT 
 Detects RIF resistance 
 High sensitivity for RIF 
resistance  
 Does not detect INH 
resistance 
 Reduced sensitivity in 
smear negative  
 
LED = light-emitting diode; TAT = turnaround time; PLWHA = people living with HIV/AIDS; PCR = polymerase chain 











1.2.6.2   Microscopy  
 
Sputum-smear microscopy was developed more than a century ago and currently remains the most 
common method of diagnosing TB worldwide.18 This method entails the microscopic observation of 
bacteria in sputum samples provided by the suspected TB-infected individual. The bacteria, 
otherwise referred to as acid fast bacilli (AFB), are identified by one of two staining methods, namely 
the Ziel-Neelsen (ZN) or fluorescent auramine staining. Approximately 80% of the results should be 
available from the laboratory within 48 hours, hence the short turnaround time (TAT).5 However, due 
to smear microscopy often failing to detect active TB in individuals with either non-cavitary pulmonary 
disease or a low sputum-bacillary load (often immune-compromised patients), it is anticipated that 
molecular testing will soon replace microscopy as the first choice in TB diagnostics.5 Table 1.2 
describes the interpretation of various smear microscopy results.  
 
Table 1.2: Interpretation of smear microscopy results4,5 
 
ZN Staining Auramine Staining 
Number of bacilli seen on 
smear 




No AFB per 100 oil immersion 
field 
0 No AFB on slide 0 
1 - 9 AFB per 100 oil immersion 
field 
Scanty <1 AFB per field + 
10 - 99 AFB per 100 oil 
immersion field 
+ 1 - 9 AFB per field ++ 
1 - 10 AFB per 1 oil immersion 
field (min 50 fields) 
++ 10 - 99 AFB per field +++ 
>10 AFB per 1 oil immersion 
field (min 20 fields) 
+++ >100 AFB per field ++++ 
 
ZN = Ziel-Neelsen; AFB = acid fast bacilli  
 
An individual with a +++ ZN stain result will, therefore, be classified as more infectious than an 
individual with a + result. Sputum smear-negative individuals will, therefore, be less infectious than 
individuals showing a positive test of any kind.  
 
The patients presenting with a smear-negative result are often difficult to classify clinically because 
there is a vast differential diagnosis. In addition, other chronic respiratory conditions may be 











1.2.6.3   Culture  
 
This method of TB diagnostics is considered to have a greater sensitivity than microscopy because 
it is able to detect a larger proportion of TB cases among symptomatic individuals.5 Despite its 
accreditation as the apparent gold standard in TB diagnostics,47 it does, however, present with a 
number of drawbacks that include high cost, slow turnaround time (TAT) and lack of accessibility to 
all. It is found to be useful in patients with paucibacillary TB (containing few bacilli), such as HIV-
positive persons and children.5 
 
1.2.6.4   Molecular testing / PCR-Based assays  
 
This includes the molecular testing of a sputum sample and there are currently two different 
techniques used in SA, namely the Gene Xpert (GXP) and the Line Probe assay. Molecular testing 
is considered to be the future of TB diagnostics and is often regarded as the first choice in identifying 
a new suspect because it is able to diagnose both TB and drug-resistant TB.5 
 
1.2.6.4 (a)   Gene Xpert (GXP) 
 
This test is commonly referred to as the Xpert MTB/RIF (M Tuberculosis/Rifampicin) and allows for 
the rapid identification of M tuberculosis in a sputum sample. This test has also recently been 
recommended by the WHO for its rapid results.18 In addition, it identifies rifampicin susceptibility and 
resistance, which allows health care professionals to treat both uncomplicated and drug-resistant 
cases of TB aptly. The test is also specific for MTB and is, therefore, able to distinguish M 
tuberculosis from other mycobacteria.5 Unfortunately, Xpert is unable to distinguish between live and 
dead bacteria and is thus limited to diagnostic status at present. Since Xpert has a higher sensitivity 
than smear microscopy, it is possible for an individual with TB to present with an Xpert positive test 
but produce smear-negative sputum.  
 
Gene Xpert was rolled-out in South Africa in 2011, largely as a replacement for sputum microscopy 
given its sensitivity.48 According to statistics released by the WHO in 2014, South Africa had 207 
reported sites performing this molecular testing as of 2013, cementing its use as a primary diagnostic 
tool in the country.5 
 
1.2.6.4 (b)   Line probe assays (LPA) 
 
This test is specific because it is used primarily on smear-positive sputum samples and isolates from 
both solid and liquid culture.5 It is similar to the Xpert since it also detects MTB and rifampicin 






resistance, but is additionally able to identify isoniazid resistance, which allows for the rapid 
diagnosis of MDR-TB. It is, however, labour intensive, costly and is dependent on smear results.5 
 
1.2.6.5   Chest x-rays (CXR) 
 
Chest X-rays are often an invaluable tool in patients who are unable to produce a satisfactory sputum 
sample, in HIV-positive individuals who tested negative via Xpert and in cases of EPTB (TB occurring 
outside of the lungs).5 X-rays have previously been viewed as responsible for either over- or under-
diagnosing TB and should, therefore, be interpreted together with a full clinical examination and 
reliable patient history.5 
 
1.2.6.6   Other diagnostic tools available for use  
 
These include, but are not limited to interferon gamma release assays (IGRA), blood culture, TB-
LAM (lateral flow version), histological examination, tuberculin skin test, ultrasound, computerized 
tomography (CT scan), magnetic resonance imaging (MRI), erythrocyte sedimentation rate (ESR) 
and the test for adenosine deaminase (ADA).5 These are, however, not as widely used. 
 
 
1.3       RELATIONSHIP BETWEEN TUBERCULOSIS AND NUTRITION     
 
1.3.1    Nutritional Response to TB  
 
Any infection targeting a ‘host’, very often the human body, will result in a fierce battle between the 
host defences and the onslaught of the attacking organisms.49,50 The severity of the metabolic 
response and concomitant tissue loss, is dependent upon the result of the conflict. The preliminary 
protection against attacking bacteria is mounted by the innate immune system, which is crucial in 
preventing infection dissemination to the remainder of the body.51 Soon thereafter, the adaptive 
immune response takes over and generates detailed pathogen responses to combat the infection.51 
 
As a result of infection with M tuberculosis,  the body attempts to ward off the threat via the activation 
of cytokines, which are protein-like structures.50 These cytokines can either be pro-inflammatory 
(TNF-α, IL-1β, IL-6, IFN-γ) or anti-inflammatory (IL-10, TGF-β, IL-4) in nature. The cytokines 
consequently activate a catabolic response in the body, often referred to as an ‘acute phase 
response (APR)’, which leads to a derangement in protein metabolism, accompanied by loss of both 
lean body mass and fat tissue. These metabolic manifestations can often be observed during other 






cases of infection, such as HIV/AIDS or cancer, in which occurrences of cachexia are frequently 
described. 
 
In a recent study conducted in South Africa, a group of newly diagnosed PTB patients was compared 
with a control group of patients presenting with various surgical/medical complications (similar stress 
response; although unrelated to TB).52 It was noted that even though the control group was not 
‘healthy’ in the conventional sense, the TB group still presented with higher levels of platelets, C-
reactive protein (CRP), ferritin, cortisol and vital signs, indicating the propensity for a heightened 
APR in TB patients.52 
 
1.3.2     Malnutrition and TB 
 
Malnutrition is indicative of both over- and undernutrition, although the latter appears to be more 
synonymous with TB.50,53 The complex relationship between the two conditions can be likened to a 
‘vicious cycle’ because undernutrition can be hypothesised to be both a risk factor for TB disease, 
as well as a common consequence thereof.54 Numerous studies have investigated the phenomenon 
of wasting associated with TB and its effects on body composition.55,56 Tuberculosis was initially 
referred to as ‘phthisis’ (wasting away) by the Greeks and later termed ‘consumption’ in the 18th and 
19th centuries by those attempting to illustrate the clinical changes in an infected individual.50  Figure 
1.1 highlights some of the main factors involved in the so-called ‘vicious cycle’ between TB and 
malnutrition.  
 
Tuberculosis-induced wasting seems to be mainly due to loss of both fat mass and lean body mass.57 
Prior to the implementation of anti-tuberculosis chemotherapy, diet and enhanced environmental 
conditions were used as both defence and treatment against tuberculosis, thus highlighting the 
recognised importance thereof.45,58 
 
Malnutrition can have a significant impact on the cell-mediated immunity (CMI) of the body, which is 
ultimately responsible for protection against TB.53 Malnutrition, specifically protein energy 
malnutrition (PEM), has been highlighted as playing a contributory role in the progression of TB in 
terms of affecting the severity of the disease, reducing immune function, decreasing anti-tuberculosis 
medication efficacy, thus heightening mortality risk.59 In an individual who has already been infected 
with TB but has not progressed from the latent stage, undernutrition may be the catalyst in the 
development of active TB.60 
 
Some studies have shown an increased risk for developing active TB in underweight persons.61,62 
Recruits of the United States Navy showed a four-fold higher risk in those who were ≥ 10% 






underweight at baseline, compared with their overweight counterparts.61 Similarly, a large cohort 
study conducted with Norwegian participants older than 15 years showed a five-fold higher risk of 
developing TB among the lowest body mass index (BMI) group when compared with the individuals 
in the highest BMI group.62 
 
1.3.2.1    Changes in anthropometrics / body composition  
 
Some studies have shown that the presence of a low BMI and/or inadequate weight gain whilst on 
TB treatment increases the mortality risk in individuals,60 and has an impact on treatment success 
rates.63 A low BMI can also result in a heightened risk of developing various micronutrient 
deficiencies.64 This TB-spurred weight loss can often be attributed to the following factors: reduced 
dietary intake due to periods of anorexia; increased energy expenditure;50 nutrient losses from 
gastro-intestinal complications; medication side-effects; and metabolic modifications caused by the 
infection itself, as reflected in Figure 1.1.60 
 
One of the proposed mechanisms for the metabolic changes seen during wasting in TB and other 
inflammation-driven states is known as the ‘anabolic block’.50,55 This describes the phenomenon 
often seen in tuberculosis patients, compared with healthy controls and non-infected malnourished 
persons, in which a greater proportion of protein (derived from oral intake) is used for oxidation and 
subsequently, the provision of energy compared with the more desirable endogenous synthesis of 
the important macronutrient.  
 
Other studies have shown the high prevalence of impaired nutritional status of TB patients compared 
with healthy controls at baseline, often ranging from 20% to 71.6%.59 Karyadi et al. showed that in 
66% of patients presenting with PEM, the mean BMI of TB patients was 20% less than in healthy 
controls.65 African data assessing the prevalence of a decreased BMI at baseline showed 71.6% of 
participants in Tanzania had a BMI <18.5 kg/m2,66 whilst a Ghanaian study demonstrated 51% of the 
participants to be below the same BMI cut-off point.67 In addition, a Malawian study showed 57% of 
patients to be malnourished on admission.68 It was, however, mentioned that the high rates of 
baseline malnutrition could be attributed to other confounding factors, and not necessarily solely to 
the TB disease.67,69  These contributing factors could link strongly to the socio-economic climate of 
the population since developing African countries are often known to be strongly affected by issues 
such as extreme poverty and food insecurity with a spin-off effect of reduced health-seeking 
behaviours.67,69  






                    
Figure 1.1: Flow diagram depicting ‘vicious cycle’ between malnutrition and tuberculosis 
(Adapted from Kant et al.; Gupta et al.; Cegielski et al.)45,53,70 






Epidemiological findings also seem to indicate that the presence of wasting or a reduced BMI on 
admission could result in increased mortality, as was shown in the previously mentioned Malawian 
study conducted by Zachariah et al., in which a BMI of less than 17.0 (moderate to severe thinness) 
was linked to a two-fold increased risk of early mortality.68 Similarly, patients who had a decreased 
BMI at diagnosis, as well as those failing to gain more than 5% weight between time of diagnosis 
and end of treatment, were both significantly related to relapse risk.61 Unfortunately, many patients 
who present with a decreased BMI upon admission often remain in this category even after 
completion of successful treatment.66,71  
 
Findings have shown that individuals with TB disease often have lower levels of body weight, mid-
upper arm circumference (MUAC), skinfold thickness, fat mass, lean body mass (LBM),65 bone 
mineral mass,55 arm muscle area (AMA), arm fat area (AFA)56 and BMI,56,72 when compared with 
healthy controls.73 A study conducted by Villamor et al. in 2006 investigated the link between disease 
severity and anthropometry and found a noticeably worse prognosis for both daily activity scores 
and degree of disease in patients with an impaired nutritional status (low BMI, triceps skinfold and 
MUAC).69  
 
In a study conducted by Paton et al., it was found that although wasting is considered synonymous 
with an overall loss of both LBM and fat mass, it appeared that the limbs (or periphery) suffered more 
LBM loss, whilst the trunk or central area showed more of a fat mass depletion.55 Since the authors 
in this particular study investigated body composition in TB patients co-infected with HIV, they also 
proposed that TB, not HIV, seemed to be the main driving force behind the wasting phenomenon 
because the virus did not appear to have a noticeable effect on body composition.55 
 
The literature also reports that several studies document weight gain in TB patients during the course 
of treatment,54-56,71,73-76 but state that this is somewhat of a given arising from a successful treatment 
campaign. Whilst some studies have proposed that changes in body weight are linked to predictions 
of therapeutic success, especially in drug sensitive individuals,77-80 others have alluded to the 
unreliability of using weight gain as a marker for successful treatment response.66  
 
Despite reports of TB patients showing promising increases in weight whilst on treatment, there is 
some concern as to the composition of the weight gained. Although the most widely used form of 
assessing nutritional status remains either body weight or BMI, this often does not provide sufficient 
information as to the body composition of the patient.81 This is where more specific measurements 
such as LBM and fat mass are invaluable.82,83  
 






Another study by Paton et al. in 2004 showed that whilst the initial period of TB treatment produced 
a significant increase in LBM, the latter periods depicted the majority of weight gain to be due to fat 
mass, which is undesirable57 because LBM gain is linked to beneficial aspects such as longevity, 
increased functionality and quality of life.57,66,84 There could also be a gender-specific difference in 
body composition changes in patients suffering from TB.81 It has been found that despite patients 
successfully completing their course of anti-tuberculosis therapy and showing an overall weight gain, 
this does not necessarily signify an increase in body protein, which can be deleterious for future 
health.54  
 
Some studies have hypothesized that providing adjuvant treatment to TB patients in the form of 
nutritional intervention (macro- or micronutrient supplementation and/or nutrition education) may be 
important in the faster recovery from active disease, as well as an expedited improvement in 
nutritional status.50,53,56-58,64,68,85 Whilst in theory, this reasoning may seem sound, a recent Cochrane 
review conducted in 2011 could not find sufficient evidence to support the provision of blanket 
nutritional interventions for TB-related PEM sufferers and recommended a greater number of large-
scale studies be undertaken.86 Additional recommendations include the possible benefit of targeting 
undernourished groups at risk of TB infection (children, the elderly, TB contacts, etc.) in the hope of 
decreasing incident TB cases,58 although evidence is not conclusive in this regard. In seeming 
support of this recommendation, a local study performed at a facility in Cape Town, South Africa 
showed that provision of vitamin A and zinc in supplemental form resulted in no significant difference 
in the treatment outcomes of those with PTB at two months post-treatment.87 
 
An initiative on behalf of the Nutrition Directorate of the Department of Health, suitably named the 
Nutritional Therapeutic Programme (NTP), aims to provide adults and children diagnosed with active 
TB and an impaired nutritional status with suitable supplementation in the form of an enriched 
porridge and/or oral drink. Qualifying criteria in the Western Cape Province for entry of adults into 
the programme include either an unintentional weight loss (>10% during the past six months or >5% 
during the past month) or a BMI<18.5 kg/m2.88 This programme (as is common with other 
supplemental feeding programmes) is however, not without its limitations in respect of both product 
utilisation by patients and distribution via the health facilities.  
 
1.3.3     Micronutrient Depletion in TB 
 
Appropriate assessment of micronutrient status is often lacking in TB studies. Micronutrients are 
postulated to play a role in impairment of immunity / weight gain, as well as interfere with treatment 
success and could therefore be considered a valuable component of a TB treatment plan.57 Table 
1.3 gives a brief summary of the important current micronutrient role players in TB disease.  






Table 1.3: The role of micronutrients in immunity and tuberculosis 
 
Micronutrient  Function  Findings in TB patients  
Vitamin A  T- and B-lymphocyte functioning 
 Macrophage activity  
 Involved in antibody responses and mucosal 
immunity89,90 
 At risk of deficiency in TB 65,91-93 
 Lower levels shown64,94,95 
Vitamin C  Anti-oxidant properties 
 Scavenging of ROS96 
 Lower levels shown95 
Vitamin D  Modulates macrophage activity in the body45 
 Protects innate immune system against 
invasive or infectious pathogens96,97 
 Also used in early 20th century as part of TB 
treatment (diet or sunlight exposure) before 
aetiological aspects of condition were better 
understood98 
 Preliminary research = decrease inflammatory 
cytokines raised in IR99 
 Lower levels shown100,101 
 Systematic Review (2008) - Vitamin D levels 
0.68 SD lower in individuals with TB than in 
healthy controls101  
 
 Vitamin D deficiency: 
 Increase in peripheral IR 
 Reduction in secretion of insulin from β-
cells in pancreas and insulin sensitivity99  
 Supplementation resulted in increased 
insulin sensitivity and secretion in some 
study populations99,102  
Vitamin E  Anti-oxidant characteristics  
 May have protective function against failure of 
T lymphocytes96 
 Risk of deficiency in TB103 
 Lower levels shown94,95  
Vitamin B6  Synthesis of nucleic acid and proteins 
 Affects DNA and mRNA synthesis96 
 Risk of deficiency in elderly TB patients104 
Folate   Synthesis of nucleic acid and proteins 
 Deficiency has profound effect on immunity96 
 Risk of deficiency in TB105,106 
Iron   Involved in electron transfer, regulation of 
genes, oxygen reactions, cell differentiation 
and growth 
 Cytokine metabolism = production and action 
 Protein kinase C activation96 
 Deficiency could lead to anaemia (shown in 
many adults with PTB)65  
 Lower levels shown94,107 
 Often linked to low haemoglobin levels52 and 
anaemia65,107  
Zinc  Vital role in various immune processes108 
 Deficiency = increased susceptibility to 
infections58 
 Anti-oxidant properties  
 Role in Vitamin A metabolism45 
 Risk of deficiency in TB65 
 Lower levels shown64,94,109-111  
Selenium   Anti-oxidant or anti-inflammatory properties58  
 Necessary for cell-mediated and humoral 
immunity112 
 Function in redox regulation  
 Protects against DNA-related damage 
 Aids membrane integrity96 
 Lower levels shown64,94,109 
Copper   Expansion and preservation of immune system 
 Can affect neutrophil, monocyte, T-cell 
functioning96 
 Higher levels shown107,109 due to positive 
acute phase reactant status  
 
TB = tuberculosis; ROS = reactive oxygen species; IR = insulin resistance; SD = standard deviation; DNA = deoxyribonucleic acid; mRNA 











1.3.4  Biochemical Changes in TB 
 
Several studies have also documented the noticeable alterations in biochemical parameters in 
patients with active TB disease. The biochemical markers occurring most frequently in the literature 
are discussed below.  
 
1.3.4.1   Cholesterol 
  
A reduced cholesterol level among TB patients is a common phenomenon and has often been 
reported in literature.45,113,114 This is, however, a similar bi-directional phenomenon to that of 
malnutrition and TB because it is unclear whether hypocholesterolaemia predisposes to TB or vice 
versa.113 It has been hypothesised that cholesterol (or lipids) may play a vital role in mycobacteria 
survival since cholesterol is vital for macrophage and lymphocyte action and if these are not 
functioning at full might, it may result in the initiation or progression of PTB.113 Recent results from 
animal studies published in 2011, however, suggested that the mycobacteria do not rely solely on 
cholesterol as an energy or nutritional source during times of infection.115  
 
It is also thought that prolonged persistence of mycobacteria may over time lead to cholesterol 
breakdown.116 Similarly, patients with higher levels of cholesterol have been shown to have less 
severe radiological symptoms, with faster sterilisation of sputum after treatment 
commencement.113,117  
 
1.3.4.2   Albumin  
 
Serum albumin levels are often considered to be a reliable marker of nutritional status.118 
Additionally, during times of extreme stress, such as trauma, surgery, burn injuries or inflammatory 
states,119 albumin is often considered a ‘negative’ acute phase protein, which indicates the tendency 
of the protein to decrease noticeably during a typical APR in the body.52,111 Some studies have shown 
lowered albumin levels among TB patients when compared with healthy controls,114 whilst a study 
conducted in Brazil between 2001 and 2003 credited depleted albumin levels at hospital admission 
to be independently linked to in-hospital mortality rates among TB patients.120 Albumin levels have 














Although not as widely documented, pre-albumin is also a ‘negative’ plasma protein but presents 
with a shorter half-life than albumin and is generally considered to be a more sensitive marker.121 
Reduced levels of this compound have been reported in TB patients.121   
 
1.3.4.4 C-reactive protein (CRP)  
 
As is albumin, CRP is also an acute phase protein, although conversely, it is a ‘positive protein’, 
meaning that it increases in times of stress. It is also a non-specific measure of systemic 
inflammation in the body.114 Raised CRP levels have been observed in several studies conducted 
among TB patients,52,114,122-124 with reduced levels detected over time concomitant to treatment 
administration.46,107,122-126 Although markers such as these are not able to diagnose certain 
conditions, they may be utilised when differentiating between inflammatory and non-inflammatory 
conditions or in the understanding of inflammation intensity,46,119 which can be helpful in assessing 
treatment response in TB.123 
 
1.3.4.5 Erythrocyte sedimentation rate (ESR) 
 
Another marker of the acute phase response, ESR, which is associated with fibrinogen 
concentration,119 performs similar to CRP in times of stress. However, the use of CRP levels when 
evaluating a patient is preferred because the ESR seems to have a slower response to a change in 
condition and appears to have a longer half-life when compared with CRP.119  
 
1.3.4.6 Cytokines  
 
These compounds are generally described as polypeptides that are involved in various signalling 
processes between activated body cells.119 Cytokines play an invaluable role in the mediation of both 
the immune and the inflammatory response in the host, which is of crucial importance during 
mycobacteria infection.123 Cytokines are very often a by-product of macrophages/monocytes, and 
some (mainly pro-inflammatory cytokines) play a key role in the generation of the acute phase 
proteins (i.e. CRP).119 Raised cytokine levels are often linked to a reduced BMI, decreased appetite, 
and certain micronutrient deficiencies,64,65 as well as to the severity of infection.127 It is important to 
note that the types and amounts of cytokines, as well as the degree of the APR, differ according to 
the type of inflammatory disorder;119 noticeable changes in cytokine levels have been observed in 
TB patients, which is indicative of the inflammatory state present. Increased levels of interleukin-6 
(IL-6),65,124,127-129 tumour necrosis factor-α (TNF-α),123,127 interleukin-10 (IL-10)128-130 and interleukin-






1 receptor antagonist (IL-1ra)65 have been described. Although studies regarding TB have shown 
inconclusive results for certain cytokines such as interferon-gamma (IFN-ƴ), there also seems to be 
evidence of diminished cytokine levels with the extended duration of treatment.123,124,131 
 
There has recently been investigation into the role of leptin and ghrelin in malnutrition seen in TB. 
Leptin is largely implicated as a protein hormone that exerts its effects by reducing the appetite and 
causing anorexia,132 whilst ghrelin has the converse effect of improving the appetite.133 These 
hormones have also been investigated concerning their role as regulators in the immune 
system.133,134 Findings regarding the interaction of these compounds in TB have to date been 
conflicting, with some studies showing higher leptin levels in TB patients135-137 and others showing 
lower levels.40,64,138,139 Investigations into ghrelin levels in TB patients have also yielded conflicting 
results.127,135,140,141 More research is, therefore, clearly needed in this area to understand further the 
process of cytokine-driven and hormone-assisted wasting in TB.  
 
 
1.4 INSULIN RESISTANCE (IR) 
 
1.4.1    What is Insulin?  
 
Insulin is a peptide-based (or protein-based) hormone that has numerous functions, which include 
its primary function of glucose homeostasis in the body,13,142 its function of stimulation of cell growth 
and differentiation and its roles in lipid and protein metabolism and storage.13 A deficiency of insulin 
(as is often seen in type 1 diabetics) can have disastrous effects because it can lead to wastage of 
protein, ketoacidosis and ultimately, mortality.143 
 
During a fasting state, no insulin is secreted, and glucose is generated for energy via the biochemical 
processes of gluconeogenesis and glycogenolysis.144 Conversely, as soon as an individual has 
consumed exogenous dietary sources, insulin is released from the pancreas and thus inhibits the 
previous gluconeogenesis and glycogenolysis pathways, in order to maximise glucose uptake and 
distribution.144 
 
1.4.2    Definition of Insulin Resistance  
 
Insulin resistance is defined as “a condition in which the cells of the body become more resistant to 
the effects of insulin”.8-11 It can furthermore be described as a “state in which higher than normal 
concentrations of insulin are required for a normal response”.12 As a result of the ineffective action 
of insulin on both the peripheral and hepatic cells of the body, the glucose remains in the 






bloodstream, which in turn results in the hyperinsulinaemic conditions mentioned above. 
Unfortunately, this is not without consequences because a high output of insulin often weakens the 
pancreatic β-cells, leading to constant hyperglycaemia and the progression to type 2 diabetes.9 It 
has also been shown that individuals who are normoglycaemic but have high levels of plasma insulin 
are often already suffering from IR.9  
 
A similar term, namely insulin sensitivity, is often referred to in literature. It can be defined as the 
efficacy of insulin to lower the blood glucose levels via promotion of glucose absorption into muscle 
and adipose tissue.144 It also entails increasing glycogen storage in the liver and in so doing, 
decreasing glucose production in this organ.10 The concept of insulin sensitivity differs from IR 
because it is the reciprocal form of IR.6 Therefore if an individual is said to have ‘normal insulin 
sensitivity’, it would imply that the person has a normal insulin and glucose metabolism in their body. 
Similarly, if one suffers from IR, it is implied that they have a decreased level of insulin sensitivity, 
especially in the peripheral areas.13 
 
1.4.3      Prevalence of Insulin Resistance 
 
Several studies that determined the prevalence of IR in the general population found rates of the 
condition (and other associated morbidities) to be as high as 20 - 40% of persons, the majority of 
whom were classified as healthy.145-146 Furthermore, an estimated 25% of the non-diabetic 
population in developed countries (i.e. not South Africa) is suspected to be as insulin resistant as 
their type 2 diabetic counterparts.14 
 
 In comparison, the International Diabetes Federation (IDF) estimates that approximately one-
quarter (20 - 25%) of the global adult population is suffering from the metabolic syndrome (discussed 
at a later stage),9 whereas in the United States (US), this estimated prevalence rises to an alarming 
40%.147 Other North American and European data has estimated the prevalence of the syndrome to 
be between 15% and 25%.148 The occurrence of the metabolic syndrome also seems to be related 
to age, gender and ethnicity since prevalence rates differ between different populations and 
groups.149 The syndrome tends to occur more among males and older patients (>50 - 60 years).148 
 
1.4.4 Postulated Development of Insulin Resistance 
 
Although IR is not classified as a disease or having a specific diagnosis, it has been implicated in 
the aetiology of morbidities such as cardiovascular disease (CVD), hypertension, polycystic ovarian 
syndrome (PCOS), type 2 diabetes, obesity and metabolic syndrome.14,15,150,151 
 






The aetiology of IR is often attributed to being of either genetic or environmental causation.15 Genetic 
factors could lead to a syndrome-related form of IR, whilst environmental aspects can result from 
dietary intake, low levels of physical activity, aging, smoking or specific drug use (including the use 
of thiazide diuretics, beta adrenergic antagonists and glucocorticoids).15,152 Although the 
development of primary IR in individuals of normal body weight is possible, IR is mainly associated 
with obesity, especially with excess amounts of visceral adipose tissue (VAT).12,15,153 The mere 
condition of being overweight (BMI >25 kg/m2) has been shown to increase the risk of developing 
type 2 diabetes threefold.154 Obesity is also very often associated with a chronic, albeit low level of 
inflammation in the body,17,155 which in turn, has been shown to have a deleterious effect on insulin 
signalling pathways.156 
 
Studies have shown that the presence of visceral obesity (intra-abdominal obesity or central 
adiposity) may be an even greater determinant of IR, diabetes and cardiovascular disease than a 
generalised obesity state measured by BMI.157-162 Not only is VAT responsible for increasing free 
fatty acids (FFA) and triglycerides in peripheral muscle, but it is also linked to a reduced production 
of adiponectin (an anti-inflammatory cytokine), which is a molecule accredited with anti-diabetic, anti-
atherosclerotic and anti-inflammatory properties,163 all of which would prove useful in reducing the 
risk of IR development. 
 
Insulin resistance typically ensues as a result of FFA release from visceral tissue, concomitant to the 
release of various hormones and cytokines from adipose tissue.164 It is due to the latter that IR is 
often considered to be an inflammatory state since associations have been found between IR and 
increased levels of inflammatory markers such as TNF- α, IL-6, macrophage chemo-attractant 
protein-1 (MCP-1), CRP, resistin and plasminogen activator inhibitor-1 (PAI-1).144,165-167 It can thus 
be postulated that because TB is considered to be an inflammatory state,19 so too are IR and 
obesity.155 The chronic, low-grade form of inflammation often seen in obesity has also been 
postulated to be the determinant of the type of micro-organisms found in the gut.155 
 
Upon closer investigation of the effects of FFA relating to IR in the body, it can be seen that in 
addition to impeding glucose oxidation and transport, FFAs can also lead to atherogenic 
dyslipidaemia.9 This process ultimately results in increased triglycerides and apolipoprotein B (ApoB) 
as well as reduced high density lipoprotein (HDL) cholesterol, all of which are synonymous with the 
metabolic syndrome.9 
 
Other factors have also been shown to correlate positively with IR.168 These factors include: 
anthropometric measures (BMI, waist and hip circumference); biochemical measures (raised fasting 
triglycerides, lowered HDL-cholesterol, glucose, insulin and hepatic enzymes);169 clinical 






manifestations (acantosis nigricans, visceral obesity, acne, hirsuitism and hepatic steatosis)15,149,170 
and additional variables such as blood pressure and family history of diabetes.171-174 These variables 
can be seen as being risk factors for the development of IR (e.g. increased BMI or abdominal obesity) 
or as a direct result of the IR state in the body, often seen in the clinical and biochemical presentation 
of the individual.   
 
There are several factors involved in altering insulin sensitivity/resistance, such as recent physical 
activity or exogenous dietary intake. It is thus imperative that these are taken into account before 
any measurements evaluating IR status are commenced. Means of avoiding exercise and correct 
fasting procedures should be adequately communicated to study participants prior to testing.13 
 
1.4.5     Metabolic Syndrome 
 
The metabolic syndrome, also referred to as Syndrome X,14 the Deadly Quartet175 or the insulin 
resistance syndrome,176-177 was first proposed in the late 1980s by Gerald Reaven in his Banting 
lecture.14 It is characterised by the following indicators: abdominal obesity, atherogenic 
dyslipidaemia, elevated blood pressure, IR (with glucose intolerance), a pro-inflammatory state and 
a pro-thrombotic state. All are indicated in Figure 1.2.14-17 
 
Insulin resistance is considered by many to be the epicentre of the metabolic syndrome storm 
because it is regarded as a key component in the development of the condition. Figure 1.2, adapted 
from Van Zwieten et al.,148 depicts the various processes that are linked to the metabolic syndrome.  
 










1.4.5.1   Diagnostic criteria of the metabolic syndrome 
 
The 2006 IDF criteria (shown in Table 1.4) were largely born through the WHO, the National 
Cholesterol Education Program – Third Adult Treatment Panel (NCEP ATP III or ATP III criteria) and 
the European Group for the Study of Insulin Resistance (EGIR) due to the lack of standardisation for 
existing definitions. These guidelines are shown in Table 1.4.  
 
It is clear that the core aspects of these are similar to the IDF guidelines (central obesity, 
dyslipidaemia and irregularities in glucose tolerance), although the WHO considers the presence of 
IR and microalbuminuria, as well as central obesity measured through waist:hip ratio. Interestingly, 
the WHO definition for IR states that it should be assessed under hyperinsulinaemic, euglycaemic 
conditions, and glucose uptake should be below the lowest quartile for the background population 
under investigation.178 The American Association of Clinical Endocrinologists (AACE), also included 
DM = diabetes mellitus; CRP = C-reactive protein 
 
Figure 1.2: Pathological processes involved in the metabolic syndrome148 
 






in Table 1.4, offers yet another definition of the metabolic syndrome, although this relies heavily on 
the subjective assessment of the particular clinician.179 It has, however, been mentioned that the 
ATP III criteria are more user friendly than the WHO criteria, with the former being used more in daily 
clinical practice.149  
 
Although the IDF guidelines are the most recent (2006), there is a lack of consensus as to which of 
the guidelines to utilise in diagnosing the syndrome, both on a global and national scale This is, in 
part, due to the lack of population-specific waist circumference cut-offs, especially for Sub-Saharan 
Africa. The IDF recommends persons in Sub-Saharan Africa be classified according to European 
cut-off points, which could prove problematic given noticeable differences in body composition.180 
The shortcomings of the IDF criteria have been noted by the consensus group, and mention is made 
that the definition will continue to change with the incorporation of new information.180 Since the IDF 
and ATP III guidelines are very similar in their diagnostic criteria, these seem to be the most widely 
used (with the WHO definition in certain cases) and will be the tools discussed in this study.  
 
In addition, the IDF has devised a secondary set of guidelines to be used in more complex research 
studies. These guidelines are shown in Addendum A of this study, and factors highlighted in bold 
indicate those tested for in this research.  
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Description of Criteria  
Increased waist circumference is a pre-
requisite for IDF classification, combined 
with ≥ 2 of the other risk factors 
(increased triglycerides, decreased HDL-
cholesterol, increased blood pressure and 
increased fasting glucose) or treatment for 
any of these conditions 
 
≥ 3 of the generalised 
metabolic syndrome 
criteria mentioned need 
to be present for the 
ATP III classification. 
In order to make a diagnosis 
of the metabolic syndrome, 
a patient must present with 
glucose intolerance, 
impaired glucose tolerance 
(IGT) or diabetes and/or IR, 
together with ≥ 2 of the 
following components  
IR (defined as 
hyperinsulinaemia, top 
25% of fasting insulin 
values among the non-
diabetic population) plus 
two or more of the 
following: 
No defined number of 
risk factors is specified – 
diagnosis of the 
syndrome is thus left to 
the clinical judgement of 
the practitioner  
Waist Circumference >94 cm (Male) 
>80 cm (Female) 
>102 cm (Male) 
>88 cm (Female) 
 ≥94 cm (Male) 
≥80 cm (Female) 
 
Raised triglycerides >1.7 mmol/L >1.7 mmol/L ≥1.7 mmol/L >2.0 mmol/L ≥1.69 mmol/L 
Reduced HDL-cholesterol <1.03 mmol/L (Male) 
<1.29 mmol/L (Female) 
<1.03 mmol/L (Male) 
<1.29 mmol/L (Female) 
<0.9 mmol/L (Male) 
<1.0 mmol/L (Female) 
<1.0 mmol/L <1.04 mmol/L (Male) 
<1.29 mmol/L (Female) 










Raised fasting plasma 
glucose 
>5.6 mmol/ ≥6.1 mmol/L  ≥6.1 mmol/L Between 6.1 and 7.0 
mmol/L 
Impaired glucose 
regulation or diabetes  
  Present together with IR or 
singularly  
 2 hour post-glucose 




  Under hyperinsulinaemic 
euglycaemic conditions – 
glucose uptake < lowest 




Central obesity    Waist:hip ratio >0.9 (Male) 
Waist:hip ratio >0.85 
(Female) 
  





 Urinary albumin excretion rate 
≥20 g/minute or albumin: 





Other factors  
 
 
European data for waist circumference 
used until such a time as more specific 
data for Sub-Saharan Africa becomes 
available  
   Family history of type 2 
DM, HPT or CVD 
PCOS 
Sedentary lifestyle  
Advancing age 
Ethnic groups having high 
risk for type 2 DM or CVD 
IDF = International Diabetes Federation; ATP = Adult Treatment Panel; WHO = World Health Organization; EGIR = European Group for the study of insulin resistance; AACE = American Association of 
Clinical Endocrinologists; HDL – high density lipoprotein; IR = insulin resistance; BMI = body mass index; DM = diabetes mellitus; HPT = hypertension; PCOS = polycystic ovarian syndrome; CVD = 
cardiovascular disease  
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1.4.5.2   Complications and treatment of the metabolic syndrome   
 
Persons diagnosed with the metabolic syndrome are often faced with a dire prognosis because 
statistics show that they have a two-fold greater chance of having a heart attack148 and a three-fold 
greater chance of a stroke compared with healthy individuals. The more prevalent type 2 diabetes is 
also a significant threat because sufferers of the syndrome have a five times greater chance of 
developing the chronic condition.9 This form of diabetes is synonymous with increased 
cardiovascular risk, as well as the premature development of various morbidities and ultimately, 
mortality risk.183,184 In addition to the these morbidities, the metabolic syndrome can also result in the 
following life-altering conditions: cholesterol gallstones, sleep apnoea, polycystic ovarian syndrome 
(PCOS) in females, hypogonadism in males, microalbuminuria, left ventricular hypertrophy, fatty liver 
and certain types of cancer.16,148 Unfortunately, the consequences of the metabolic syndrome (mainly 
due to diabetes and cardiovascular complications) have far-reaching implications on both the social 
and economic functioning of a country.  
 
A multifaceted approach is needed in the treatment of the syndrome due to the multiple conditions 
found. The IDF recommends a rather aggressive approach in treatment in order to minimise the risk 
of developing cardiovascular complications and type 2 diabetes.9,180 This strategy is two-fold since 
the primary approach entails the adoption of a healthy and sustainable lifestyle,16,185 which 
encompasses a 5 – 10% intentional weight loss in the first year, as well as increased physical activity 
and appropriate dietary adaptations.9,148,180,186 Nutritional management takes all aspects of the 
syndrome into account and focuses largely on weight reduction via a reduced energy intake, a low 
intake of saturated and trans fats, a high intake of dietary fibre, fruits and vegetables, a decreased 
intake of refined carbohydrates, and a reduced alcohol and sodium intake.180,186 In addition, patients 
are strongly advised to stop smoking.148 
 
The secondary and more radical approach consists of pharmaceutical therapy to treat the underlying 
components of the condition, namely antithrombotic medication, antihypertensives, oral antidiabetic 
agents (i.e. metformin), lipase inhibitors (orlistat) and lipid lowering medication (e.g. statins).148,180 In 
extreme situations, behavioural therapy or bariatric surgery may also be implemented in the 















1.5 METHODS OF MEASURING INSULIN RESISTANCE 
  
1.5.1       General 
 
As can be seen by the multi-faceted effects of IR on varying disease aetiologies, it is imperative that 
reliable methods of diagnosing IR are identified. The following section of this literature review 
provides information on the current methods used as popular diagnostic tools for diagnosing IR as 
well as their respective techniques, strengths and limitations.  
 
A variety of methods are currently available for the identification of IR status in individuals.168,171 
These include the gold standard method of the hyperinsulinaemic-euglycaemic clamp 
(HEC),6,13,187,188 the frequently sampled intravenous glucose tolerance test (FSIVGTT) and other 
simpler, surrogate indices such as the homeostasis model assessment of IR (HOMA-IR) and the 
quantitative insulin sensitivity check index (QUICKI) derived from oral glucose tolerance test (OGTT) 
data.13,171 Whilst some of the methods mentioned above investigate peripheral (or muscle) insulin 
sensitivity, such as the clamp and FSIVGTT methods, the fasting indices consider insulin sensitivity 
in the hepatic tissues.189-190 Although these fasting indices focus mainly on hepatic IR, they can also 
be considered valid when comparing them with the clamp method because there is a proposed close 
relationship between peripheral and hepatic IR levels.146 
 
A detailed comparison of the most relevant methods used in the measurement of IR is given in 
Tables 1.5 to 1.7. Table 1.5 indicates the invasive indices (requiring intravenous insulin/glucose 
infusions), Table 1.6 depicts the non-invasive indices (measurements that do not require the 
administration of either exogenous insulin or glucose via the intravenous route) and Table 1.7 
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Table 1.5: Technique and uses of invasive IR tests 
 






















 Considered to be the ‘gold-standard’ 
reference method of assessing insulin 
sensitivity in humans6,187,191  
 Conducted under very controlled 
circumstances 
 Intravenous infusion of insulin and 
glucose is administered for up to 
three hours (steady-state conditions) 
 Entire body glucose disposal 
calculated (‘M’)190 
 Insulin infused to create 
hyperinsulinaemic state, whilst 
glucose is concomitantly infused to 
maintain euglycaemia191  
 
 First line test to evaluate insulin 
sensitivity in vivo 
 Direct measure of insulin action 
under steady-state conditions 
 Displays known precision and 
reproducibility188,191 
 Able to assess insulin 
secretion192  
 Can be used in all population 
types, including patients with 
diabetes (amount and rate of 
insulin infused can be adjusted 
according to the population13,193 
 Can differentiate between 
hepatic and peripheral insulin 
resistance193 
 
 Specialised equipment 
(intravenous catheters, 
calibrated pumps and online 
glucose-level determination) 
 Suitably trained staff 
 Time-consuming (up to three 
hours/test)  
 Costly  
 Impractical for use in large 
epidemiological studies, 
clinical investigations or for 
routine clinical 
purposes6,13,142,188 
 Slight level of patient 
discomfort13,142  
 Not considered suitable 
when estimating normal 
insulin and glucose action 
 Viewed as ‘un-physiological’ 
= post-prandial dynamic 
conditions not 
portrayed10,188,194 
 Difficulty in repeating studies 
 Higher than normal insulin 
levels post infusion  
 Clamp instability6  
 No fixed consensus on 
important parameters when 
using the clamp method 
(optimal procedure duration, 
infusion rate of insulin and 
normalisation of glucose 
infusion rate)  
 Comparison between 




 IR estimated using ratio 
of mean glucose 
infusion: mean insulin 
concentration over 
previous 20 - 30 
minutes of clamp 
procedure6 
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 Derivative of HEC 
 Measures both β-cell secretory 
function and IR 
 Glucose infused at a rate to facilitate 
hyperglycaemic response6,13 
  Not in accordance with normal 
physiological response 
 Not used as widely as its 
















 Indirect method of measuring insulin 
sensitivity/resistance 
 Glucose and insulin values are 
recorded during the test  
 Values computed by a mathematical 
model that investigates the 
relationship between the glucose and 
insulin and their kinetics197  
 Mathematical model is referred to as 
the minimal model analysis 
(MINMOD) 
 Test also requires subjects to have 
intravenous infusions of glucose / 
glucose and insulin, as well as 
frequent blood sampling10 
 
 Analysis of both insulin and 
glucose levels is done using 
the computer program 
MINMOD = increased accuracy 
levels142  
 Also determines both early and 
late phases of insulin secretion 
from a single test13  
 Highly reliable and reproducible 
 Many international studies 
attest to its validity 
 Often referred to as the ‘silver’ 
standard after the HEC198,199  
 More cost-effective and less 
labour intensive to execute 
than HEC6,198 
 Able to identify and distinguish 
between different components 
of glucose disposal10 
 Describes more of a dynamic 
relationship between insulin 
and glucose142 
 This method also requires a 
rather intense testing 
procedure 
 Subjects need intravenous 
catheterisation as well as 
frequent blood draws (up to 
25 - 30 samples over three 
hours) 
 Limited use in large 
epidemiological 
studies6,10,13,142,193  
 Test depends on the 
accuracy and availability of 
the appropriate computer 
software = greater financial 
implications13.142 
  Reliability of results also 
diminished in known insulin 
resistant populations such as 
type 2 diabetics13 
 
 Specialised computer 














 Direct measurement of insulin 
sensitivity/resistance200  
 Test includes administration of 
somatostatin (a hormone preventing 
the release of other hormones) after 
an overnight fast, which subsequently 
inhibits endogenous insulin 
production200  
 Pre-determined amounts of glucose 
and insulin then infused at a constant 
rate 
 First of its kind to use steady-
state insulin levels to allow for 
disposal of a glucose load 
 Less labour intensive than the 
clamp method13,188   
 
 Difficult to implement in large 
epidemiological studies or 
routine clinical settings13,188 
 Additional risks to the study 
population that include risks 
of hypoglycaemia and 
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Name of IR test  Techniques & Uses Advantages Disadvantages  Interpretation of results  
Insulin 
suppression test 
 Recorded at set intervals during the 
test 
Continuous 




 Based on principle of assessing the 
response of both insulin and glucose 
post-intravenous glucose 
infusion193,201 
 Glucose administered over one hour 
 Three phlebotomy samples required 
  Not very widely validated or 
utilised in research studies 
thus far193,201   
 
 Consultation with 
computer-assisted 







tests and short 
insulin tolerance 
test6 
 Both tests used to identify possible 
insulin resistance following an 
intravenous administration of insulin 
 
 Insulin sensitivity test: Very similar to 
the HEC, but does not require such 
intensive sampling procedures 
 
 Short insulin tolerance test: Observes 
the rate of glucose decrease post-
intravenous administration of an 
insulin bolus 
 Both tests ultimately less labour 
intensive = executed over a 
shorter duration of time6 
 
 Both tests not as well 
reported as HEC or FSIGVTT 
methods6 
 
 Insulin sensitivity test:  
     Steady-state plasma 
glucose calculated 
using mean of glucose 
levels over previous 30 
minutes6 
 
 Short insulin tolerance 
test: 
      Insulin sensitivity 
approximated from 
slope of regression line 
of logarithm of glucose 
concentration vs. time6 
 
IR = insulin resistance 
 
Stellenbosch University  https://scholar.sun.ac.za
Stellenbosch University  https://scholar.sun.ac.za
32 
 
Table 1.6: Technique and uses of non-invasive IR tests 
 











 Often the standardised test used in 
diagnosing glucose intolerance and 
type 2 diabetes in clinical practice13,202  
 Pre-determined amount of glucose 
(75g) – dissolved in 250ml of water is 
administered orally after an overnight 
fast 
 Glucose and/or insulin values are 
collected at specific times according to 
the purpose of the test (either clinical 
diagnosis or estimation of insulin 
sensitivity/secretion)145  
 Intends to determine the rate of 
glucose removal from the subject’s 
blood stream142 
 Gives indication of insulin sensitivity in 
peripheral (not hepatic) tissues13 
 Much simpler to perform than 
the invasive techniques (HEC, 
FSIVGTT, etc.) since glucose 
administered orally and not 
intravenously 
 More physiological than 
invasive methods10,13,142  










 Not an ideal ‘typical meal 
situation’13 
 Labour intensive (Two hours 
per test) 
 Provides information 
regarding glucose tolerance 
of a subject, not IR142 
 Reason for devising 
surrogate indices that 
incorporate OGTT results to 
determine IR13 
 OGTT gives indication of 
insulin sensitivity in 
peripheral (not hepatic) 
tissues13 
 
Once the OGTT has been 
performed under the correct 
conditions, the 
interpretation thereof is as 
follows:3  
 Impaired fasting 
glucose (IFG):              
<7.8 mmol/L 
 Impaired glucose 
tolerance (IGT):        
7.8 – 11.0 mmol/L 
 Diabetes:                     
>11.1 mmol/L  
 






















Different variations available (more 
precise calculations/formula shown in 
Addendum B) 
 
Avignon index:  
 Considers fasting insulin and glucose 
values taken prior to the test, as well 
as two hours post-test 
 Incorporates estimates of glucose 
Volume of Distribution (VD) = 
150mL/kg body weight], which was 
then compared with the Bergman 
model as mentioned previously in this 
review204  
Belfiore index:  
 Utilises the Area Under the Curve 
(AUC) of both insulin and glucose205  
Gutt index:  
 Simply an adaptation of the 
Cederholm index (as can be seen in 
Addendum B) 
 Unlike the OGTT alone, these 
indices are able to provide 




 Efficacy of surrogate indices in 
measuring insulin resistance 
among a Finnish non-diabetic 
population investigated by 
Lorenzo et al. = found to be 
valid indicators211  
 However, three indices 
(Matsuda, Avignon and 
SIisOGTT) = better correlation 
with HEC211  
 A similar study investigating 
surrogate indices and relation 
to cardiovascular risk factors in 
overweight and obese post-
menopausal women = found 
 Labour intensive 
 Rely upon reproducibility of 
OGTT  
 Lack of standardised 
reference ranges = inter-
study comparisons not 
always feasible13 
 Insulin sensitivity not single-
handedly responsible for 
altered plasma glucose and 
insulin values. These 
alternations can also be 
attributed to other biological 
processes (e.g. rate of 
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Matsuda index:  
 Utilises a combination of fasting and 
mean OGTT values to allow use in 
subjects with varying ranges of 
glucose tolerance 
 Both peripheral and hepatic insulin 
sensitivity are investigated145  
Stumvoll index: 
 Makes use of plasma insulin and 
glucose levels, as well as the body 
mass index (BMI) of a subject 
 Positively correlated with the HEC 
thus far206  
Oral glucose insulin sensitivity (OGIS):  
 Formula not shown in Addendum B 
(the appropriate online reference is 
given) because it is a more 
complicated formula due to varying 
parameters that differ according to 
author’s/researcher’s discretion   
SIisOGTT 
 Shown promising validation results in 
recent studies conducted among 
middle-aged, inactive males207 and 
non-obese, non-diabetic healthy 
participants respectively208 
Liver insulin resistance index:  
 Relatively new index, derived by 
Vangipurapu et al. in 2011209 
 Good correlation with the HEC209  
 Considers insulin values recorded 
during an OGTT, as well as high 
density lipoprotein (HDL) cholesterol 
and anthropometry measurements 
(such as BMI and body fat 
percentage)209 
Insulinogenic index (IGI):  
 Often used to determine pancreatic β-
cell function (derived from OGTT)210  
variability in inter-index 
results212  
 Quite specific study 
populations in studies 
mentioned above = therefore 
indices should be 
tested/validated in many other 
population groups with a 
variety of glucose tolerance 
ranges and insulin sensitivity 
before adopting into clinical 
practice13 
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 Has not undergone stringent 
validation  
 Often used during initial stages of 
OGTT execution (first half hour) to 
determine insulin response as a result 
of a direct glucose challenge142 
Glucose insulin (GI) product:  
 Uses the product of plasma glucose 
and insulin concentrations obtained 
during the OGTT 
 Found by some researchers to display 
a good correlation with insulin-
mediated glucose disposal rate of the 
HEC method145  
 Formula = the higher the levels of 
plasma glucose and/or insulin, the 
greater the presence of IR 
 Conversely, the lower the GI product, 
the higher the level of insulin 
sensitivity142 
 
IR = insulin resistance
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Table 1.7: Technique and uses of fasting indices for testing IR  
 











Fasting insulin  
 Measurement taken after overnight fast 
(usually between 8 to 12 hours of fasting)10  
 Fasting insulin measurement (if >75th 
percentile of population) = previously 
considered by European Group for the 
Study of Insulin Resistance (EGIR) to be 
relatively good indicator of IR214  
 Considered a practical means 
of measuring IR215 
 Very simple to perform  
 Inexpensive (true for all 
fasting indices)13 
 Viewed as being able to 
identify IR in individuals prior 
to development of clinical 
morbidity142  
 Healthy subjects with 
normoglycaemia, but 
concomitant 
hyperinsulinaemia, shown to 
display higher levels of IR, 
compared with those with 
normal levels of insulin142 
 Not true for glucose-intolerant 
persons / diabetics = typically 
present with hyperglycaemia 
but lower than normal insulin 
levels142 
 Use of test is limited 
 Considerable  lack of 
standardisation regarding 
insulin assay procedure 
(various assays used in 
laboratories) = difficulty with 
inter-study comparisons142 
 Large number of false-
positive results recorded142  
 Fasting indices generally 
considered to be more 
reliable for normoglycaemic 
individuals than type 2 
diabetics due to variability 
of fasting insulin values194  
 Formulae make use of >1 
reference value (i.e. insulin 
and glucose or insulin and 
triglycerides) =  more 
reliable than those that use 
insulin in isolation194  
 
 Currently no available 
standardised cut-off 
reference values to 
identify IR by using 
fasting insulin 
measurement193 
 Cut-offs proposed but 

















 (Please see Chapter 2.6.3.4 for the HOMA-
IR formula in question)  
 Also known as HOMA-IR 
 First described more than a quarter of a 
century ago by Matthews et al.7 
 Proven useful in large epidemiological 
studies 
 Shows positive correlations with 
HEC13,187,196,216  
 HOMA-IR, together with QUICKI: two of the 
most popular fasting indices to determine 
IR7,20 
  Utilises both the fasting glucose and insulin 
values to determine basal IR6 
 Surrogate of IR phenotype 
(identifies individuals with IR 
without measuring action of 
insulin)219,220 
 Simpler test 
 Not labour intensive or time 
consuming for the participant 
 Easy to calculate 
 More cost-effective 
 Minimally invasive for the 
participant10,13,142,189  
 Largely able to predict 
steady-state glucose and 
insulin levels in a fasting 
state142  
 Measurements are not yet 
accredited as a standard for 
determining IR171  
 Applicability of all fasting 
indices seems weaker in 
healthy populations, normal 
weight individuals and 
those with primarily 
peripheral IR13,190,223 
 Lack of standardised 
reference values 
 Less relevance in certain 
ethnic groups13   
 Efficacy is often restricted in 
certain endocrinological 
abnormalities such as 
 Lack of standardised 
reference values 
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 Product of fasting glucose and insulin 
computed to determine predicted β-cell 
response and IR risk13 
 Mean of three samples (taken at five minute 
intervals) recommended = pulsatile nature 
of insulin release7  
 Single sample of insulin found to produce 
similar results in large research studies196  
 Adaptation of original HOMA formula to 
allow for addition of certain anthropometrical 
measurements (e.g. BMI) has shown 
improvements in IR identification13  
 
Alternatives for HOMA/HOMA-IR: 
 
HOMA2: 
 New and improved version of the original 
HOMA calculation196  
 Available via Oxford University on the 
following online link: 
www.dtu.ox.ac.uk/homacalculator/index.php  
 Also takes into consideration any possible 
differences in hepatic and peripheral 
glucose resistance217 
HOMA-β: 
 Formula designed to complement original 
HOMA formula  
 Allows estimation of insulin secretion by β-
cells of the pancreas7 
HOMA-S 
 Adjusted HOMA formula 
 Relates to insulin sensitivity of an individual 
 Neither it nor HOMA-β formula can state 
with certainty whether an individual displays 
IR or not196 
Log HOMA 
 Noted that this formula often produces more 
comparable results (in relation to reference 
methods for IR) because fasting insulin 
levels not often normally distributed13,194,218  
 Useful tool in epidemiological 
research 
 Validated by Insulin 
Resistance and 
Atherosclerosis Study 
(IRAS),221 conducted among 
1 460 individuals 
 Able to identify any variances 
in insulin sensitivity levels 
between different population 
groups13   
 Useful in long-term studies in 
which patients are followed 
up6  
 ‘Fasting’ indices (including 
HOMA, QUICKI, etc.) 
generally produce more 
reliable results among 
normoglycaemic individuals 
than those already presenting 
with type 2 diabetes11  
 Role of fasting indices in 
estimating cardio metabolic 
risk also valid = IR shown 
positive link to intima-media 
thickness (IMT) of carotid 
artery in cardiovascular-
based research222 (Important 
given strong link between IR 
and progressive development 
of cardiovascular disease 
insulinoma and primary 
hyperaldosteronism224  
 Needs further validation in 
insulin-dependent 
individuals142 
 Lack of reliability of any of 
the fasting indices when 
investigating certain groups 
(e.g. elderly or uncontrolled 
or type 1 diabetics)20,225,226i  
 All fasting indices: Quality 
of output dependent on 
reliability of input 
measurements (namely 
insulin and glucose)196 
 Lower reproducibility than 
QUICKI (few studies)227,228 
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 (Please see Chapter 2.6.3.4 for the QUICKI 
formula in question). 
 QUICKI =  inverse logarithm of HOMA  
 First described by Katz et al. in 2000, 
approximately 15 years after HOMA20 
  Positive correlations found between QUICKI 
and HEC in a varied population comprising 
non-obese, obese and type 2 diabetic 
individuals20  
 Whilst some studies have shown improved 
performance of QUICKI in relation to HOMA 
when validated against the clamp 
method,229 others have shown no difference 
between the two fasting indices in relation to 
the FSIVGTT method of identifying IR230 
 
Alternatives for QUICKI: 
 
Revised QUICKI – (R-QUICKI) 
 Simply the original QUICKI formula with 
plasma free fatty acids incorporated into the 
equation 
 Allows for improvement in IR identification 
among a leaner population231 
 
 Several studies showed 
promising correlations 
between its use and the HEC 
in a variety of study 
populations20,218,226,,229,232,233  
 Produces fairly consistent 
results  




 Same limitations as for 
HOMA since they are 
mathematically related 
 Significant lack of 
information regarding 
stimulation of 
glucose/insulin systems in 
the body because 
peripheral insulin sensitivity 
is not evaluated10  
 Validity in type 1 diabetics 
and measurements taken 
directly post-exercise also 
queried20,234 
 Problems identified in 




 Lack of standardised 
reference values 
 Normal reference 
ranges for QUICKI 



















 Makes use of two variables (fasting insulin 
[µIU/mL] and fasting triglyceride [mmol/L] 
levels)168 
 These variables proposed to be most useful 
in predicting possible insulin sensitivity 
 
TyG index:  
 Devised by Geurrero-Romero et al.236  
 Utilises fasting triglycerides and glucose 
 
Antuna-Peunte et al. 
 Responsible for devising new index for use 
among  mainly healthy subjects 
TyG index: 
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 Primarily focusing on fasting non-esterified 
fatty acids (NEFA) and atherogenic index13 
 
These lipid-incorporating formulae should, 
therefore, still be tested in the hope of 
increased identification of insulin resistant 




 Utilises fasting glucose (G) and insulin (I) 
values in the formula G/I to calculate a 
suitable ratio172,237,238  
 Used in several studies  
 Easily calculated  
 
 Remains a theoretically 
imperfect index of insulin 
sensitivity/resistance  





 Index proposed by Duncan et al. in 1995  
 Uses following formula to aid in calculation 
of possible IR: FIRI = (fasting glucose x 
fasting insulin) / 25239 
   
 
IR = insulin resistance;  HOMA-IR = homeostasis model assessment – insulin resistance; BMI = body mass index  
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1.5.2     Research on Surrogate Indices for Insulin Resistance 
 
A recent meta-analysis published by Otten et al. in 2014 investigated the correlation between surrogate 
measures of insulin sensitivity and the gold reference standard, the HEC.240 A total of 120 articles were 
included in this meta-analysis, which reviewed the majority of the commonly used IR surrogate indices. 
The fasting indices that showed the strongest correlation with the HEC included the revised QUICKI 
(r=0.68), the QUICKI (r=0.61), the log HOMA-IR (r=-0.60) and the computer-generated HOMA for insulin 
sensitivity (r=0.57). Indices devised from OGTT-based values that showed the most promising 
correlation with HEC included the Stumvoll metabolic clearance rate (r=0.70), oral glucose insulin 
sensitivity (r=0.70), Matsuda index (r=0.67), Stumvoll insulin sensitivity index (r=0.67) and the Gutt index 
(r=0.65).240 
 
1.5.3    Other Markers Under Investigation  
 
With global interest in the timely identification of insulin resistant individuals in order to prevent further 
development of chronic disease, attention is now focused on alternative means of identifying IR. Of 
these alternative substrates, classic inflammatory markers are gaining popularity as possible markers 
of IR.142 
 
These alternative markers include, but are not limited to the following (of which a comprehensive 
analysis is beyond the scope of this literature review): insulin growth factor binding protein-1 (IGFBP-1), 
soluble CD 36 (sCD36), CRP, ferritin, adiponectin, TNF-α, resistin, C3 complement, glycosylated 
haemoglobin (HbA1c), protein kinase C in microangiopathy and sex hormone-binding globulin (SHBG) 
in hyperandrogenic syndrome.142 
 
1.5.4 Choosing the Most Appropriate Method for Measuring Insulin Resistance 
 
Groop et al. highlighted five criteria with which an IR measuring tool should comply: (1) to achieve high 
enough insulin levels to stimulate glucose metabolism and to identify minimal differences in sensitivity 
of glucose uptake in relation to insulin; (2) to differentiate between hepatic and peripheral insulin 
sensitivity; (3) to record steady-state conditions adequately; (4) to rely on physiologically based notions 
regarding the body’s glucose system; (5) to achieve some level of hyperglycaemia that is not un-
physiologic.241 The ideal method of ‘diagnosing’ IR should also allow for inter-individual comparison with 
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minimal risk to the persons involved, be cost-effective and be simple to perform.241 As is clear from the 
analysis of available methods, no one tool stands out from the rest.  
 
It has been mentioned that the best measure for assessment of IR is dependent on glucose status,168 
and this is, therefore, something that should be considered in the planning stages of a research study.194 
Similarly, the decision of which IR diagnostic measure to use is, therefore, not a decision to be taken 
lightly because there are many factors to take into consideration when choosing a suitable means of 
assessing IR. These factors include the study population under investigation, the proposed research 
question, the type of IR in question and available resources.13,193,196 In considering all the resource-
based factors having an effect on IR method selection, it is valuable to assess the impact of the time 
available for study completion, the budgetary constraints, available materials and equipment as well as 
the target sample size.13,194 It is also of the utmost importance that one evaluates previous studies to 
gain more insight into appropriate methods used and to avoid preventable complications.194 
 
It can be advantageous to make use of more than one IR index in a study both to corroborate findings 
between indices and prevent incorrect conclusions from being drawn.194 
 
The following diagrammatical representations (Table 1.8 and Figure 1.3) depict certain considerations 
in the selection of an appropriate technique for the assessment of IR in research.  Addendum C is 
another variation of selecting an appropriate tool. 
 
Table 1.8: Criteria for studies in which non-invasive ‘simple’ indices of IR may be used194 
Study objectives: 
1. Large clinical practice and epidemiological investigations 
2. Assessment of direct IR is not required  
3. Outcome of IR is of secondary interest  
4. Requirements of reference techniques unavailable (e.g. equipment, trained staff, budget) 
5. Evaluation of new simple index  
6. Investigation of validity and pitfalls of simple indices in specific clinical conditions  
 
    IR = insulin resistance 
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Figure 1.3: Types of insulin resistance studies194 
 
It is important to note that if IR status is measured via the fasting indices mentioned above, additional 
means of assessing an individual’s IR status should ideally be employed due to the stated limitations. 
Thus, the determination of classical risk factors such as those highlighted in both the IDF and ATP III 
definitions of the metabolic syndrome (waist circumference, blood pressure, lipid profile, etc.) should 
also be considered in conjunction with the results from fasting indices.13,187 
 
 
1.6 RELATIONSHIP BETWEEN TUBERCULOSIS AND INSULIN RESISTANCE 
 
If one considers the global epidemics of TB and diabetes, it seems that they have an inverse 
relationship. As the incidence of TB is slowly decreasing, the number of individuals suffering from 
diabetes is increasing at an alarming rate. This appears to be true in South Africa.242 
 
The following section attempts to uncover more detail regarding the relationship between the two 
phenomena, which was first documented more than a thousand years ago.243 
* All techniques include those mentioned in the review although the first choice remains the clamp technique, 
followed by the FSIVGTT and then the simple indices. 
** Simple indices are used when the clamp technique and FSIVGTT are not possible to conduct. 
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1.6.1     Tuberculosis Resulting in Insulin Resistance  
 
It is hypothesised that the stress experienced during a significant long-term infection (such as TB or 
HIV) could result in increased IR. As a result of infection with the mycobacteria, macrophages, which 
form a vital part of the innate immune system, are often the first line of defence against these harmful 
organisms.8 As is found with any infection, an increased amount of pro-inflammatory cytokines (such as 
IL-6 and TNF-α) is usually produced. This inflammatory attempt by the body to ward off possible 
pathogens such as TB might have a role to play in increasing IR, subsequently lowering insulin 
production and ultimately leading to hyperglycaemia in the host.244 This process may also be 
accompanied by the release of certain stress hormones such as epinephrine, cortisol and glucagon, 
which further impair the action of insulin.245 
 
In some cases, the hyperglycaemia resolves with duration of treatment,246,247 but in other circumstances, 
may result in the development of a diabetic state or place patients at risk of developing DM at a later 
stage.242 This condition is often referred to as ‘transient hyperglycaemia’, which occurs when glucose 
intolerance upon diagnosis subsides after active TB treatment.248,249 The term ‘stress hyperglycaemia’ 
is also often used to describe the metabolic changes seen shortly after diagnosis of TB.242 This may 
result in the erroneous classification of individuals as diabetic since the hyperglycaemia may, in fact, 
only occur due to the presence of the TB disease.242,250,251  
 
Because HIV is also considered a chronic infection, much research has focused on the effects of the 
disease and the consequences of antiretroviral therapy (ART) on the body. Infected persons, especially 
those on ART, show a greater likelihood of developing the metabolic syndrome, which includes the 
component of IR.22,252 In general, HIV infected patients have reported high rates of IR.253 
 
There seem to be many cases investigating the prevalence of hyperglycaemia, impaired glucose 
tolerance (IGT) or DM in documented TB cases but as far as the researcher is aware, none appear to 
have specifically investigated IR prevalence in the same population.  
 
A case-control study performed in 2011 in Tanzania showed an increase in hyperglycaemia among TB-
infected cases, but not in the healthy controls.254 It was postulated that these elevated levels could be a 
result of IR accompanying severe infection, as is found in TB.255 Other studies have demonstrated a 
temporary increase in glucose levels in cases of active TB.246,251 It has also been shown that infectious 
states can often lead to impaired glycaemic control in patients diagnosed with DM.256  
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In a local study conducted in the Eastern Cape Province of South Africa, differences between untreated 
TB patients (cases) and healthy, non-infected controls were assessed.257 Results documented higher 
levels of glucose and insulin among cases compared with the controls. A delay in the clearance of insulin 
was also found, suggesting a defective internalisation of insulin.257 These results seem to suggest that 
insulin-glucose metabolism is altered in patients with TB. This is in agreement with findings of an older 
study by Karachunskii et al. (1995), showing that carbohydrate metabolism is altered in TB patients, 
with emphasis placed on an enhanced secretion of insulin resulting in insulin deficiency and concomitant 
hyperglycaemia.258 
 
In a case-control study published in 2014, researchers in Japan compared TB patients with non-
diseased controls in order to assess the prevalence of glucose intolerance.259 The study found a 
significantly higher prevalence of glucose intolerance among the TB cases compared with the controls 
(males: 34.2% vs. 14.4% in controls; females: 18.3% vs. 10.0% in controls).259 Although the study found 
that those participants who displayed glucose intolerance had a higher BMI than their non-intolerant 
counterparts, the researchers did not exclude overweight/obese patients from their study population. 
Because HIV status was unknown at the time of recruitment, this remained unknown for the participants.  
 
Rifampicin, one of the pharmaceutical agents used in the treatment of TB, has also been found to result 
in transient hyperglycaemia in the beginning stages of treatment due to it strengthening glucose 
absorption in the intestine.260 
 
In a systematic review conducted by Jeon et al. in 2010,251 a total of 30 studies were included in the 
review: 12 studies screened patients with diabetes mellitus for TB, and the remaining 18 studies 
attempted to screen TB patients for diabetes mellitus. The findings from this review showed that the 
diabetic patients had a TB prevalence rate of between 1.7% and 36%.251 Those persons diagnosed with 
TB showed a diabetes prevalence rate of between 1.9% and 35%.251 Both of these findings showed high 
rates of co-morbidities.  
 
A research study conducted among the Indian population in the year 2000 provided researchers with 
the following statistics: Of prevalent PTB cases, 14.8% were classified as having diabetes, whilst an 
increased proportion (20.2%) of all smear-positive TB cases also suffered from diabetes.261  
 
A spate of recent, globally conducted studies showed the heightened risk of TB patients displaying a 
higher prevalence of either DM or pre-DM. Viswanathan et al.262 found prevalence rates of DM among 
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TB patients in India to be 25.3% (of which 9.3% of these were newly diagnosed diabetics) and pre-
diabetic rates to be 24.5%. When compared with DM prevalence in the general population, it was much 
higher among TB patients.262 Similarly, Balakrishnan et al. found 44% of their study population in India 
to have DM, which comprised 23% known diabetics and 21% newly diagnosed cases.263 Upon perusal 
of DM prevalence in the United States and Mexico, Restrepo et al. found a 39% prevalence rate among 
TB patients in Texas, whilst Mexican TB patients displayed a slightly lower DM prevalence of 36%, 
although their study population included HIV-infected persons.264 In the 2011 Tanzanian case-control 
study cited previously, TB cases had a DM prevalence rate of 16.7% versus the control group 
prevalence of only 9.4%.254 When considering IGT rates in the same study, the TB group was again 
found to have a higher prevalence (37.6%) compared with 21.4% in the control group.  
 
Another hypothesis that came to the fore many years ago involved the theorising of Schwartz, who 
hypothesised that the pancreas could be assaulted by TB by two possible means, namely concomitant 
pancreatitis (resulting in heightened susceptibility to inflammation and/or amyloidosis) or via the forced 
habitation of the pancreas.265,266 It was, therefore, postulated that this could ultimately give rise to a 
greater incidence of diabetes among TB patients.  
 
It is also suggested that patients with latent TB have a greater risk of developing active TB if they become 
IR during this time.8 Moreover, the persistence of TB bacteria in adipose tissue has been hypothesised 
to be a possible causative factor for systemic IR.267 
 
1.6.2     Insulin Resistance/Diabetes Resulting in Tuberculosis 
 
The unforeseen association between DM and TB has long been suspected although possible 
explanations for its existence are not definitive as yet.250,254,261,266,268-270 Before the discovery of insulin 
as a means of controlling blood glucose levels, life expectancy for diabetic patients was severely 
reduced, and the main cause of mortality was often found to be TB.266 It has been suggested that an 
impaired immune system could be responsible for the development of TB8 and sub-optimal blood 
glucose control,152,271 but further investigation is still required. Persons with DM are often seen to present 
with a higher incidence of infections than non-DM patients as well as more infection-related 
complications,272 of which one of the multiple causes is postulated to be defects in the innate immune 
system.273 Diabetic patients often present with dysfunctional immune processes due to impaired 
macrophages, monocytes and T-lymphocytes, which can also affect the quality of phagocytosis.274-276 
This results in an impaired CMI, which is ultimately responsible for protection against TB.274 
Stellenbosch University  https://scholar.sun.ac.za







The effect of a poorly controlled diabetic state has been postulated to affect deleteriously the functioning 
of protective macrophages and lymphocytes, which can result in a diminished phagocytic attack against 
the invading mycobacteria.250 Macrophages are normally tasked with the role of destroying any 
intracellular bacteria, but this is suggested to be altered in an IR state.8,277 The macrophages develop a 
resistance to the higher insulin levels, leading to a decrease in phagocytosis activity. It is hypothesised 
that this can subsequently lead to increased survival of the mycobacteria within the macrophages, thus 
potentiating the risk for development of active TB.8 Additional TB pre-disposing factors in DM patients 
include a deficiency of interferon gamma, pulmonary microangiopathy and a lack of various vitamins 
and/or minerals.278 
 
Results obtained in a recent systematic review by Jeon et al. (2008) showed that persons with DM had 
approximately a three times greater risk of developing TB compared with those without DM.269 In addition 
to this, it is thought that diabetes contributes to approximately 8% of incident tuberculosis cases each 
year.38 Pulmonary tuberculosis is ranked ninth on the list of most frequent DM complications.279 
 
Another systematic review conducted by the Jeon et al. group in 2011 showed that having active 
diabetes increased the risk of mortality, TB treatment failure and death combined, as well as the risk of 
TB relapse.280 The systematic review highlighted the need for increased awareness of TB control 
programmes in diagnosing, treating and monitoring the dual burden of disease. This is largely being 
addressed via the Collaborative Framework for Care and Control of Tuberculosis and Diabetes,38 which 
is affiliated to the WHO and the International Union Against Tuberculosis and Lung Disease.  
.  
This is a worrying phenomenon because despite positive actions being taken to decrease the incidence 
of TB cases, the rapidly spreading diabetes epidemic may hamper these actions and result in sub-
optimal TB care and monitoring.242 
  
It is evident from the research that many of the findings are merely based on hypotheses at present, 
and that further, more conclusive evidence is essential in the understanding of these phenomena, 
namely, to ascertain which occurred first –TB or IR/DM.250 This is often difficult to determine because 
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1.7       CONCLUSION AND MOTIVATION FOR THE STUDY 
 
The association between TB and the development of an IR state is somewhat of an enigma because 
evidence establishing or disputing the possible relationship is, to the knowledge of the researcher, 
currently not available. Since this study hopes to embark on novel research, especially in ambulatory 
PTB patients, it can be viewed similarly to a pilot project or front-runner in that it may give rise to similar 
research ventures and contribute to the available knowledge of the subject.   
 
Given the nature of the TB epidemic in South Africa, and especially in the Western Cape, this study is 
definitely of relevance. South Africa is often viewed as having a double burden of disease and there is, 
therefore, great emphasis placed on the preventative care and treatment of the communicable disease 
aspect of this liability. This also correlates with the MDGs (due to be replaced with the SDGs in 2015), 
specifically Goal 6: Combat HIV/AIDS, malaria and other diseases.  
 
If persons with TB were proved to exhibit a greater prevalence of IR compared with non-infected 
individuals, this would hopefully improve the current management of TB patients. Previously, much of 
the dietary treatment provided to persons with TB focused on curative care. New findings from this study 
could, however, signal a transition to a more preventative course of nutritional therapy induced action. 
Given the propensity of IR to result in CVD and DM, it would be beneficial to identify individuals at risk 
post haste.   
 
The value of a multi-disciplinary approach in the treatment of IR in TB patients would thus be of critical 
importance because it would allow for medical, nutritional and other forms of therapy to aid in the 
‘reversal’ or deceleration of the IR state, thus inhibiting the progression of TB disease and other IR-
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2.1          AIMS AND OBJECTIVES  
 
2.1.1     Aim 
 
The aim of this study was to determine if there is an association between tuberculosis and the 
development of insulin resistance in adults with pulmonary tuberculosis (PTB) in the Western Sub-
district of the Cape Metropole region.  
 
2.1.2        Objectives 
 
2.1.2.1 Primary objectives  
 To assess if IR was present in participants with PTB through the testing of the following parameters:  
o Anthropometry  
o Biochemistry and blood pressure  




2.1.2.2 Secondary objectives  
 To assess changes in anthropometrics and body composition at baseline and follow-up periods 
 To assess changes in biochemistry and blood pressure at baseline and follow-up periods 
 To assess changes in IR status at baseline and follow-up periods 
 To assess changes in sputum TB results at baseline and follow-up periods 
 To determine the relationship between IR status and sputum TB results at baseline and follow-up 
periods 
 To assess differences between IR and non-IR participants  
 To assess differences between sputum smear-negative and smear-positive participants   
 
A conceptual framework of the current study is depicted in Figure 2.1 and highlights the study population, 
as well as the data collected from participants. 
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IR = insulin resistance; PTB = pulmonary tuberculosis; HIV = human immunodeficiency virus; BMI = body mass index; CRP = C-
reactive protein; HOMA-IR = homeostasis model assessment–insulin resistance; QUICKI = quantitative insulin sensitivity check index 
 
Figure 2.1: Conceptual framework of study 
 
BI-DIRECTIONAL RELATIONSHIP? 
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2.2       RESEARCH QUESTION  
 
Are adults above the age of 18 years in the Western Sub-district of the Cape Metropole Region, with 
newly diagnosed PTB, at risk of developing insulin resistance?  
 
 
2.3        HYPOTHESES 
 
2.3.1 Primary Hypotheses 
 
 There is no difference in anthropometrics or body composition in adults with PTB at baseline and 
follow-up periods  
 There is no difference in biochemistry in adults with PTB at baseline and follow-up periods  
 There is no difference in blood pressure in adults with PTB at baseline and follow-up periods  
 There is no difference in IR status (via HOMA-IR/QUICKI) in adults with PTB at baseline and follow-
up periods  
 There is no difference in sputum TB results in adults with PTB at baseline and follow-up periods 
 
2.3.2     Secondary Hypotheses  
 
 There is no difference in anthropometrics, body composition, blood pressure or sputum results 
between IR and non-IR adults with PTB at baseline 
 There is no difference in anthropometrics, body composition, blood pressure or IR status between 
smear-negative and smear-positive adults with PTB at baseline  
 
 
2.4        STUDY PLAN  
 
2.4.1     Study Type  
 
A descriptive, cross-sectional study was undertaken. Due to the follow-up component of the study, a 
prospective cohort sub-section study was also performed. All data collected was quantitative in nature.  
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2.4.2     Study Population  
 
The study population consisted of 59 ambulatory adult participants, who were enrolled in the study over 
a period of 17 months. Participant recruitment and concomitant data collection began in August 2013 
and was completed in December 2014. The initial period of data collection was estimated to be 
approximately 10 months in duration. However, due to slower than expected recruitment rates, this was 
noticeably prolonged.  
 
All eligible participants were recruited from the Albow Gardens clinic, by means of non-random, 
convenience sampling, during the collection period mentioned above. The clinic in question is under 
management of the City of Cape Town (CoCT), which fell under the local government of the Western 
Cape Province of South Africa. The initial proposed data collection site was not allowed access to by 
the Western Cape Department of Health (DoH) due to structural issues, which led to the researcher 
using the Albow Gardens facility. Use of the latter facility was subsequently approved by the CoCT and 
the Health Research Ethics Committee (HREC) of Stellenbosch University (SU). (See Chapter 2.8: 
Ethical and Legal Considerations).  
 
Recruitment and screening of all participants was done on a weekly basis at the clinic by the principal 
researcher. Participants were identified and subsequently screened for compliance with the inclusion 
criteria for the study (See Chapter 2.5: Inclusion and Exclusion Criteria). Clinic staff also assisted with 
identification of new cases wherever possible.  Participants were only deemed eligible for involvement 
in the study once all inclusion criteria were met and written informed consent was obtained (See Chapter 
2.8: Ethical and legal considerations).  
 
Data collection was performed a short distance away from the clinic, at the local TB hospital, Brooklyn 
Chest. This institution is under management of the provincial government of the Western Cape, namely 
the DoH. The majority of the data collection was completed by the principal researcher, and included 
administrative aspects (explanation and signing of informed consent, completion of data collection 
sheets (See Addendum D for data collection sheet), as well as performing the anthropometry 
measurements. A different venue to the recruitment site was arranged as to alleviate any burden placed 
on the clinic, as both space limitations and personnel shortages did not allow for effective data collection 
and participant comfort and confidentiality. The distance between the two facilities did not pose a 
problem, as it is standard practice for participants to move between the two sites (either by foot, private 
vehicle or public transport) if further investigations are needed. Once at the hospital, a separate facility 
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[TASK Applied Science TB research site– affiliated to Stellenbosch University (SU)] made their premises 
and trained personnel available to the researcher, as to not overload the hospital personnel.  
 
Participants were selected for inclusion into either Group 1 (baseline measurements) or 2 (follow-up 
measurements) of the study. It was decided to include the first 30 participants that were recruited into 
Group 2, to reduce the duration of data collection. These selected participants were thus seen at 
baseline, two months and five months after treatment commencement. These follow-up dates were pre-
selected during the planning stages of the study to coincide with the sputum follow-up dates at the clinic, 
in the hope of alleviating some of the loss to follow-up. Participants were also continually reminded of 
their return visits during the five month follow-up period, by means of telephone calls, mobile phone 
texts and home visits.  
 
2.4.3   Sample Size  
 
For statistical purposes, the total number of participants needed for the baseline aspect of the study 
(Group 1 and 2), was determined to be 60 participants. This was calculated using the estimation of a 
proportion with a 95% confidence interval and a precision/percentage error of 12.7%.  
 
Furthermore, samples of size n=30 for the both Group 1 and 2 were intended to yield a power of 90% 
and detect an effect size of δ=0.64 [root mean square standardized effect (RMSSE)]. An effect size of 
δ=0.25 is regarded as small, δ=0.75 is regarded as medium and δ=1.25 is regarded as large. However, 
due to the loss of one of the original participants from the follow-up group in the final stages of data 
collection, Group 2 was reduced to 29 participants (See Chapter 3.1: Study population).  
 
Sample size for Group 1 (n=30) therefore yielded a power of 90% and an effect size of δ=0.61 (RMSSE), 
whilst Group 2 (n=29) had an effect size of 0.62 (RMSSE). Therefore, a smaller than medium effect size 
could thus be determined with a sample size used in the study, which would allow the researcher to 
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2.5       INCLUSION AND EXCLUSION CRITERIA 
 
Participants were included in the study if the following criteria were met:  
 Males and females between the ages of 18 and 65 years  
 Participants with newly diagnosed PTB, diagnosed via any of the following methods: 
o Molecular Testing [Gene Xpert (GXP) – PCR testing]  
o Microbiological (Sputum smear-positive swabs - AFB smears or cultures)  
o Radiography (Chest X-ray) 
o Clinical (productive cough >2-3 weeks; weight loss; fever; night sweats) 
 Newly registered participants – commencing with a first course of TB treatment  
 Participants placed on the standard baseline treatment protocol in accordance with CoCT / DoH 
guidelines 
 Participants attending Albow Gardens clinic  
 HIV-negative individuals  
 Participants having given informed consent  
 Participants willing to provide blood samples  
 
Any potential participants who were found to have an unknown HIV-status were encouraged to undergo 
HIV counselling and testing (HCT). Re-evaluation for study participation was then investigated if a 
participant had a negative HIV-status after undergoing HCT.  
 
Participants were excluded from the study due to the presence of any of the following:  
 Individuals who were unable to speak/understand either English, Afrikaans or isiXhosa 
 HIV-positive individuals (regardless of HIV treatment regime) or those of unknown status  
 Individuals with any other form of TB (i.e. EPTB) 
o Abdominal  
o Military  
o TB meningitis 
o Pleural effusion  
o Multi drug resistant (MDR) or extensively drug resistant (XDR) TB  
 Individuals with any pre-disposing IR conditions  
o Diabetes mellitus  
 Fasting blood glucose levels >7 mmol/L 
 Random blood glucose levels >11.1 mmol/L 
 Those with confirmed type 1 or 2 diabetes (with or without medication) 
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o Polycystic ovarian syndrome (PCOS) 
o Metabolic syndrome  
o Pregnancy  
 Individuals with severe underlying disease 
o Renal insufficiency  
o Cardiac insufficiency  
o Cancer, etc.  
 Individuals with an increased BMI ≥30 kg/m2 (i.e. obese individuals)* 
 Individuals with an increased waist circumference* 
o Males >102 cm 
o Females >88 cm  
 Individuals making use of any medications affecting IR status / glucose metabolism 
o Corticosteroids  
o Certain antipsychotic agents 
 Any conditions affecting weight profile of patient     
o Pregnancy  
o Ascites  
o Oedema  
o Organomegaly  
o Tumours 
o Other forms of fluid retention  
 Any conditions affecting body composition studies  
o Limitations for skinfolds 
 Participants directly post-exercise 
 Overheating 
 
* Screening anthropometry was primarily obtained from the patient’s folder (BMI), and additionally during face-to-
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2.6      METHODS OF DATA COLLECTION  
 
2.6.1    General Information  
 
Data was gathered for every potential patient for each of the following:  
 Age  
 Gender 
 Anonymous clinic folder number  
 Diagnosis [according to the 10th revision of the International Statistics of Diseases and related Health 
Problems (ICD-10 codes)] 
 HIV-status  
 Treatment commencement date  
 Sputum results (baseline, two and five months – if available) 
 Contact details (mobile number, telephone number and/or home address) 
 
Age and gender were obtained in order to describe patient demographics, whilst diagnosis, HIV-status 
and treatment commencement dates were gathered to ensure compliance with inclusion criteria. Patient 
privacy was ensured by the use of an anonymous folder number, but also allowed the researcher access 
to the linked records at the facility. Contact details were recorded for the follow-up participants, as to 
facilitate reminder telephone calls and/or home visits.  All other recorded variables formed part of the 
data collection panel outlined by the researcher (See Chapter 2.6.3: Data Collected from Participants 
once Enrolled in Study).  
 
2.6.2   Recruitment Process  
 
As previously mentioned, recruitment of participants from Albow Gardens clinic was performed on a 
weekly basis by the principal researcher. Potential participants were identified according to new 
admissions in the facility’s TB register, as well as faxed sputum results from the National Health 
Laboratory Service (NHLS). Participant’s clinic folders were then screened for compliance with the 
inclusion criteria for the study.  
 
The researcher made contact with the potential participants, either via a face-to-face encounter if the 
person was present at the clinic at the time of the researcher’s recruitment visit, or otherwise, by means 
of a telephone call.  Participants were subsequently given an appointment date and time to report to the 
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clinic and required to have undergone an overnight fast of ten hours to accommodate the biochemical 
testing. Participants recruited for the study were enrolled within a maximum time frame of two weeks 
after notification and/or treatment initiation, due to logistical issues and not desiring treatment to be a 
confounding factor.   
 
2.6.3   Data Collected from Participants once Enrolled in Study   
 
2.6.3.1    Anthropometry  
 
The following anthropometrical data was collected and/or calculated for each of the study participants: 
 Weight 
 Height 
 Body mass index (BMI) 
 Waist circumference (WC) 
 Hip circumference  
 Waist:hip ratio (WHR) 
 Elbow width (frame size) 
 Body composition via skinfolds (triceps, biceps, subscapular, suprailiac)  
 
2.6.3.1 (a)  General  
 
All anthropometrical measurements were performed by the principal researcher. There was, therefore, 
no need for standardisation of field workers. The researcher is a registered dietician (RD) and was 
adequately experienced to perform the above measurements.  
 
The average of three measurements was taken for weight, height, waist and hip circumferences, as well 
as skinfold measurements. Height and elbow width were the only two variables to be measured at 
baseline, whilst all remaining anthropometrical measurements were performed at all follow-up visits. 
The BMI and waist:hip ratio were subsequently calculated once the necessary variables had been 
measured.  
 
The calibrated beam-balance scale and fixed stadiometer were the property of the TASK Applied 
Science TB research site at Brooklyn Chest Hospital. The non-stretch tape-measure, elbow width 
calliper and skinfold calliper were the property of the principal researcher.  Privacy of participants was 
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ensured by performing all measurements separately in an isolated room at the TASK site. The 
measurements were all carried out during normal working hours, in accordance with operating hours of 
the facility.  
 
2.6.3.1 (b)  Weight 2 
 
Body weight was recorded for each participant at each visit with the help of a calibrated, beam-balance 
scale. The participant was instructed to remove any unnecessary clothing and was weighed with the 
least amount of clothing possible. The participant was required to stand stationary and unassisted on 
the scale platform, with their weight firmly distributed on both feet. The measurement was read to the 
nearest 0.1kg.  
 
2.6.3.1 (c)   Height 2 
 
A fixed stadiometer was used to measure the height of each participant at the baseline visit. The 
participant was instructed to remove their shoes/socks and anything covering their heads before the 
measurement was taken. The participant was asked to place the heels of the feet together, with the legs 
straightened, arms to the side and relaxed shoulders. The head was positioned in the Frankfurt 
horizontal plane. The participant was requested to inhale before the measurement was taken to facilitate 
an accurate measurement. The headboard of the stadiometer was lowered onto the highest point of the 
head, with sufficient pressure to compress the hair. The measurement was recorded to the nearest 
0.1cm.  
 
2.6.3.1 (d)   BMI 2 
 
This index was calculated for each participant by dividing the weight in kilograms (kg) by the height in 
metres squared (m2). Each participant was classified according to Table 2.1 which depicts all the 
possible BMI classification categories. Participants in this study were however excluded if they had a 
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Table 2.1: BMI classification – World Health Organization281 
 
Interpretation BMI Classification (kg/m2) 
Severe Thinness (Grade 3 Malnutrition) <16.00 
Moderate Thinness (Grade 2 Malnutrition) 16.00 – 16.99 
Mild Thinness (Grade 1 Malnutrition) 17.00 – 18.49 
Normal range 18.50   - 24.99 
Overweight (Pre-obese) 25.00 – 29.99 
Class I Obesity 30.00 – 34.99 
Class II Obesity 35.00 – 39.99 
Class III Obesity ≥ 40.00 
   
     BMI = body mass index  
 
2.6.3.1 (e)  Waist circumference 282 
 
A non-stretchable tape measure was used to determine the waist circumference of each participant. 
The participant was measured with no clothing covering the abdomen. The participant was instructed to 
stand upright, with his/her arms at the sides, feet together and abdominal muscles relaxed. The 
measurement was taken horizontally around the abdomen halfway between the last rib and the ileac 
crest. The measurement was taken after maximum exhalation, and the tape-measure fitted tightly 
around the abdomen, without compressing the skin. The measurement was recorded to the nearest 
0.1cm.  
 
Participants were classified according to the cut-off points shown in Table 2.2 below.  
 
Table 2.2: Waist circumference classification - World Health Organization282 
 
Waist circumference classification Female Male 
Increased >80 cm >94 cm 
Substantially increased >88 cm >102 cm 
 
2.6.3.1 (f)  Hip circumference 282 
 
The same non-stretchable tape measure used for the waist circumference was utilised for the hip 
circumference measurement. The participant was requested to remove any excess clothing around the 
hip area, and stand upright with his/her arms at the side and feet together. The measurement was taken 
in a horizontal position, at the widest part of the greater trochanters. The tape measure fit tightly around 
the hips, but did not compress the skin. The measurement was recorded to the nearest 0.1 cm.  
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2.6.3.1 (g)  Waist:hip ratio 282 
 
This ratio was calculated by dividing the waist circumference (cm) by the hip circumference (cm).282 
Study-specific cut-off points for this variable are shown below in Table 2.3. 
 
Table 2.3: Waist:hip ratio classification - World Health Organization282 
 
Interpretation Female Male 
Normal <0.80:1 <0.90:1 
At risk ≥0.85:1 ≥0.90:1 
 
 
2.6.3.1 (h)  Frame size 2 
 
This variable was determined by the use of an elbow width measurement. The participant was requested 
to stand upright, with his/her right arm held up perpendicularly to the body. The forearm was flexed to 
allow the elbow to form a 90° angle. The participant’s fingers were turned upward, with the palm facing 
the participant. A specialised elbow width calliper was used to measure between the lateral and medical 
epicondyles of the humerus. The soft tissue was compressed by the calliper and the measurement was 
read to the nearest 1 mm.  
 
Frame size was then classified according to the elbow width and height of each participant by making 
use of Table 2.4. 
 
Table 2.4: Elbow width classification for males and females of various heights2 
 
Height (cm) Small frame Medium frame Large frame 
Males    
155 - 158 <64 mm 64 – 73 mm         >73 mm 
159 - 168 <67 mm 67 – 73 mm >73 mm 
169 - 178 <70 mm 70 – 76 mm >76 mm 
179 - 188 <70 mm 70 – 90 mm >79 mm 
≥ 189 <73 mm 73 – 83 mm >83 mm 
    
Females    
145 - 148 <57 mm 57 – 64 mm >64 mm 
149 - 158 <57 mm 57 – 64 mm >64 mm 
159 - 168 <60 mm 60 – 67 mm >67 mm 
169 - 178 <60 mm 60 – 67 mm >67 mm 
≥179 <64 mm 64 – 70 mm >70 mm 
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2.6.3.1 (i)  Body composition via skinfolds  
 
i)       Skinfolds – General  
All measurements were taken on the right hand side of the body. Each skinfold measurement (consisting 
of both skin and subcutaneous fat) was grasped approximately 1 cm above the mark indicating the 
skinfold site, and the skinfold was grasped between the thumb and index finger of the left hand. The 
skinfold calliper was calibrated to zero before each measurement was taken, and blades were placed 
in the middle of the base and top of the skinfold. The calliper dial faced upwards and the researcher was 
careful to read the measurement approximately two to three seconds after releasing the blades. The 
researcher also maintained pressure whilst holding the skinfold for the duration of the measurement. An 
interval of 15 seconds was allowed between measurements to allow the skinfold site to return to normal. 
Each reading was recorded to the nearest 1 mm.2 
 
ii)   Triceps skinfold  
The researcher carefully calculated the middle point of the right arm, by measuring midway between the 
lateral projection of the acromion process of the scapular and the inferior margin of the olecranon 
process of the ulna. The elbow was bent at a 90° angle and the palm of the participant’s hand faced 
upwards. The triceps skinfold measurement was taken on the posterior side of the right arm, over the 
triceps muscle. The measurement was taken at the same level as the midpoint of the arm, with the arm 
hanging loosely at the side. The skinfold was taken parallel to the vertical axis of the arm.2 
 
iii)    Biceps skinfold  
The midpoint of the arm was also used in the measurement of this skinfold. The participant was seated 
for the biceps skinfold, with the right arm resting on the participant’s leg and the palm facing upwards. 
The measurement was taken on the anterior side of the right arm, over the biceps muscle. The skinfold 
was taken at the same level as the midpoint of the arm and ran parallel to the vertical access of the 
arm.2 
 
iv)    Subscapular skinfold  
The participant stood in an upright position, with his/her arms hanging loosely at the sides and feet 
together. The measurement was taken 1cm below the inferior angle of the scapular on the right hand 
side. The skinfold was taken at a 45° angle, and the skin was grasped 1 cm above and medial to the 
side along the axis.2 
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v)    Suprailiac skinfold  
The participant stood in an upright position, with his/her feet together and the left arm hanging loosely 
at their sides. The right arm was folded across the chest, to ensure that it did not impede the skinfold 
measurement. The measurement was taken 2 cm above the ileac crest, in the mid-axillary line, on the 
right hand side of the participant’s body. The skinfold ran diagonally forward.2 
 
vi)    Analysis of skinfold measurements 
Skinfolds were calculated using the average of each of the three measurements taken for the triceps, 
biceps, subscapular and suprailiac skinfolds. Certain skinfolds (triceps, subscapular and sum of triceps 
and subscapular) were interpreted according to standardised reference tables (percentile charts) and 
frame size, whereby appropriate classifications were made.2 
 
vii)     Body density  
Body density was computed in order to indicate the percentage body fat of each patient. The sum of the 
four skinfolds mentioned above was entered into the age and gender appropriate formula depicted in 
Table 2.5 and the subsequent body density (D) calculated.283  
 
Table 2.5: Equations for determining body density (D) according to age and gender283  
 
   * Σ4SKF = Sum of 4 x skinfolds (triceps, biceps, subscapular, suprailiac) in mm 
 
viii) Body fat percentage  
Upon calculation of the body density (D) value, the fat mass of each participant was calculated according 
to the following equation:284 
 
Fat mass (kg) = weight (kg) x [4.95/D – 4.5] 
 
The percentage body fat was then calculated according to the following equation:284 
 
% Body fat = [fat mass (kg) / weight (kg]) x 100 
 
Men: Women: 
17 - 19 years D = 1.1620 – 0.0630 X (log Σ4SKF*) 17 - 19 years D = 1.1549 – 0.0678 X (log Σ4SKF*) 
20 - 29 years D = 1.1631 – 0.632 X (log Σ4SKF*) 20 - 29 years D = 1.1599 – 0.0717 X (log Σ4SKF*) 
30 - 39 years D = 1.1422 – 0.0544 X (log Σ4SKF*) 30 - 39 years D = 1.1423 – 0.0632 X (log Σ4SKF*) 
40 - 49 years D = 1.1620 – 0.0700 X (log Σ4SKF*) 40 - 49 years D = 1.1333 – 0.0612 X (log Σ4SKF*) 
50+ years D = 1.1715 – 0.0779 X (log Σ4SKF*) 50+ years D = 1.1339 – 0.0645 X (log Σ4SKF*) 
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Once this percentage value was obtained, it was interpreted according to the values shown in Table 
2.6.   
 
Table 2.6: Normal values for percentage body fat in adults2 
 
 
2.6.3.2      Biochemistry  
 
The following biochemical data was collected for each of the study participants at baseline and 
subsequent follow-up visits: 
 Serum albumin  
 White cell count (WCC) 
 Fasting glucose 
 Fasting insulin  
 C-reactive protein (CRP) 
 Lipid profile  
o Triglycerides  
o Total serum cholesterol  
o LDL–cholesterol  
o HDL–cholesterol  
 
Males: 
Age (years) Underweight  Slim Satisfactory Heavy Excessive 
20-29 ≤7 8-11 12-18 19-24 ≥25 
30-39 ≤7 8-15 16-20 21-25 ≥26 
40-49 ≤10 11-18 19-22 23-25 ≥26 
50-59 ≤10 11-18 19-22 23-25 ≥26 
60-69 ≤10 11-18 19-23 24-25 ≥26 
70+ ≤10 11-18 19-21 22-25 ≥26 
 
Females: 
Age (years) Underweight Slim Satisfactory Heavy Excessive 
20-29 ≤20 21-25 26-30 31-33 ≥34 
30-39 ≤20 21-26 27-29 30-34 ≥35 
40-49 ≤20 21-28 29-32 33-37 ≥38 
50-59 ≤24 25-29 30-34 35-38 ≥39 
60-69 ≤24 25-30 31-33 34-37 ≥38 
70+ ≤21 22-28 29-33 34-36 ≥37 
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Table 2.7 depicts the necessary samples and equipment needed for the biochemical analysis of the 
above tests.  
 





Equipment used in analysis Serum vs. 
plasma sample 
Quantity of sample needed 
Albumin  Siemens Advia 1800 Serum 1 yellow top tube (4 – 5 ml) 
White cell count Siemens Advia 2120 Plasma  1 purple top tube (4 – 5 ml) 
Glucose (fasting) Siemens Advia 1800 Plasma 1 grey top tube (1 ml) 
CRP  Siemens Advia 1800 Serum 1 yellow top tube (4 – 5 ml) 
Lipid profile  Siemens Advia 1800 Serum 1 yellow top tube (4 – 5 ml) 
LDL-cholesterol  Friedewald formula (using total 






Insulin  Siemens Centaur XP Serum (spun and 
frozen as soon 
as possible) 
1 yellow top tube (50 
microlitres) 
    
  CRP = C-reactive protein; LDL = low density lipoprotein 
The above phlebotomy samples were taken by a professionally trained nursing sister employed by the 
TASK Applied Science TB research site. Blood samples were all collected on the morning of data 
collection after a ten-hour overnight fast. After the blood samples were drawn, the principal researcher 
transported them in suitable and secure containers, under the correct storage conditions (carefully 
ensuring samples were not haemolysed), to the laboratory at Tygerberg Academic Hospital (TAH). The 
laboratory is administered by the NHLS. Samples were duly analysed and results were conveyed via 
email to the researcher for capturing of data (See Addendum E for a copy of the form used for the 
NHLS). Blood volumes used for the biochemistry panel above were in line with normal quantities used 
in government health facilities across the country (did not exceed 15 ml per draw). There was, therefore, 
no additional ethical risk posed to participants enrolled in the study, as larger volumes of blood were not 
necessary, which is in line with guidelines in this regard.285,287 
The methods utilised in the analysis of biochemical markers by the NHLS for this study are detailed in 
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Table 2.8: Methods used in the analysis of biochemical markers288    
 
Biochemical marker  Method/s  
Insulin  A serum sample to determine fasting insulin was used and the 
sensitivity/assay range fell between 0.1 – 300 mU/L 
 The assay used was the ADVIA Centaur® Insulin Lite Reagent and Solid 
Phase 
Albumin   This substrate was tested by means of using bromocresol green solution 
(BCG) as a binding dye and required a human serum and plasma sample 
Cholesterol   This method is based on an enzymatic method that makes use of 
cholesterol esterase and cholesterol oxidase conversion, followed by a 
Trinder endpoint 
 It also makes use of a human serum and plasma sample 
Direct HDL-cholesterol  This method was used to quantify the HDL-cholesterol value and consisted 
of two steps 
 (1) Separate all the ‘non-HDL’ particles from the sample  
 (2) Allow specific measurement of HDL-cholesterol 
 This was also measured in the serum and plasma 
Triglycerides  This method is based on the Fossati three-step enzymatic reaction, 
utilizing a Trinder endpoint  
 A human serum and plasma sample is also needed and was analysed by 
the ADVIA chemistry system  
 
  HDL = high density lipoprotein 
 
The following cut-off points shown in Table 2.9 were used to classify biochemical values as normal, 
increased or decreased.  
 
Table 2.9: Biochemical reference ranges – National Health Laboratory Services289 
 
Biochemical value Normal range  
Albumin  35 – 52 g/L 
White cell count 4.0 – 10 x 10^9/L 
Fasting plasma glucose 4.1 – 5.9 mmol/L 
Fasting insulin  3.0 – 25 mU/L 
CRP 0.0 – 10 mg/L 
Lipid profile   
Total cholesterol ≤5mmol/L 
Triglycerides  0.5 – 1.5 mmol/L 
Cardiovascular risk stratification and cholesterol targets  
 Category 1 risk* Category 2 risk** 
Cholesterol <4.5 <5.0 
Triglycerides <1.7 <1.7 
HDL-cholesterol (males) >1.0 >1.0 
HDL-cholesterol (females) >1.2 >1.2 
LDL-cholesterol <2.5 <3.0 
 
   CRP = C-reactive protein; HDL = high density lipoprotein; LDL = low density lipoprotein 
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*Category 1 Risk289 
 Established atherosclerosis  
 Coronary heart disease 
 Peripheral vascular disease 
 Diabetes type 2 
 Diabetes type 1 with micro-albuminuria or proteinuria  
 Genetic dyslipidaemias e.g. Familial hypercholesterolaemia 
 
**Category 2 Risk289 
 Primary prevention and all other categories of dyslipidaemia  
 
In addition, the latest South African dyslipidaemia guidelines suggest the following for an initial ten-year 
CVD event risk (Table 2.10). 
 
Table 2.10: LDL-cholesterol goals relating to 10-year cardiovascular disease event risk290 
 
Cardiovascular disease event risk LDL-cholesterol target 
<15% ten-year CVD event risk <3.0 mmol/L 
15% - 30% ten-year CVD event risk <2.5 mmol/L 
>30% ten-year CVD event risk <1.8 mmol/L 
   
  LDL = low density lipoprotein; CVD = cardiovascular disease 
 
2.6.3.3   Blood pressure291 
 
The blood pressure of each participant was taken by the same registered nurse responsible for the 
phlebotomy testing. This was done according to standardised methods as each participant was seated 
and relaxed, whilst the nursing sister placed an inflatable cuff around in the brachial artery of the arm. 
This cuff was then inflated until the pressure in the cuff surpassed that of the artery. The nurse then 
listened for the presence of Korotkoff sounds, with the first sound indicative of the systolic blood pressure 
and the subsequent disappearance of Korotkoff sounds signalled the diastolic blood pressure reading. 
Measurements were performed by the on-site sphygmomanometer belonging to the TASK Applied 
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Table 2.11: Classification of blood pressure in adults292 
 
Classification Blood Pressure (mm Hg) 
Normal <120/80 
Pre-hypertension 120 - 139 / 80 - 89 
Stage 1 140 - 159 (systolic)  /  90 – 99 (diastolic) 
Stage 2 ≥160 (systolic) or ≥100 (diastolic) 
 
 
2.6.3.4   HOMA-IR and QUICKI measurements 
  
The HOMA-IR diagnostic test was performed according to the following formula:7  
 
Fasting serum insulin (µU/ml) x fasting plasma glucose (mmol/L) / 22.5 
 
The denominator (constant) of the above equation refers to the normalisation (based on normal fasting 
values). Laboratory values reported glucose values in mmol/L, whilst serum insulin values were reported 
in mU/L. The latter is not problematic as this equates to the same value when converting to µU/ml.285  
 
The QUICKI measurement is simply the inverse logarithm of the HOMA-IR calculation, namely:20  
 
1 / (log(fasting insulin µU/ml) + log(fasting glucose mg/dL)) 
 
In order to convert the glucose value from mmol/l to mg/dL, a conversion factor of 18.018 was used. 
(I.e. 1 mmol/L = 18.018 mg/dL or mg/dL x 0.0555 = mmol/L).285 
 
The above formulae were entered into a Microsoft Excel spreadsheet and subsequent values were 
determined. As there is currently no standardised cut-off point for either the HOMA-IR or the QUICKI 
measurement, the data generated by this study was used to calculate a relevant HOMA-IR cut-off point. 
This was based on the lower limit of the upper quartile (P75), as has been performed in similar 
studies.293-296  
 
Once the HOMA-IR cut-off had been calculated, the corresponding QUICKI value was determined by 
means of a receiver operating characteristic (ROC) curve analysis. Any individual having a HOMA-IR 
value greater than the calculated cut-off point, as well as below the QUICKI cut-off point, classified a 
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participant as having possible IR. The HOMA-IR was used as the primary tool for identifying IR and the 
QUICKI was calculated to reinforce or compare results.  
 
2.6.3.5   Sputum results  
 
The baseline sputum (smear result) of each participant was recorded as part of the eligibility screening 
performed by the researcher. Results were classified via ZN staining (as shown in Table 1.2). 
Participants that had a positive sputum result at baseline were required by DoH / CoCT guidelines to 
have repeat sputum tests at two and five months after treatment commencement. These results (if 
available) were also recorded by the researcher.  
 
2.6.4   Reliability and Validity  
 
2.6.4.1   Anthropometry  
 
Reliability of anthropometric measurements was ensured by using a single, calibrated scale and a fixed 
stadiometer. The elbow width calliper, skinfold calliper and tape-measure used by the researcher for 
performing measurements were used throughout the duration of data collection. Reliability was further 
ensured through the use of the standardised measuring techniques explained above and taking the 
average of three measurements for the majority of variables. All of the anthropometrical measurements 
were performed by the principal researcher, therefore ensuring the absence of inter-observer variation.  
 
Validity of body weight was ensured via adequate and regular calibration of the available scale. Formal 
calibration was performed by the TASK site on an annual basis and informal calibration was done by 
the researcher on a weekly basis by means of a known 1 kg and 10 kg weight.  
 
2.6.4.2    Biochemistry  
 
The analysis of biochemical samples was performed by the NHLS throughout the duration of the study. 
The NHLS is a South African National Accreditation System (SANAS) accredited laboratory and all the 
tests that were requested by the researcher appeared on the accreditation schedule of the NHLS. South 
African National Accreditation System accreditation stipulated strict proof of laboratory performance and 
documentation of all procedures in accordance with pre-set standards. Quality controls were run on an 
internal daily basis at six, eight or twelve hourly, depending on the sample under analysis. The laboratory 
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2.7 DATA ANALYSIS  
 
2.7.1   General  
 
Socio-demographic data was recorded on the specially designed data capturing form (Addendum C). 
Participant anthropometrical data and blood pressure values were also captured on this form. Results 
of the socio-demographic portion of the study (age and gender distributions) are graphically depicted in 
the results section (Chapter 3). Biochemical results were received electronically via email (researcher’s 
work email address, to which only she had access).  
 
Variables were recorded as continuous values for all measurements and basic descriptive statistics 
were used to identify trends and associations. This was done as differences among groups for certain 
variables (such as BMI), are more easily identified if the data is recorded in its continuous form, as 
opposed to categorical data.  
 
Data was also transformed into categorical data at a later stage in order to assess for inter-group 
changes and to identify risk of IR development.  
 
The relevant cut-off points for variables (anthropometrical, biochemical, blood pressure, HOMA-IR/ 
QUICKI etc. are depicted in Chapter 2.6.3).    
 
2.7.2   Statistical Analysis 
 
The researcher was assisted during the planning and statistical analysis stages by a statistician 
assigned by the Division of Human Nutrition of the University of Stellenbosch. Once data had been 
recorded on the data capturing sheet, it was captured onto a designed Microsoft Excel spreadsheet and 
duly submitted to the statistician for assistance with analysis. STATISTICA version 12 (StatSoft Inc. 
(2014) STATISTICA (data analysis software system, www.statsoft.com) was used to analyse the data.  
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Summary statistics were used to describe variables such as participant demographics. Distributions of 
variables were presented with frequency tables and/or histograms. Medians or means were used as 
measures of central location for ordinal and continuous responses and standard deviations and quartiles 
as indicators of spread.  
 
The relationship between two continuous variables (such as weight and BMI) was analysed with 
regression analysis and the strength of the relationship measured with Pearson correlation or Spearman 
correlation (if continuous variables were not normally distributed).  
 
The relationship between continuous response variables and nominal input variables (i.e. weight and 
gender), was analysed using appropriate analysis of variance (ANOVA) and appropriate repeated 
measures analysis of variance (RMANOVA) when responses were measured at specific time intervals. 
Variables were included as co-variates in appropriate analysis of covariance (ANACOVA) to account for 
possible confounding variables (e.g. age).  
 
Non-parametric ANOVA methods were used when comparing ordinal response variables to a nominal 
input variable. The Mann-Whitney or Kruskal-Wallis tests were used for completely randomized designs. 
The relationship between nominal variables (such as gender and race) was investigated with 
contingency tables and appropriate chi-squared tests such as the Maximum-Likelihood (M-L) chi-square 
test or the McNemar test.  
 
Bootstrap procedures (a computer performed re-sampling procedure performed on current data) were 
used in cases where the residuals were not normally distributed.297 ROC curves were performed to 
calculate the corresponding QUICKI cut-off point at baseline. These analyses play a pivotal role in both 
the assessment and utilisation of various diagnostic tools, of which the HOMA-IR and QUICKI are two 
such examples.298 
 
A p-value of p<0.05 represented statistical significance in hypothesis testing and 95% confidence 
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2.8     ETHICAL AND LEGAL CONSIDERATIONS  
 
Initial ethical approval was granted by the HREC of SU for the study in October 2012 (Project number: 
S12/08/227). Due to problems experienced with gaining approval from the DoH for the initial study site 
(Delft Community Health Centre), an amended research proposal with a different recruitment site, 
namely Albow Gardens clinic, was submitted and approved in April 2013 (Addendum F). The TASK 
Applied Science TB research site (affiliated to SU) also granted the researcher permission to conduct 
the data collection on their premises at Brooklyn Chest Hospital, use their afore-mentioned equipment 
and utilise the services of their nursing personnel.  
 
A detailed research proposal and application package was submitted to the City of Cape Town 
regulatory body. Permission was granted by the CoCT to recruit participants from Albow Gardens clinic 
in April 2013 (Addendum G). The facility manager/s at both the clinic and TASK site were well informed 
of the study and researcher intentions (See Addendum H for a copy of facility request letter).  
 
Participants were required to give written informed consent prior to data collection (See Addendum I for 
informed consent forms in English, Afrikaans and isiXhosa). A short overview of the study and 
explanation of the consent form was shared with all participants prior to commencement of data 
collection. Provision was made for illiterate participants, as they were allowed to provide a thumbprint 
as an alternative to a signature. Consent forms were available in English, Afrikaans and isiXhosa in 
order to accommodate the language preference of participants. An interpreter was available on request 
of the participant if they were unable to understand the written consent form. Any significant 
modifications made to the consent form would necessitate re-signing of the forms but this was not 
necessary at any stage of this study. Participants were provided with personalised copies of the consent 
form to keep for their records.  
 
The privacy and confidentiality of each participant was ensured by the researcher at all times during the 
study by making use of an anonymous approach. This was achieved as participant names were not 
recorded, although each person was issued with a unique identification number for the duration of the 
study (i.e. a randomly allocated facility folder number). This identification number was used on all data 
capturing sheets, NHLS forms/phlebotomy samples and Excel spreadsheets. In addition, data was 
securely stored by the researcher and confidentiality of information was thus ensured. The researcher 
was the sole person who had access to this privileged information.  
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Participants were also compensated for their transport costs and missed working hours according to 
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3.1    STUDY POPULATION  
 
Fifty-nine (n=59) participants were enrolled in this study out of a possible 504 admissions (11.7%) to the 
Albow Gardens clinic during the period August 2013 to December 2014. Figure 3.1 shows a detailed 
flow diagram depicting the inclusion of participants into the study.  
 
A slight loss to follow-up occurred during this study (n=8, 13.6%). This was due to mortalities, leaving 
the Western Cape Province or country without notifying the clinic/researcher, as well as general 
defaulting of TB treatment. The data collected from the above-mentioned eight participants (who had 
been seen once or twice out of a possible three visits) was then transferred to Group 1 and a new 
participant was sourced to replace those lost to follow-up. 
 
Unfortunately, within the last two weeks of official data collection in December 2014, the pen-ultimate 
follow-up participant defaulted his five-month appointment. It was decided that replacing this participant 
would result in an indefinite prolonging of the data collection period and research output, therefore, the 
follow-up group (Group 2) of participants was completed with 29, and not the originally desired 30, 
participants.  
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*Group 1 = Participants seen at baseline only; Group 2 = Participants seen at baseline, two and five months 
TB = tuberculosis; PTB = pulmonary tuberculosis; HIV = human immunodeficiency virus;  
BMI = body mass index; DM = diabetes mellitus 
 
Figure 3.1: Flow diagram for inclusion of study participants 
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3.2       DEMOGRAPHIC DATA  
 
3.2.1    Total Study Population (n=59) 
 
The main demographic data of the total study population is summarised in Table 3.1. Of the fifty-nine 
participants included in the total study population, the majority (n=48, 81.4%) were males whilst the 
remaining 18.6% (n=11) were females. The mean age for all participants was 33.95 (SD 12.02) years 
and the greatest number of study participants fell into the 18 – 30 year age category (n=32, 54.2%), with 
the fewest participants (n=12, 20.3%) found in the category of 46 - 65 years. With regard to racial 
distribution, the majority of participants were black African (n=36, 61.0%) whereas coloured participants 
consisted of 28.8% of the population (n=17) and white participants the remaining 10.2% (n=6).  
 
Table 3.1: Demographic characteristics of the total study population (n=59) 
 









Gender  n 
Male  32 (88.9%) 13 (76.5%) 3 (50.0%) 48 (81.4%) 
Female  4 (11.1%) 4 (23.5%) 3 (50.0%) 11 (18.6%) 
Age  n 
18-30 years 22 (61.1%) 8 (47.1%) 2 (33.3%) 32 (54.2% 
31-45 years 9 (25.0%) 5 (29.4%) 1 (16.7%) 15 (25.4%) 
46-65 years  5 (13.9%) 4 (23.5%) 3 (50.0%) 12 (20.3%) 
 
 
3.3       BASELINE ANTHROPOMETRY RESULTS  
 
3.3.1  Baseline Mean Values  
 
As expected, there were no significant differences seen between Groups 1 and 2 for the variables shown 
in Table 3.2 (anthropometry measurements), as well as the categorical variables (BMI classification, 
frame size, waist circumference classification, etc.). The two groups were, therefore, comparable.  
 
Table 3.2 provides a comprehensive overview of all gender-specific anthropometrical variables 
measured at baseline. As the participants were never stratified and / or recruited according to gender, 
any possible conclusions should be interpreted with caution.  
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Table 3.2: Baseline gender-specific anthropometry measurements of total study population 
(n=59) 
 







Weight  kg  57.70 (9.06) 48.14 (7.18) <0.01 32.80-83.00 
Height  m 1.72 (0.07) 1.56 (0.06) <0.01 1.49-1.88 
BMI  kg/m2 19.49 (2.46) 19.73 (3.11) 0.77 14.58-26.38 
Waist circumference  cm 71.0 (7.70) 71.0 (8.04) 0.84 58.80-99.20 
Hip circumference  cm 84.28 (6.50) 86.45 (9.90) 0.15 64.80-102.70 
Waist:hip ratio - 0.84 (0.07) 0.83 (0.08) 0.56 0.72-1.11 
Elbow width  cm 6.80 (0.36) 5.93 (0.23) <0.01 5.70-7.60 
Biceps skinfold  mm 2.69 (0.87) 4.91 (2.26) <0.01 1.60-8.00 
Triceps skinfold  mm 5.76 (2.73) 13.90 (6.02) <0.01 2.90-22.20 
Subscapular skinfold  mm 7.16 (2.70) 9.54 (4.37) 0.04 3.60-19.00 
Suprailiac skinfold  mm 5.07 (3.55) 7.48 (3.63) 0.01 2.60-20.90 
Sum of skinfolds  mm 20.69 (9.18) 35.83 (14.59) <0.01 10.90-66.10 
Body density  D 1.07 (0.01) 1.05 (0.01) <0.01 1.02-1.09 
Fat mass  kg 5.99 (3.78) 11.48 (4.49) <0.01 1.64-21.84 
Fat free mass  kg 51.71 (7.12) 36.66 (4.41) <0.01 27.00-76.89 
Percentage body fat  % 9.99 (4.96) 23.31 (6.56) <0.01 3.27-33.12 
 
  * Mann-Whitney U Test 
   SD = standard deviation; BMI = body mass index  
   Bold and shaded variables indicate statistical significance  
 
Upon consideration of Table 3.2 above, the majority of anthropometrical variables seem to differ 
significantly when assessing for the effect of gender. The only variables that showed no difference when 
factoring in gender were the BMI, waist circumference, hip circumference and the waist:hip ratio. Males 
displayed significantly higher measurements for weight, height, elbow width, body density and fat free 
mass, whereas their female counterparts showed significantly higher values for all four skinfold 
measurements, sum of skinfolds, fat mass and percentage body fat.  
 
3.3.2    BMI Classification  
 
The various BMI classifications of the total study population (n=59) are reflected in Figure 3.2. The figure 
shows that the majority of participants (n=36, 61.0%) enrolled in the study at baseline had a BMI in the 
normal range (18.50 - 24.99 kg/m2) according to WHO cut-off points. Thirty-three point nine percent of 
the participants (n=20) had a BMI of <18.5 kg/m2 at baseline. Although there were three participants 
(5.1%) who fell into the overweight BMI group (≥25 kg/m2), this was in line with the inclusion criteria of 
the study which excluded obese participants (BMI ≥ 30kg/m2) from recruitment. 
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BMI = body mass index 
 
Figure 3.2: Baseline BMI classification of total study population (n=59) 
 
 
3.3.3    Waist Circumference  
 
Of the total male study population, the majority (n=47, 97.9%) had a waist circumference that was 
classified as normal. The majority of female patients also had a normal waist circumference value (n=9, 
81.8%). This data can be seen in Table 3.3. A normal waist circumference for males is <94 cm, whilst 
for females it is <80 cm.  
 
 













<94 cm 48 n=47 (97.9%) <80 cm 11 n=9 (81.8%)  
>94 cm 48 n=1 (2.1%)  >80 cm 11 n=2 (18.2%) 






















BMI Classification  
Stellenbosch University  https://scholar.sun.ac.za







3.3.4     Waist:hip Ratio (WHR) 
 
Of the male participants in the total study population, the majority (n=35, 72.9%) had a normal WHR, 
whilst the female population showed a higher prevalence of an increased WHR (n=5, 45.5%). Table 3.4 
depicts these values, where a normal WHR for males is <0.90, whereas for females it is <0.85.  
 
 
Table 3.4: Classification of baseline waist:hip ratio cut-off points according to gender  
 
WHR (Males) Total n n (%) WHR (Females) Total n n (%) 
<0.90 48 n=35 (77.1%) <0.85 11 n=6 (54.5%)  
≥0.90 48 n=13 (22.9%)  ≥0.85 11 n=5 (45.5%)  
 
    WHR = waist:hip ratio 
 
3.3.5     Frame Size  
 
The majority of participants in the total study population (n=35, 59.3%) were classified as having a 
medium frame size, whilst the remainder (n=24, 40.7%) had a small frame size. There were no 
participants with a large frame size in the study population.  
 
3.3.6 Interpretation of Skinfolds  
 
Considering the actual skinfold measurements for triceps, subscapular and sum of triceps and 
subscapular skinfolds, as well as percentile distributions of the above, the skinfolds were interpreted in 
the following way at baseline: The majority of participants fell into the ‘lean’ category for interpretation 
of triceps skinfold (n=24, 40.7%), subscapular skinfold (n=31, 52.5%) and sum of triceps and 
subscapular skinfolds (n=28, 47.5%), followed by either the ‘below average’ or ‘average’ categories.  
 
3.3.7   Interpretation of Percentage (%) Body Fat  
 
The majority of study participants (n=30, 50.8%) fell into the ‘slim’ category when considering their body 
fat percentages. ‘Underweight’ participants were the second most frequent occurring category (n=20, 
33.9%), whereas only one participant fell into the ‘excessive body fat’ category (1.7%). These results 
are shown in Figure 3.3 below.  
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Figure 3.3: Baseline interpretation of % body fat of total study population (n=59) 
 
If comparing the interpretation of percentage body fat at baseline between genders, males presented 
with 56.3% (n=27) in the ‘slim’ category, followed by 33.3% (n=16) in the ‘underweight category’. 
Females showed the greatest number of participants falling into the ‘underweight’ category (n=4, 
36.4%).  
 
3.3.8 Comparison of Baseline Anthropometrical Variables with Demographic Data 
 
Please note that the groups of all demographic variables (gender, race and age) were compared with 
least square means (LS means), which considers the differing sample sizes of groups. This is ensured 
by using the mean square error (MSE) as the measure of error variance, and not the variance of the 
individual groups.  
 
As was true for gender, any findings generated from other demographic variables such as age and race, 









Underweight Slim Satisfactory Heavy Excessive body fat
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There were no significant differences between any of the baseline anthropometrical variables when 
compared with the race of the participants. With regard to the effect of age on the baseline 
anthropometrical variables, the only significant variables are indicated in Table 3.5.  
 
Table 3.5: Comparison of baseline anthropometrical variables with age (n=59) 
 
Variable (Baseline) Unit r-value  p-value * 
Waist circumference  cm 0.27 0.04 
Waist:hip ratio - 0.35 0.01 
Body density  D -0.44 0.00 
Fat mass  kg 0.36 0.01 
Percentage body fat  % 0.44 0.00 
 
     * Spearman rank order correlation 
       BMI = body mass index  
      Bold and shaded variables indicate statistical significance 
 
When considering Table 3.5 above, the following variables showed a correlation with age of the 
participants: waist circumference, waist:hip ratio, body density, fat mass and percentage body fat. Of 
these variables, only body density showed a negative correlation with age, whilst the others showed a 
positive correlation.  
 
 
3.4       FOLLOW-UP ANTHROPOMETRY RESULTS  
 
Follow-up data refers to results from participants in Group 2 that were seen at baseline, and followed 
up two and five months thereafter.  All measurements were done on this group and the sample size 
was, twenty-nine (n=29), for all variables.  
 
A repeated measures ANOVA, with the compound symmetry assumption on the correlation structure 
over time, was mostly used to compare all the biochemical variables of the participants over the three 
periods of measurement. Please note that parametric methods (ANOVA) were used for the majority of 
data analyses, and confirmed with the non-parametric test if necessary. Therefore, if both parametric 
and non-parametric tests were performed, the latter would be used purely for confirmatory purposes 
and not as the initial test. If the ANOVA was not used, the alternative statistical test will be stated. This 
is true for any results presented in this chapter.  
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As is shown in Table 3.6, the null hypothesis of equality of means was rejected for all of the 
anthropometrical variables, except for the biceps skinfold as no significant differences were seen over 
time for this sole variable. The p-values shown in Table 3.6 indicate a hypothesis test to determine 
whether the mean values at baseline, two months and five months are the same. The bold and shaded 
variables indicate that the hypothesis of equal means is rejected (as given by a p-value of <0.05) and 
the three mean measurements differ significantly. Bonferroni multiple comparisons procedures were 
duly performed to assess where the differences occurred.  
 
Table 3.6: Changes in anthropometrical variables over time in Group 2 (n=29) 
 
 









Weight  kg F(2,56) = 39.51  56.83 (10.66) 59.76 (11.65) 61.37 (11.26) <0.001 
BMI  kg/m2 F(2,56) = 39.34  19.65 (2.62) 20.66 (2.93) 21.21 (2.68) <0.001 
Waist 
circumference  
cm F(2,56) = 38.44  70.38 (8.84) 72.95 (9.32) 75.40 (9.18) <0.001 
Waist:hip ratio - F(2,56) = 36.29 0.83 (0.08) 0.85 (0.09) 0.88 (0.09) <0.001 
Biceps skinfold  mm F(2,56) = 1.81  3.16 (1.45) 3.36 (1.96) 3.49 (2.02) 0.174 
Triceps skinfold  mm F(2,56) = 10.05  7.01 (4.05) 7.49 (4.29) 8.13 (4.63) <0.001 
Subscapular 
skinfold  
mm F(2,56) = 10.22  7.77 (2.85) 8.26 (2.69) 8.79 (3.35) <0.001 
Suprailiac 
skinfold  
mm F(2,56) = 6.81  6.10 (4.61) 7.32 (5.50) 7.57 (5.11) 0.002 
Sum of skinfolds  mm F(2,56) = 8.64  24.03 (11.79) 26.43 (13.47) 27.99 (14.18) <0.001 
Fat mass  kg F(2,56) = 17.63   7.22 (4.34) 8.38 (4.39) 8.73 (4.50) <0.001 
Fat free mass  kg F(2,56) = 38.11   49.61 (9.56) 51.38 (10.13) 52.63 (10.23) <0.001 
Percentage body 
fat  
% F(2,56) = 10.89  12.58 (6.53) 13.85 (5.96) 14.19 (6.31) <0.001 
 
SD = standard deviation; BMI = body mass index  
Bold and shaded variables indicate statistical significance  
 
3.4.1     Weight  
 
The mean weights of the participants increased over time and a Bonferroni multiple comparisons 
procedure revealed differences between baseline and two months (p<0.001), baseline and five months 
(p<0.001) and two months and five months (p=0.009) as shown in Figure 3.4.  
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Figure 3.4: Changes in weight of participants over five-month follow-up period (n=29) 
 
 
3.4.2     BMI  
 
The mean BMI of the participants increased over the follow-up period (as seen in Figure 3.5) and a 
Bonferroni multiple comparisons procedure revealed that all three periods differ from one another: 
namely baseline and two months (p<0.001), baseline and five months (p<0.001) and two and five 
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BMI = body mass index 
 
Figure 3.5: Changes in BMI of participants over five-month follow-up period (n=29) 
 
 
3.4.3     Waist Circumference  
 
Upon evaluating changes over time, there was a significant increase over the five month period, as 
shown in Figure 3.6. A Bonferroni multiple comparisons procedure revealed that there was a difference 
between baseline and two months (p<0.001), as well as between baseline and five months (p<0.001) 
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3.4.4     Waist:hip Ratio (WHR) 
 
The WHR experienced a significant increase over the five-month period (Figure 3.7) whereby a 
Bonferroni multiple comparisons procedure revealed that there was a difference between all three 
periods: namely, baseline and two months (p<0.001), baseline and months (p<0.001) and two months 
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Figure 3.7: Changes in waist:hip ratio of participants over five-month follow-up period (n=29) 
 
 
3.4.5     Triceps Skinfold  
 
Despite an increase over time, a Bonferroni multiple comparisons procedure showed that there was 
only a difference between baseline and five months (p<0.001) and two to five months (p=0.039). There 
was no difference between baseline and two months (p=0.189). These findings were confirmed by a 
bootstrap test, due to the residuals not being normally distributed.  
 
3.4.6  Subscapular Skinfold  
 
Although there was an increase in mean values over the follow-up period, a Bonferroni multiple 
comparisons procedure only showed a difference between baseline and five months (p<0.001). No 
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3.4.7     Suprailiac Skinfold  
 
Despite an increase over time, a Bonferroni multiple comparisons procedure showed that there was 
only a difference between baseline and two months (p=0.018) and baseline and five months (p=0.003). 
No difference was found between two and five months (p=1.000).  
 
3.4.8  Sum of Skinfolds 
 
Figure 3.8 shows an increase in mean values over time, and a Bonferroni multiple comparisons 
procedure revealed that there was a difference between baseline and two months (p=0.046), as well as 
baseline and five months (p<0.001). There was no difference between two and five months (p=0.329).  
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3.4.9  Fat Mass 
 
There was an overall increase in the fat mass over the five-month follow-up period, whereby a Bonferroni 
multiple comparisons procedure showed that there was a difference in both baseline to two months 
(p<0.001) and baseline to five months (p<0.001). There was no difference between the two and five 
month mean measurements (p=0.571).  
 
3.4.10   Fat Free Mass  
 
There was an increasing trend for the measurement over all follow-up periods (Figure 3.9). A Bonferroni 
multiple comparisons procedure revealed that differences were found between baseline and two months 
(p<0.001), baseline and five months (p<0.001) and two and five months (p=0.002).  
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3.4.11   Percentage Body Fat  
 
Despite showing an upward trend, a Bonferroni multiple comparisons procedure only showed a 
difference between baseline and two months (p=0.003) and baseline and five months (p<0.001). There 
was no difference between the two and five month mean measurements (p=1.000).  
 
In addition, no difference was found if comparing the effect of BMI classification on percentage body fat 
measurements, as the interaction between percentage body fat and BMI classification was not 
significant [(F (8, 48) = 1.53 (p=0.173)].  
 
 
3.5       BASELINE BIOCHEMISTRY RESULTS  
 
Table 3.7 provides a comprehensive overview of all biochemical variables measured at baseline. It is 
apparent from the above-mentioned table that whilst the mean CRP level was noticeably raised 
(indicated in Table 3.7 in bold), the mean values of albumin, white cell count and fasting glucose levels 
were all in the normal ranges. The mean HDL level was decreased for both genders (also indicated in 
bold in Table 3.7). All baseline observations discussed in this section are based on reference values 
provided by the NHLS (See Chapter 2.6.3.2). 
 
Table 3.7: Baseline biochemistry measurements of total study population (n=59) 
 
Variable Unit Reference 
values  
Mean SD Range Prevalence of 
abnormalities (n=59) 
Albumin  g/L 35.0-52.0 39.32 4.35 28.00-48.00 Decreased: n=9 (15.3%) 
White cell count  10ˆ9/L 4.0-10.0 8.84 3.56 3.68-19.15 Increased: n=20 (33.9%) 
Decreased: n=2 (3.4%) 
Fasting glucose  mmol/
L 
4.1-5.9 4.82 0.80 3.60-8.10 Increased: n=3 (5.1%) 
Decreased: n=5 (8.5%) 
Fasting insulin  mU/L 3.0-25.0 11.37 19.20 0.90-142.30 Increased: n=4 (6.8%) 
Decreased: n=6 (10.2%) 
CRP  mg/L 0.0-10.0 60.18 50.92 3.00-202.00 Increased: n=50 (84.7%) 
Total cholesterol  mmol/
L 
≤5.0 3.47 0.90 1.70-6.20 Increased: n=2 (3.4%) 
Triglycerides*  mmol/
L 
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Variable Unit Reference 
values  















<3.0 2.08 0.70 0.40-4.60 Increased: n=5 (8.5%) 
 
SD = standard deviation; CRP = C-reactive protein; HDL = high density lipoprotein; LDL = low density lipoprotein 
*Category 2 risk (see Table 2.9 for classification) 
 
Upon consideration of Table 3.7 above, the most noteworthy of biochemical results show that the 
majority of participants (n=50, 84.7%) had raised CRP levels at baseline, whilst 69.5% (n=41) of 
participants had a lowered HDL-cholesterol level. Thirty-three point nine percent (n=20) of participants 
presented with an increased white cell count at baseline despite the mean value falling in the normal 
range.  
 
There appeared to be noticeably raised values for both fasting glucose and fasting insulin levels when 
considering the upper range of the study population (indicated in the shaded blocks in Table 3.7). 
Although some of these values far exceed the normal reference values, they were captured correctly 
and were not erroneous outliers.  
 
3.5.1  Comparison of Baseline Biochemical Variables with Demographic Data 
 
Once again, it is important to note that as the participants were not stratified according to the above 
demographics, any possible conclusions should be interpreted with caution. Any significant differences 
between biochemical variables and demographic data (gender, race or age) are discussed below.  
 
No significant results were found between any of the demographic variables and biochemical measures 
studied although the LDL-cholesterol (p=0.050, Mann-Whitney U test) seemed to mimic the findings of 
the total cholesterol when compared with gender. There were no further notable findings with regard to 
either race or age and the remaining biochemical findings.  
 
3.5.1.1   Total cholesterol - gender 
 
When evaluating the effect of gender on baseline biochemical values, it was apparent that only the total 
cholesterol displayed a significant difference between males and females [Males: 3.37mg/L (0.88); 
Females: 3.89mg/L (0.88); p=0.036; Mann-Whitney U-test). Figure 3.10 below depicts the difference 
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* Mann-Whitney U-test 
 
Figure 3.10: Difference between total cholesterol values (baseline) vs. gender (n=59) 
 
 
3.5.1.2   Total cholesterol – race  
 
With regard to the effect of race on total cholesterol, Figure 3.11 depicts a significant difference between 
the black African and coloured groups (p=0.038) and black African and white groups (p=0.014). There 
was no difference between the coloured and white groups (p=0.784). This was documented with a 
Bonferroni multiple comparisons procedure. The white population group displays the highest total 
cholesterol value, whilst the black African group has the lowest [African: 3.18mg/L (0.77); Coloured: 
3.81 (0.95); White (4.25 (0.79); p=0.021; Kruskal-Wallis). 
 
p=0.036* 
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Figure 3.11: Difference between total cholesterol values (baseline) vs. race (n=59) 
 
 
3.5.1.3    LDL-cholesterol - race 
 
The baseline LDL-cholesterol of the total study population also showed significant differences when 
evaluating the impact of race (Figure 3.12). Once again the white population group showed the highest 
LDL levels, while the black African group displayed the lowest levels [African: 1.86 mmol/L (0.61); 
coloured: 2.34 (0.77); white (2.59 (0.56); p=0.021; Kruskal-Wallis). The LDL-cholesterol followed a 
similar trend as the total cholesterol, with a Bonferroni multiple comparisons procedure showing a 
significant difference between the black African and coloured group (p=0.049) and black African and 
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LDL = Low Density Lipoprotein 
 
Figure 3.12: Difference between LDL-cholesterol values (baseline) vs. race (n=59) 
 
 
3.5.1.4    Fasting insulin - age 
 
Only the fasting insulin value showed any correlation with age when considering the baseline 
biochemical measurements (r= -0.37; p=0.004, Spearman rank order correlation). This variable showed 
a negative correlation with age. Therefore, as the age of the participants increased, the fasting insulin 
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r= -0.37; p=0.004, Spearman Rank Order Correlation 
 
Figure 3.13: Correlation of baseline fasting insulin with age of participants (n=59) 
 
The presence of a much increased single value indicated in Figure 3.13 (fasting insulin value of 142.3 




3.6       FOLLOW-UP BIOCHEMISTRY RESULTS  
 
Statistical analysis of follow-up biochemical data was performed similarly to the anthropometrical follow-
up data with repeated measures ANOVA. The p-values shown in Table 3.8 also indicate a hypothesis 
test to determine whether the mean values at baseline, two months and five months are the same. The 
shaded variables indicate that the hypothesis of equal means is rejected (as given by a p-value of <0.05) 
and the three mean measurements differ significantly.  
 
As is shown in Table 3.8, the null hypothesis of equality of means was rejected for the following 
biochemical variables: albumin, CRP, total cholesterol, HDL-cholesterol, LDL-cholesterol and white cell 
count, as significant changes were documented among these variables.  
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Table 3.8: Changes in biochemical variables over time in Group 2 (n=29) 
 









Albumin g/L F(2,56) = 15.36 39.97 (4.06) 42.55 (3.90) 43.41 (3.77) <0.001 
Fasting glucose  mmol/L F(2,56) = 2.11 4.78 (0.61) 4.83 (0.58) 4.57 (0.50) 0.131 
CRP mmol/L F(2,56) = 21.63 56.72 (50.83) 27.54 (32.11) 12.48 (15.07) <0.001 
Fasting insulin  mU/l F(2,56) = 1.16 14.62 (25.98) 11.91 (15.81) 8.99 (6.77) 0.320 
Total cholesterol  mg/L F(2,56) = 10.43 3.55 (0.95) 4.20 (1.06) 3.94 (0.84) <0.001 
Triglycerides  mmol/L F(2,56) = 0.85 0.85 (0.30) 0.93 (0.38) 0.89 (0.38) 0.432 
HDL-cholesterol mmol/L F(2,56) = 14.50 0.99 (0.30) 1.30 (0.46) 1.31 (0.38) <0.001 
LDL-cholesterol  mmol/L F(2,56) = 4.97 2.17 (0.75) 2.48 (0.87) 2.22 (0.70) 0.010 
White cell count 10ˆ9/l F(2,56) = 16.30 8.74 (4.18) 6.98 (2.91) 5.92 (2.01) <0.001 
 
SD = standard deviation; CRP = C-reactive protein; HDL = high density lipoprotein; LDL = low density lipoprotein 
Bold and shaded variables indicate statistical significance  
 
 
3.6.1  Albumin  
 
The mean albumin level of the participants increased and a Bonferroni multiple comparisons 
procedure revealed that baseline and two months differ (p=0.001) and baseline and five months 
(p<0.001), as shown in Figure 3.14. There was no difference between mean values at two and five 
months (p=0.567).  
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Figure 3.14: Changes in albumin of participants over five-month follow-up period (n=29) 
 
 
3.6.2  White Cell Count 
 
The mean white cell count of the participants decreased over time as shown in Figure 3.15. A Bonferroni 
multiple comparisons procedure showed that baseline and two months differ (p=0.002), as well as 
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Figure 3.15: Changes in white cell count of participants over five-month follow-up period (n=29) 
 
 
3.6.3  CRP  
 
The mean measurement decreases over time, as is seen in Figure 3.16. There was a difference in mean 
CRP values between baseline and two months (p<0.001) and baseline and five months (p<0.001) 
(Bonferroni multiple comparisons procedure). There was no difference in mean CRP between two 
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CRP = C-reactive protein 
 
Figure 3.16: Changes in CRP of participants over five-month follow-up period (n=29) 
 
 
3.6.4  Total Cholesterol  
 
The mean measurement increases between baseline and two months, and then decreases slightly 
between two and five months, as shown in Figure 3.17. A Bonferroni multiple comparisons procedure 
revealed that there was a difference between baseline and two-month mean values (p<0.001) as well 
as between baseline and five months (p=0.028). No difference was found between two and five month 
mean values (p=0.209).  
 
The LDL-cholesterol measurement followed a similar pattern to the total cholesterol measurement. The 
mean LDL increased between baseline and two months, but then decreased between two and five 
months, as seen in Figure 3.20. A Bonferroni multiple comparisons procedure revealed that there was 
only a difference between baseline and two month mean values (p=0.014), whereas no differences were 
found between baseline to five months or two to five months.  
p<0.001 
p<0.001 
Stellenbosch University  https://scholar.sun.ac.za









































Figure 3.17: Changes in total cholesterol of participants over five-month follow-up period 
(n=29) 
 
3.6.5  HDL-Cholesterol  
 
The mean measurement increases sharply between baseline and two months, and experiences a slight 
increase between two and five months, as shown in Figure 3.18. There was a difference between 
baseline and two month mean values (p<0.001) as well as between baseline and five months (p<0.001) 
(Bonferroni multiple comparisons procedure). No difference was found between two and five month 
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      HDL = high density lipoprotein 
 




3.7       BASELINE BLOOD PRESSURE RESULTS  
 
Table 3.9 provides a comprehensive overview of blood pressure results measured at baseline.  
 
Table 3.9: Baseline blood pressure measurements of total study population (n=59) 
 
Variable  Valid n Mean SD Range 
Systolic Blood Pressure (mmHg) 59 120.73 16.53 84.00-169.00 
Diastolic Blood Pressure (mmHg) 59 76.59 12.05 48.00-110.00 
 







Stellenbosch University  https://scholar.sun.ac.za







3.7.1  Baseline Classification of Blood Pressure  
 
According to the cut-off values for blood pressure (see classification table in Chapter 2.6.3.3), the 
following was observed: The majority of participants presented with a blood pressure in the normal range 
(<120/80 mmHg) (n=40, 67.8%), followed by 18.7% in the pre-hypertensive stage (120 – 139 / 80 – 89 
mmHg). The minority of patients were classified with hypertension according to baseline readings. This 
information is depicted in Figure 3.19. Please note that due to the presence of a relatively small study 
population, blood pressure values were not classified according to age-specific categories, as these 
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3.7.2  Comparison of Baseline Blood Pressure Variables with Demographic Data 
 
Upon consideration of the effect(s) of gender, race and age on blood pressure measurements, there 
were no significant differences found (Table 3.10).  
 
Table 3.10: Differences between baseline blood pressure and demographic variables (n=59) 
 
Baseline Gender Race Age 
 p-value p-value p-value 
Systolic Blood Pressure 0.599* 0.853** 0.852*** 
Diastolic Blood Pressure  0.586* 0.608** 0.918*** 
 
*    Mann-Whitney U test 
**   Kruskal-Wallis 
*** Spearman rank order correlation 
 
 
3.8       FOLLOW-UP BLOOD PRESSURE RESULTS  
 
Analysis of follow-up data was performed similarly to the anthropometrical follow-up data with repeated 
measures ANOVA. The p-values shown in Table 3.11 also indicate a hypothesis test to determine 
whether the mean values at baseline, two months and five months are the same. 
 
Table 3.11: Changes in blood pressure variables over time in Group 2 (n=29) 
 












mmHg F (2, 56) = 2.64  120.69 (SD15.32) 126.03 (12.31) 127.93 (17.32) 0.081 
Diastolic blood 
pressure  
mmHg F (2, 56) = 2.45 76.00 (9.25) 80.86 (8.42) 78.76 (13.27) 0.096 
 
SD = standard deviation  
 
As is shown in Table 3.11, the null hypothesis of equality of means over the three repetitions was not 
rejected for either systolic or diastolic blood pressure, indicative of no significant difference over time. 
Despite the lack of significance, both systolic and diastolic blood pressure values seemed to show an 
upward trend over time.     
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3.9       BASELINE DIAGNOSTIC INSULIN RESISTANCE TESTS  
 
Table 3.12 provides a comprehensive overview of the diagnostic IR tests measured at baseline. Both 
the HOMA-IR and QUICKI values were calculated as per the formulae shown in Chapter 2.6.3.4. In 
order to calculate these values, both the fasting glucose and fasting insulin values were needed.  
 
Table 3.12: Baseline diagnostic IR test measurements of total study population (n=59) 
 
Variable  Mean SD Range 
HOMA-IR 2.72 5.74 0.17-42.37 
QUICKI  0.37 0.05 0.24-0.54 
 
   SD = standard deviation; HOMA-IR = homeostasis model assessment-insulin resistance; QUICKI = quantitative insulin sensitivity check  
   index  
 
3.9.1  Comparison of Baseline Diagnostic Insulin Resistance Tests with Demographic Data 
 
Table 3.13 depicts the effects of gender, race and age on the HOMA-IR and QUICKI values at baseline.  
 
Table 3.13: Differences between baseline insulin resistance tests and demographic variables 
(n=59) 
 
Baseline Gender Race Age 
 p-value p-value p-value 
HOMA-IR 0.778* 0.897** 0.014*** 
QUICKI 0.778* 0.897** 0.014*** 
 
    *    Mann-Whitney U test 
    **   Kruskal-Wallis 
    *** Spearman rank order correlation 
    Bold and shaded variables indicate statistical significance  
 
The only significant differences found occurred between the HOMA-IR and QUICKI tests and age. 
This signifies that whilst HOMA-IR has a negative correlation with age, the QUICKI has a positive 
correlation. Therefore, as age increases the HOMA-IR decreases, whilst the QUICKI increases. The 
correlation between HOMA-IR and age is shown graphically in Figure 3.20 below.  
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r = -0.32; p=0.014; Spearman Rank Order Correlation 
HOMA-IR = homeostasis model assessment – insulin resistance 
 
Figure 3.20: Correlation of baseline HOMA-IR with age of participants (n=59) 
 
 
None of the other variables showed any significant difference when comparing the effects of gender or 
race (Table 3.13).  
 
 
3.10      FOLLOW-UP DIAGNOSTIC INSULIN RESISTANCE TESTS  
 
Analysis of follow-up data was performed as for the anthropometrical follow-up data (Refer to Chapter 
3.4 for more detail regarding statistical methods used). The p-values shown in Table 3.14 also indicate 
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Table 3.14: Changes in diagnostic IR test measurements over time in Group 2 (n=29) 
 









HOMA-IR F (2, 56) = 1.19 3.53 (7.70) 2.79 (4.35) 1.87 (1.49) 0.311 
QUICKI F (2, 56) = 0.72  0.36 (0.05) 0.36 (0.06 0.37 (0.05) 0.491 
 
   SD = standard deviation; HOMA-IR = homeostasis model assessment-insulin resistance; QUICKI = quantitative insulin sensitivity check   
   index  
 
As is shown in Table 3.24, the null hypothesis of equality of means over the three repetitions was not 
rejected for either of the diagnostic IR tests, which indicates no significant difference over time.   
 
3.10.1    HOMA-IR 
 
As the results were not normally distributed, a bootstrap test was performed (Figure 3.21), which 
confirmed that there were no significant differences present (p=0.311) between the three groups even 
though the HOMA-IR values experienced a slight decrease over time. No Bonferroni procedure was 
performed due to there being no difference in HOMA-IR means over time.  
 


























HOMA-IR = homeostasis model assessment-insulin resistance (p=0.311) 
 
Figure 3.21: Changes in HOMA-IR values of participants over five-month follow-up period 
(n=29) 
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3.10.2    QUICKI 
 
Similarly to the HOMA-IR findings, the QUICKI results were also not normally distributed. A bootstrap 
test was performed and revealed that there were no significant differences present between the three 
groups despite a corresponding increase in QUICKI values over time.  
 
 
3.11      METABOLIC SYNDROME INVESTIGATION 
 
Participants were also assessed according to the IDF and ATP III criteria for metabolic syndrome to 
investigate whether any of the study participants presented with the syndrome after study inclusion. 
These two frameworks were selected purely because all of the reference frameworks were investigated 
in the current study (See Table 1.4 for comprehensive summary of available criteria).  
 
3.11.1     Baseline Findings  
 
3.11.1.1  International Diabetes Federation (IDF) criteria  
 
According to the most recent IDF criteria, in order to diagnose the metabolic syndrome, a waist 
circumference of more than >94 cm for males and >80 cm for females is needed.9 If these cut-off points 
are applied to the total study population, there were two females (n=2) and one male (n=1) who had 
waist circumference’s more than the cut-off’s at baseline. The male was part of Group 2 seen on three 
occasions (male ‘a’), whilst both females were part of Group 1 that were only seen once-off (females ‘a’ 
and ‘b’). Table 3.13 shows that both of the females with an increased waist circumference were classified 
as having the metabolic syndrome according to the IDF framework.  
 
3.11.1.2  Third Adult Treatment Panel (ATP III) criteria  
 
According to the ATP III criteria for the identification of metabolic syndrome, ≥three (3) of the tabulated 
variables need to be present in an individual. Of the two individuals that were identified by the IDF criteria 
to have the metabolic syndrome at baseline, only one (female ‘a’) was identified by the ATP III criteria 
for the same condition (n=1, 1.7%). Female ‘a’ also presented with an increased HOMA-IR and 
decreased QUICKI at this point. Female ‘b’ had normal HOMA-IR and QUICKI values at baseline.  
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The male did not meet the criteria, which is shown in Table 3.15 (together with the females ‘a’ and ‘b’). 
There were, therefore, no male participants identified with the metabolic syndrome at 
baseline according to both classification methods. 
 
Table 3.15: Participants meeting IDF and ATP III criteria for metabolic syndrome at baseline 
 










IDF Criteria       
Female ‘a’ Yes  No Yes Yes Yes 
Female ‘b’ Yes No Yes Yes No 
Male ‘a’ Yes No Yes No No 
ATP III Criteria      
Female ‘a’ No  No  Yes  Yes  Yes  
Female ‘b’ No  No  Yes  Yes  No  
Male ‘a’ No  No  Yes  No  No  
 
 IDF = International Diabetes Federation; ATP = Adult Treatment Panel; HDL = high density lipoprotein 
 ‘Yes’ denotes the presence of the condition 
 ‘No’ denotes the absence of the condition  
 ‘a’ and ‘b’ denote different study participants (male and female) 
 Participants identified as having the metabolic syndrome are shown in bold (shaded area)  
 
The IDF and ATP III criteria thus differ at baseline according to the classification of participants.  
 
3.11.2      Follow-up Findings    
 
For the male participant (‘a’) with the increased waist circumference (IDF) in Group 2, his metabolic 
syndrome markers over the five-month period are shown in Table 3.16.   
 
For Male ‘a’, both the IDF and ATP III criteria show that he does not present with the metabolic syndrome 
at either baseline, two months or five months. His HOMA-IR was increased and QUICKI decreased at 
baseline and five months, but not at the two-month follow-up.  
  
A second participant (Male ‘b’) was not identified by the IDF criteria to present with the metabolic 
syndrome (due to the absence of an increased waist circumference), but was however found to meet 
the ATP III criteria at his two-month follow-up. This was due to the presence of reduced HDL-cholesterol, 
raised blood pressure and increased fasting glucose level at two months (as shown in Table 3.16). He 
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presented with an increased HOMA-IR and decreased QUICKI at baseline and two months, but not at 
five-month follow-up.  
 
Table 3.16: Male participants in Group 2: 
Changes in metabolic syndrome criteria over time 










IDF Criteria       
Male ‘a’ – Baseline   Yes  No Yes No  No 
Male ‘a’ – two months  Yes No No Yes  No 
Male ‘a’– five months Yes No No No  No 
ATP III Criteria      
Male ‘a’ – Baseline   No  No Yes No  No 
Male ‘a’ – two months  Yes  No No Yes  No 
Male ‘a’– five months Yes   No No No  No 
      
IDF Criteria       
Male ‘b’ – Baseline   No No Yes No  Yes  
Male ‘b’ – two months  No No Yes  Yes  Yes 
Male ‘b’– five months No No No No  No 
ATP III Criteria      
Male ‘b’ – Baseline   No No Yes No  Yes 
Male ‘b’ – two 
months  
No No Yes  Yes  Yes  
Male ‘b’– five months No No No No  No 
 
IDF = International Diabetes Federation; ATP = Adult Treatment Panel; HDL =high density lipoprotein 
‘Yes’ denotes the presence of the condition 
‘No’ denotes the absence of the condition 
‘a’ and ‘b’ denote different study participants (males)  
Participants identified as having the metabolic syndrome are shown in bold (shaded area) 
 
The ATP III classification differs to that of the IDF, as none of the follow-up participants were classified 
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3.12      CORRELATION BETWEEN METABOLIC SYNDROME CRITERIA AND DIAGNOSTIC   
             INSULIN RESISTANCE TESTS 
 
When considering the individual effect of the diagnostic criteria used in both the IDF and ATP III 
definitions, the correlation between each variable (waist circumference, triglycerides, HDL-cholesterol, 
blood pressure and fasting glucose) and diagnostic IR tests (HOMA-IR/QUICKI) was investigated. The 
effects at baseline regarding the total study population (n=59) are shown in Table 3.17. The effect of 
each variable on HOMA-IR / QUICKI values at all stages of follow-up (baseline, two months and five 
months) is shown in Table 3.16.  
 
Table 3.17: Correlation between metabolic syndrome criteria and diagnostic IR tests at 
baseline (n=59) 
 






Waist Circumference  0.13 0.34 -0.13 0.34 
Triglycerides  0.14 0.30 -0.14 0.30 
HDL-cholesterol -0.19 0.16 0.19 0.16 
Systolic blood pressure  0.14 0.28 -0.14 0.28 
Diastolic blood pressure  0.15 0.25 -0.15 0.25 
Fasting glucose**  0.40 <0.01 -0.40 <0.01 
 
*Spearman rank correlation co-efficient 
HOMA-IR = homeostasis model assessment-insulin resistance; QUICKI = quantitative insulin sensitivity check index; HDL = high density 
lipoprotein 
Bold and shaded variables indicate statistical significance  
 
It is evident from the above table that the only variable to show a correlation with HOMA-IR and QUICKI 
values was fasting glucose (which is indicated in bold in Table 3.17). 
  
Table 3.18 shows a similar correlation between HOMA-IR / QUICKI and fasting glucose at all three 





Stellenbosch University  https://scholar.sun.ac.za







Table 3.18: Correlation between metabolic syndrome criteria and diagnostic IR tests at follow-
up periods (Group 2) (n=29) 
 






Waist circumference  0.04 0.85 -0.04 0.85 
Triglycerides  0.32 0.09 -0.32 0.09 
HDL-cholesterol -0.30 0.11 0.30 0.11 
Systolic blood pressure  0.25 0.20 -0.25 0.20 
Diastolic blood pressure  0.29 0.12 -0.29 0.12 
Fasting glucose  0.56 <0.01 -0.56 <0.01 






Waist circumference  0.15 0.43 -0.15 0.43 
Triglycerides  0.10 0.62 -0.10 0.62 
HDL-cholesterol -0.33 0.08 0.33 0.08 
Systolic blood pressure  0.15 0.43 -0.15 0.43 
Diastolic blood pressure  0.14 0.48 -0.14 0.48 
Fasting glucose  0.54 <0.01 -0.54 <0.01 






Waist circumference  0.12 0.53 -0.12 0.53 
Triglycerides  0.19 0.32 -0.19 0.32 
HDL-cholesterol -0.21 0.27 0.21 -0.27 
Systolic blood pressure  0.13 0.51 -0.13 0.51 
Diastolic blood pressure  0.00 1.00 0.00 1.00 
Fasting glucose**  0.59 <0.01 -0.59 <0.01 
 
*Spearman rank correlation co-efficient 
HOMA-IR = homeostasis model assessment-insulin resistance; QUICKI = quantitative insulin sensitivity check index; HDL = high density 
lipoprotein 
Bold and shaded variables indicate statistical significance  
 
The fasting glucose showed a positive correlation (Spearman rank correlation co-efficient) with HOMA-
IR and a negative correlation with QUICKI. Therefore, as fasting glucose increased, so did HOMA-IR, 
whereas the QUICKI decreased. This was observed at all time periods (Table 3.18). This is, however, 
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3.13    DETERMINATION OF HOMA-IR CUT-OFF POINT 
 
3.13.1    General  
 
The data of all fifty-nine participants was used to calculate an individualised HOMA-IR value for the 
study population. Data was categorised into various percentiles and the lower limit of the upper quartile 
(P75) was chosen as the cut-off point for classifying IR in this study population (Table 3.19). Although 
there is currently a lack of consensus in terms of a standardised HOMA-IR cut-off point, several studies 
have adopted the approach of using the lower limit of the upper quartile, namely the 75th percentile, in 
the calculation of a suitable HOMA-IR value.293-296 
 
Table 3.19: Various percentile cut-off points for current study data (n=59) 
 
Percentile classification  Number of participants (n) Corresponding HOMA-IR value 
50th Percentile (P50) 59 1.394 
66th Percentile (P66) 59 1.954 
75th Percentile (P75) 59 2.477 
80th Percentile (P80) 59 2.766 
90th Percentile (P90) 59 3.302 
 
     HOMA-IR = homeostasis model assessment-insulin resistance 
 
If the above cut-off of HOMA-IR >2.477 is considered to classify a participant with IR, then the following 
is true for the total study population at baseline: 25.4% of participants (n=15) had HOMA-IR values of 
>2.477 at baseline, which is shown in Figure 3.22. Of the total number of participants with IR (n=15), 
males had a total prevalence of 25.0% (n=12/48) and females, 27.3% (n=3/11).  
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IR = insulin resistance; HOMA-IR = homeostasis model assessment-insulin resistance 
 
Figure 3.22: Classification of total population at baseline according to determined HOMA-IR 
cut-off point (n=59) 
 
Of the follow-up participants (n=29), there was an IR prevalence rate of 31.0% at baseline (n=9), 27.6% 
at two months (n=8) and 20.7% at five months (n=6). This was determined using the same HOMA-IR 











HOMA-IR < 2.477 HOMA-IR > 2.477
























R n=44; 74.6% 
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IR = insulin resistance; HOMA-IR = homeostasis model assessment-insulin resistance 
 
Figure 3.23: Prevalence of IR according to HOMA-IR values in Group 2 (n=29) 
 
Of the nine participants that were classified as having IR in Group 2 at baseline, four of these persons 
were still classified as having IR at the five-month follow-up period (n=4; 44.4%), whereas two 
participants (n=2) who presented with normal HOMA-IR levels at baseline developed IR at both two and 
five-month follow-up periods.    
 
This data is presented slightly differently in Table 3.20 and shows how the IR participants were 
distributed over the follow-up period. Some patients who did not have IR at baseline developed it at a 
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Table 3.20: Changes in IR participants over all three time periods (baseline, two and five 
months) 
 
Time period Number of participants classified with IR 
(n) 
IR at baseline only 3 
IR at baseline and two months 2 
IR at baseline, two and five months 2 
IR at two months only  2 
IR at two and five months 2 
IR at baseline and five months 2 
IR at five months 0 
 
                          IR = insulin resistance 
 
3.13.2    Calculation of Corresponding QUICKI Cut-off Point  
 
A ROC analysis was done to determine the optimal QUICKI cut-off point at baseline. This analysis was 
based on the pre-determined HOMA-IR cut-off value of 2.477 (P75) to identify IR in study participants. 
This test, therefore, assumes that the HOMA-IR value is the true reading. Upon performing this statistical 
analysis, a corresponding QUICKI value of 0.336 was identified using the Youden index (Figure 3.24). 
In contrast to the HOMA-IR value (where the higher the value, the more insulin resistant an individual 
is), the QUICKI is the opposite as the lower the value, the more IR is present.  
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QUICKI = quantitative insulin sensitivity check index 
 
Figure 3.24: Scatterplot of sensitivity against 1-specificity 
 
As the QUICKI and HOMA-IR are mathematically related, the identified QUICKI cut-off mentioned above 
classified the same participants as having IR as the HOMA-IR cut-off value (i.e. 15 of the 59 participants 
at baseline). The sensitivity and specificity of the two cut-off values was, therefore, 100%. This confirms 
the accuracy between the two measures.  
 
3.13.3    Exclusion of Participants Identified Post-study Entry with Metabolic Syndrome  
 
As was mentioned previously in Chapter 3.11, it was discovered that two of the female participants 
entered onto the study were identified as having metabolic syndrome according to the IDF guidelines, 
whereas the ATP III guidelines only identified one of these two participants as having the syndrome at 
baseline. It was decided to recalculate the HOMA-IR cut-off point/s by excluding both the IDF and ATP 
III participants from a sub-analysis in order to improve accuracy of the results, as the syndrome is known 
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to be synonymous with IR prevalence. The reworked cut-off points were still calculated by using the 
lower limit of the upper quartile and are shown in Table 3.21.  
 
In addition to this, the two participants who had raised fasting glucose levels (although not confirmed 
diabetics) were also excluded in a sub-analysis to determine the effect on the HOMA-IR cut-off value. 
This sub-analysis produced the same HOMA-IR cut-off as the IDF excluded participants (seen below in 
Table 3.21) 
 








75th Percentile (P75) 59 2.477 25.4% (n=15) 
75th Percentile (P75) 57  
(Excluding n=2: IDF criteria) 
2.334 24.6% (n=14) 
75th Percentile (P75) 58 
(Excluding n=1: ATP III 
criteria) 
2.276 25.9% (n=15) 
75th Percentile (P75) 57  
(Excluding n=2: possible DM) 
2.334 24.6% (n=14) 
 
     HOMA-IR = homeostasis model assessment-insulin resistance; IR = insulin resistance; DM = diabetes mellitus; IDF = International   
     Diabetes Federation; ATP = Adult Treatment Panel 
 
If comparing the re-calculated results to those of the total study population (n=59), the prevalence rates 
of IR of the total population was 25.4%, whereas the prevalence in the IDF re-calculated group was 
24.6% (n=14) and 25.9% (n=15) in the ATP-III re-calculated group. The ‘IDF’ group displays a 0.8% 
lower IR prevalence when compared with the total study population, whereas the ‘ATP III’ group shows 
a 0.5% increase in the prevalence of IR at baseline.  
 
When considering the impact of the new HOMA-IR cut-off points on the prevalence rates of Group 2 
(n=29), the differences are shown in Table 3.22.  
 
Table 3.22: Comparison of different HOMA-IR values in Group 2 (n=29) 
 
 Initial HOMA-IR cut-off  
(2.477) 
Re-calculated ‘IDF’ HOMA-
IR cut-off (2.334) 
Re-calculated ‘ATP III’ 
HOMA-IR cut-off (2.276) 
 n % n % n % 
Baseline 9 31.0% 9 31.0% 10 34.5% 
2 Months 8 27.6% 11 37.9% 12 41.4% 
5 Months 6 20.7% 6 20.7% 6 20.7% 
 
    HOMA-IR = homeostasis model assessment-insulin resistance; IDF = International Diabetes Federation; ATP = Adult Treatment Panel 
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Therefore, despite slight discrepancies among the number of participants being classified as having IR 
at baseline and 2 months using the three different HOMA-IR cut-off points, the five-month result shows 
that there was no difference in classification of participants as having IR between initial HOMA-IR cut-
off of 2.477 and the re-calculated values (n=6, 20.7%).  
 
3.13.4    Regression Analysis to Investigate Role of Different Variables on Insulin Resistance 
 
 A full multiple regression test was done. Thereafter, the best predictor variables (for both 
anthropometry and biochemistry data sets) were determined with an all subsets multiple regression 
analysis using Mallow’s Cp Criterium for selection of the best predictor variables.   
 
The full multiple regression model for anthropometrical data yielded the following output which 
explained only 22.5% of the variation in IR (HOMA-IR at baseline). The all subsets approach with 
Mallow’s Cp Criterion selection, yielded the following anthropometrical variables [waist circumference 
(r=0.507; p=0.011), sum of skinfold’s (r=0.353; p=0.039) and fat mass (r=-2.419; p=0.08)] as the best 
predictors of IR (HOMA-IR at baseline). This model explained only 20.4% of the variation in IR, 
showing that IR can mostly be explained with the above-mentioned anthropometrical variables. The 
other variables do not contribute to IR at all.  
 
The full multiple regression model for the biochemical data yields the following output which explained 
only 99.0% of the variation in IR (HOMA-IR at baseline). The all subsets approach with Mallow’s Cp 
Criterion selection yielded the fasting glucose (r=0.524; p=0.000) and fasting insulin (r=0.291; 
p=0.000) as the best predictors of IR. This model explains 98.9% of the variation in HOMA-IR levels 
(and ultimately IR). Thus IR is mostly associated with fasting glucose and fasting insulin, whereas 
other variables contribute minutely, if at all.   
 
The results of the multiple regression therefore show that fasting glucose and fasting insulin 
measurements are the best predictors of IR, whereas there are almost no anthropometrical variables 
that are significantly associated with IR development. The biochemical results are logical as both 
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3.14      INSULIN RESISTANT GROUP vs. NON-INSULIN RESISTANT GROUP  
 
3.14.1   Demographic Data 
 
This group consisted of fifteen participants (n=15), who were identified after data collection and analysis 
occurred. Of these IR participants, twelve were male (80.0%) and the remaining three were female 
(20.0%). Nine of the IR group were black African (60.0%), whereas five were coloured (33.3%) and the 
remaining participant was white (n=1; 6.7%).  
 
As was noted with the demographic data, the statistical validity of comparing the IR and non-IR groups 
has been accounted for with appropriate statistical tests (Mean Square Error).  
 
3.14.2    Categorical Variables   
 
When considering Table 3.23 below, the only significant differences found among the categorical 
variables when comparing the IR with the non-IR group were found in the interpretations of the 
percentage body fat, subscapular skinfold and sum of subscapular and triceps skinfold (p-values 
indicated in bold in Table 3.23).  
 
Table 3.23: Comparison of baseline variables of IR group vs. non-IR group  
(categorical variables) (n=59) 
 
    *Age groups concerned: 18-30 years; 31-45 years; 46-65 years  
   **M-L Chi-square test = Maximum-likelihood chi square test 
    BMI = body mass index; HDL = high density lipoprotein 
    Bold and shaded variables indicate statistical significance  
 
Variable  Groups assessed p-value ** 
Gender  IR vs. non-IR 0.877 
Age Groups* IR vs. non-IR 0.210 
Race  IR vs. non-IR 0.816 
BMI classification IR vs. non-IR 0.217 
Waist circumference classification IR vs. non-IR 0.122 
Waist:hip ratio classification IR vs. non-IR 0.831 
Frame size IR vs. non-IR 0.193 
Interpretation of percentage body fat IR vs. non-IR 0.022 
Subscapular skinfold interpretation IR vs. non-IR 0.021 
Triceps skinfold interpretation IR vs. non-IR 0.080 
Interpretation of sum of subscapular and triceps skinfolds IR vs. non-IR 0.042 
HDL-cholesterol classification IR vs. non-IR 0.293 
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With regard to the interpretation of percentage body fat between the two groups, the ‘underweight’ 
category showed the largest difference (non-IR: n=18, 40.9% vs. IR: n=2, 13.3%). This was corroborated 
as the IR group showed a higher percentage body fat (although not significant) when compared with 
their non-IR counterparts [as the former had participants classified in the ‘heavy’ and ‘excessive’ 
categories (n=2, 13.3% and n=1, 6.7%) respectively]. 
 
The subscapular skinfold interpretation also showed a difference between the IR and non-IR groups, as 
the ‘below average’ category had more representation from the non-IR group (n=16, 36.4%) compared 
with the IR group (n=2, 13.3%). Conversely, the ‘average’ category had more participants from the IR 
group (n=6, 40.0%) vs. that non-IR group (n=4, 9.1%). This distribution is clarified as the mean skinfold 
values were also higher among the IR group, although not significantly so.  
 
The sum of triceps and subscapular skinfolds showed similar results, in that the largest differences were 
seen in those participants classified in the ‘lean’ category (non-IR: n=24, 54.6% vs. IR: n=4, 26.7%) 
where the non-IR group had the majority. The ‘average’ category showed the converse, with the non-IR 
group showing minority representation when compared with the IR group (non-IR: n= 8, 18.2% vs. IR: 
n=7 (46.7%). Once again, this is confirmed as the IR group had a higher mean value, although it was 
also not significant.  
 
3.14.3    Continuous Variables  
 
When considering the differences shown in Table 3.24 between the IR and non-IR group with regard to 
the biochemical values, only fasting insulin and the diagnostic IR tests showed significant differences. 
The latter is due to the fact that fasting insulin is a component of the various calculations used in the 
diagnostic IR tests. Although diastolic blood pressure was very close to the significant level cut-off point, 
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Table 3.24: Comparison of baseline variables of IR group vs. non-IR group  
(continuous variables) (n=59) 
 








Age  years 35.43 (12.02) 29.60 (11.29) 0.04 
Systolic blood pressure  mmHg 119.23 (17.78) 125.13 (11.57) 0.13 
Diastolic blood pressure  mmHg 75.45 (12.46) 79.93 (10.42) 0.05 
Albumin g/L 38.75 (4.58) 41.00 (3.16) 0.17 
Fasting glucose  mmol/L 4.71 (0.69) 5.13 (1.02) 0.16 
CRP mmol/L 64.10 (53.82) 48.91 (41.01) 0.51  
Fasting insulin  mU/l 5.63 (2.43) 28.20 (33.21) <0.01 
Total cholesterol mg/L 3.39 (0.87) 3.71 (0.95) 0.30 
Triglycerides  mmol/L 0.88 (0.35) 0.95 (0.27) 0.38 
HDL-cholesterol mmol/L 0.99 (0.33) 0.93 (0.26) 0.56 
LDL-cholesterol mmol/L 1.98 (0.65) 2.35 (0.80) 0.24 
White cell count 10ˆ9/l 8.79 (3.68) 8.99 (3.30) 0.68 
HOMA-IR - 1.18 (0.54) 7.22 (10.32) <0.01 
QUICKI  - 0.39 (0.04) 0.31 (0.03) <0.01 
 
* Mann-Whitney U test 
SD = standard deviation; CRP = C-reactive protein; HDL = high density lipoprotein; LDL = low density lipoprotein; HOMA-IR = homeostasis 
model assessment-insulin resistance; QUICKI = quantitative insulin sensitivity check index 
Bold and shaded variables indicate statistical significance  
 
A graphic representation of the significant difference seen between the mean fasting insulin value of the 
IR group vs. that of the non-IR group is shown in Figure 3.25.  
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IR = insulin resistance 
* Mann-Whitney U test 
 
Figure 3.25: Comparison between IR and non-IR group vs. fasting insulin levels of participants 
(n=59) 
 
With regard to demographics, only age displayed a significant difference between the IR and non-IR 
groups. Figure 3.26 shows that the study participants in the IR groups were significantly younger than 
their counterparts (p=0.04; Mann-Whitney U test).  
 
p<0.01* 
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IR = insulin resistance 
* Mann-Whitney U test 
 
Figure 3.26: Comparison between IR and non-IR group vs. age of participants (n=59) 
 
 
3.15      BASELINE SPUTUM RESULTS 
 
3.15.1   General  
 
Of the total study population (n=59), only fifty-six participants (94.9%) had results available at baseline. 
Fifty-two participants in the total study population of fifty-nine (88.14%) were found to have tested 
positive via the Gene Xpert test, with all of these participants being drug sensitive (rifampicin 
susceptible). Individualised sputum test results (according to smear microscopy discussed in Chapter 
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Table 3.25: Sputum results of baseline participants (n=56) 
 
Sputum results  Total study population 
(n=56) 
n (%) 
Group 1  
(n=29) 
n (%) 
Group 2  
(n=27) 
n (%) 
Smear-negative  14 (25.0%) 9 (31.0%) 5 (18.5%) 
Scanty-positive  8 (14.3%) 4 (13.8%) 4 (14.8%) 
Smear-positive (+) 9 (16.0%) 5 (17.2%) 4 (18.1%) 
Smear-positive (++) 8 (14.3%) 5 (17.2%) 3 (11.1%) 
Smear-positive (+++) 17 (30.4%) 6 (20.7%) 11 (40.7%) 
 
 
The largest group of patients fell into the ‘smear-positive (+++)’ category when considering the baseline 
results (n=17; 30.4%), although this was closely followed by the ‘smear-negative’ group (n=14; 25.0%). 
Group 1 had the majority of participants fall into the ‘smear-negative’ group (n=9; 31.0%) whilst Group 
2 saw most of their participants classified in the ‘smear-positive (+++)’ group (n=11; 40.7%). The majority 
values are indicated in Table 3.24 above in bold and are shaded.  
 
In order to simplify the comparison between the various sputum groups, results were classified as either 
‘smear-negative’, ‘indecisive’ or ‘smear-positive’. A participant was classified as having an ‘indecisive’ 
sputum test if the test needed to be repeated due to uncertainty of the initial results, which is often what 
was found if the result came back as ‘scanty positive’. In clinical practice, a ‘scanty’ result is often viewed 
as being a negative test and is thus repeated for good measure.  
 
The distribution between the three sputum categories is highlighted in Figure 3.27.  
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Figure 3.27: Available sputum results of study population at baseline (n=56) 
 
If the participants in the ‘indecisive’ and ‘smear-negative’ groups were added together, twenty-two 
participants would fall into this ‘new’ smear-negative group (n=22, 39.3%), whilst the remaining 60.7% 
(n=34) would be classified as ‘smear-positive’.  
 
3.15.2   Categorical Variables (Anthropometry and Demographics) 
 
Comparisons were made between the smear-positive and-negative groups to ascertain whether any 
differences were present for any of the categorical anthropometrical variables assessed. The results are 
tabulated in Table 3.26 below and show that no significant differences, apart from ‘age group’ were 
found between any of the variables. The ‘age group’ variable showed a significant difference between 
smear-positive and-negative groups in the 18 – 30 year old age group, with more patients in the ‘smear-
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Table 3.26: Comparison of baseline categorical variables of smear-positive vs. smear-negative 
groups (categorical variables) (n=56) 
 
   *Age groups concerned: 18-30 years; 31-45 years; 46-65 years  
   **M-L Chi-square test = Maximum-likelihood chi square test 
   BMI = body mass index 
   Bold and shaded variables indicate statistical significance  
  
3.15.3   Biochemistry, Blood Pressure and Diagnostic Insulin Resistance Tests 
 
Table 3.27 indicates the comparison between the smear-negative and positive groups in terms of any 
differences occurring with regard to biochemical variables (bold and shaded variables indicate statistical 
significance).   
 
Table 3.27: Comparison of baseline biochemical, blood pressure and diagnostic IR variables of 
smear-positive vs. smear-negative groups (n=56) 
 








Systolic blood pressure  mmHg 120.32 (15.56) 121.59 (17.70) 0.97 
Diastolic blood pressure  mmHg 76.63 (12.78) 76.47 (11.85) 0.89 
Albumin g/L 39.59 (4.22) 38.88 (4.41) 0.41 
Fasting glucose  mmol/L 5.08 (1.00) 4.58 (0.52) 0.04 
CRP mmol/L 50.09 (52.34) 67.80 (50.65) 0.12 
Fasting insulin  mU/l 10.03 (11.03) 8.54 (1.46) 0.70 
Total cholesterol mg/L 3.46 (0.77) 3.45 (0.98) 0.79 
Triglycerides  mmol/L 0.83 (0.27) 0.94 (0.37) 0.37 
HDL-cholesterol mmol/L 1.03 (0.32) 0.95 (0.33) 0.31 
LDL-cholesterol mmol/L 2.04 (0.52) 2.07 (0.79) 0.91 
White cell count 10ˆ9/l 8.57 (3.75) 8.95 (3.49) 0.62 
 
Variable  Groups assessed p-value ** 
Gender  Smear-negative vs. positive 0.354 
Age groups* Smear-negative vs. positive 0.039 
Race  Smear-negative vs. positive 0.368 
BMI classification Smear-negative vs. positive 0.155 
Waist circumference classification Smear-negative vs. positive 0.827 
Waist:hip ratio classification Smear-negative vs. positive 0.158 
Frame size Smear-negative vs. positive 0.813 
Interpretation of percentage body fat Smear-negative vs. positive 0.111 
Subscapular skinfold interpretation Smear-negative vs. positive 0.985 
Triceps skinfold interpretation Smear-negative vs. positive 0.366 
Interpretation of sum of subscapular and triceps skinfolds Smear-negative vs. positive 0.544 
HDL-cholesterol classification Smear-negative vs. positive 0.588 
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HOMA-IR - 2.42 (3.34) 1.78 (1.46) 0.96 




     * Mann-Whitney U test; SD = standard deviation; CRP = C-reactive protein; HDL = high density lipoprotein; LDL = low density lipoprotein; 
HOMA-IR = homeostasis model assessment-insulin resistance; QUICKI = quantitative insulin sensitivity check index 
 
The fasting glucose of the participants with sputum-negative results were significantly higher than those 
of their smear-positive counterparts (p=0.04; Mann-Whitney U-test) 
 
3.15.4    Baseline Sputum Results (between IR and non-IR groups) 
 
Of the original group of fifteen participants identified as having IR (Chapter 3.14), only 14 of these had 
available sputum results (93.3%). The differences between the IR and non-IR groups in terms of sputum 
results are shown in Table 3.28.  
 
Table 3.28: Sputum results of baseline participants according to IR vs. non-IR groups (n=56) 
 









Smear-negative  14 (25.0%) 4 (28.6%) 10 (23.8%) 
Scanty-positive  8 (14.3%) 1 (7.1%) 7 (16.7%) 
Smear-positive (+) 9 (16.1%) 2 (14.3%) 7 (16.7%) 
Smear-positive (++) 8 (14.3%) 2 (14.3%) 6 (14.3%) 
Smear-positive (+++) 17 (30.4%) 5 (35.7%) 12 (28.6%) 
TOTAL 56 14 42 
 
    IR =  insulin resistant 
 
For both the IR Group and non-IR group, most participants fell into the ‘smear-positive (+++)’ group, 
although this was not the majority of participants. There were no significant differences between the IR 
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3.16 FOLLOW-UP SPUTUM RESULTS 
 
3.16.1   General   
 
Of the participants in Group 2 with available sputum results at baseline (n=27), there were twenty-three 
participants who had available sputum results at two months (n=23, 85.2%) and nineteen participants 
at five months (n=19, 70.4%) (Table 3.29). 
 








Five months  
(n=19) 
Smear-negative  n=5 (18.5%) n=19 (82.6%) n=18 (94.7%) 
Indecisive  n=4 (14.8%) n=2 (8.7%) n=1 (5.3%) 
Smear-positive  n=18 (66.7%) n=2 (8.7%) - 
 
Participant numbers seem to drop quite rapidly from baseline sputum results to the follow-ups between 
months two and five. As only the participants in Group 2 had sputum values recorded at two and five 
months, this accounted for the difference.  
 
Only one (n=1) of the smear-negative patients was re-tested at two months and found to be negative. 
All of the other baseline smear-negative patients in Group 2 were not tested beyond the baseline 
measurement. Of the four indecisive smear patients at baseline, all had converted to smear-negative 
by two months (100.0%). Upon consideration of the baseline smear-positive individuals in Group 2 
(n=18), fourteen of these (n=14, 77.8%) had converted by two months, whilst two (n=2, 11.1%) patients 
had converted to an indecisive result and two patients remained smear-positive (n=2, 11.1%).  
 
Only one (n=1) of the smear-indecisive patients was re-tested at five months and this was also a 
negative result. The smear-positive patients who had converted at two months (n=14) also tested 
negative at five month follow-up. Both of the patients with positive smears at two months had converted 
by five months (n=2), while one of the patients with an indecisive smear showed a negative sputum 
result (n=1). The remaining participant (n=1) from the two-month indecisive group still had an indecisive 
result at five months.  
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Therefore, of the original eighteen participants who presented with positive smears at baseline, 94.4% 
(n=17) had converted by the five-month follow-up period. Table 3.30 indicates any differences in overall 
sputum results over time.  
 
Table 3.30: Sputum results over follow-up period 
 
Time period  p-value Test  Outcome  
Baseline sputum → two-month sputum  p<0.001  McNemar-Bowker Reject null hypothesis 
Baseline sputum → five-month sputum  p<0.001  McNemar-Bowker Reject null hypothesis 
Two month sputum → five-month sputum  p=0.317  McNemar Do not reject null 
hypothesis 
 
   Bold and shaded variables indicate statistical significance  
 
There was, therefore, a significant difference between sputum results between baseline and two months 
(p<0.001), as well as baseline and five months (p<0.001) which was confirmed via a McNemar-Bowker 
test (a variation of the chi-squared test). The absence of a difference between two-month and five-month 
sputum results was shown via a McNemar test.  
 
The changes between sputum results during the follow-up period as compared with HOMA-IR and 
QUICKI values are shown in Table 3.31.  
 
Table 3.31: Changes in sputum results over time compared with HOMA-IR and QUICKI values 
 







HOMA-IR      
Baseline F (2, 53) = 1.70 3.01 (4.08) 1.40 (0.80) 1.78 (1.46) 0.76 
Two months  F (2, 21) = 0.37 3.41 (5.12) 1.31 (0.23) 0.93 (0.44) 0.47 
Five months  F (1, 18) = 0.14 2.03 (1.21) 1.56 (-) -  1.00 
QUICKI       
Baseline F (2, 53) = 0.26 0.36 (0.06) 0.37 (0.03) 0.37 (0.05) 0.76 
Two months  F (2, 21) = 0.35 0.36 (0.06) 0.37 (0.01) 0.39 (0.03) 0.47 
Five months  F (1, 18) = 0.02 0.35 (0.03) 0.36 (-) - 1.00 
 
   *Kruskal-Wallis  
   SD = standard deviation; HOMA-IR = homeostasis model assessment-insulin resistance; QUICKI = quantitative insulin sensitivity   
   check index 
 
As can be seen in Table 3.31, it appears as if the smear-negative group have both higher HOMA-IR and 
lower QUICKI values at all periods during the study, although none showed significant differences. 
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3.16.2    Follow-up Sputum Results (between IR and non-IR groups) 
 
Table 3.32 illustrates the changes the baseline IR group experienced over time. There were only nine 
of the original fifteen participants in Group 2 (follow-up group) and only eight of these had sputum results 
available at baseline.  
 
Table 3.32: Comparison between Group 2 IR and non-IR group at two and five-month follow-up 
periods 
 
Sputum result classification  IR Group  non-IR Group  
   
Baseline  n=8 n=19 
Smear-negative n=1 (12.5%) n=4 (21.1%) 
Indecisive  n=1 (12.5%) n=3 (15.8%) 
Smear-positive  n=6 (75.0%) n=12 (63.2%) 
Two month follow-up  n=7 n=16 
Smear-negative n=7 (100.0%) n=12 (75.0%) 
Indecisive  n=0 (0.0%) n=2 (12.5%) 
Smear-positive  n=0 (0.0%) n=2 (12.5%) 
Five month follow-up  n=7 n=12 
Smear-negative n=7 (100.0%) n=11 (91.7%) 
Indecisive  n=0 (0.0%) n=1 (8.3%) 
Smear-positive  n=0 (0.0%) n=0 (0.0%) 
 
     IR = insulin resistant 
 
As can be seen by the data presented in Table 3.32, all of the IR participants presented with negative 
smears at both two- and five-months, barring one participant who was not re-tested. All six of the smear-
positive patients smear-converted by two months (n=6; 100.0%).  
 
Despite the IR group having all their scanty-positive and smear-positive participants convert to smear-
negative by the two month follow-up, no differences between the IR and non-IR groups were shown 
when comparing sputum results at two months (p=0.330; M-L Chi-square) and five months (p=0.304; 
M-L Chi-square).  
 
3.17   SUMMARY OF MAIN FINDINGS 
 
Table 3.33 provides a tabulated summary of the main study findings discussed in this chapter.  
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Table 3.33: Summary of main study findings  
 
OUTCOME CATEGORY MAIN FINDINGS  
Anthropometry   The majority (61.0%) of participants in the study had a normal BMI although some 
were classified as overweight (BMI>25 kg/m2).  
 Despite the majority of patients having a BMI within the normal range, the total 
body fat was still relatively low, and most patients were classified as being either 
‘underweight’ or ‘slim’ when assessed.  
 The majority of anthropometrical measurements showed a significant increase 
whilst the patients were on treatment, with the greatest changes taking place 
during the intensive phase (first two months of treatment).  
 Some patients failed to gain more than 5% weight over the five-month period 
and/or remained in the underweight BMI category. 
 There was a significant increase in both fat and fat free mass over time. 
 The increase in fat mass seemed to be associated with gains in both the 
peripheral and trunk area (albeit slightly more in the trunk area). 
Biochemistry  The most noticeable derangements in baseline biochemical values showed the 
majority of patients having an increased CRP level and a decreased HDL-
cholesterol level  
 There were relatively few presentations of hyperglycaemia and/or abnormal 
insulin levels in the study although IR rates were found to be high.  
 CRP, albumin and white cell count all showed an improvement over time 
(especially in the intensive treatment phase). 
 Although the cholesterol levels (total, LDL and HDL) increased in the first two 
months of treatment, indicating a possible improved response to infection, there 
were no differences noted over the last few months. 
Diagnostic IR tests  Using the calculated cut-off point for HOMA-IR (2.477), the IR prevalence at 
baseline was 25.4%, which equates to 1 in 4 persons with newly diagnosed PTB 
having IR.  
 The HOMA-IR and QUICKI levels also improved with time, although not 
significantly, which may indicate a seeming reduction in IR.  
 Some patients who had IR at baseline presented with normal levels at two months 
but then redeveloped IR at five months. In addition, some patients were non-IR at 
baseline, but developed it at two and five months.  
Metabolic Syndrome 
  
 The metabolic syndrome criteria used (IDF and ATP III) failed to classify the 
majority of patients who presented with IR according to HOMA-IR and QUICKI 
calculated cut-offs. 
 Adjusting for patients with the metabolic syndrome according to both IDF and ATP 
III criteria had little effect on the total IR prevalence at baseline.  
IR vs. Non-IR participants  Differences noted in IR patients compared with their non-IR counterparts: IR 
patients were younger, had a significantly higher interpretation of skinfolds and 
percentage body fat and higher fasting insulin values.  
 Although no other significant results were noted, IR patients generally showed a 
pattern with markers of the metabolic syndrome (increased fasting glucose, 
triglycerides and blood pressure).  
 Mean CRP levels were lower in patients with IR compared with their non-IR 
counterparts although not significantly so.  
Sputum results  The majority of patients converted to sputum smear-negative by the five-month 
mark, signifying an improved clinical state.  
 When comparing differences between the sputum smear-positive and negative 
groups, only the fasting glucose measurement was significant; the sputum-
positive group had a lower fasting glucose level than the negative group and 
ultimately ‘less’ IR according to HOMA-IR and QUICKI.  
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3.18      HYPOTHESIS TESTING  
 
According to the union-intersection principle,299,300 which states that for a null hypothesis to be true, it 
needs to be true for all variables, the following can be deduced (see individual p-values in text): 
 The hypothesis stating that there is no difference in anthropometrics or body composition with 
PTB at baseline and follow-up periods was rejected. 
 The hypothesis stating that there is no difference in biochemistry with PTB at baseline and follow-
up periods was rejected. 
 The hypothesis stating that there is no difference in blood pressure with PTB at baseline and follow-
up periods was not rejected. 
 The hypothesis stating that there is no difference in IR status (via HOMA-IR/QUICKI) with PTB at 
baseline and follow-up periods was not rejected. 
 The hypothesis stating that there is no difference in sputum TB results with PTB at baseline and 
follow-up periods was rejected. 
 The hypothesis stating that there is no difference in anthropometrics, body composition, blood 
pressure or sputum results between IR and non-IR adults with PTB at baseline was rejected.  
 The hypothesis stating that there is no difference in anthropometrics, body composition, blood 
pressure or sputum results between smear-negative and smear-positive adults with PTB at 
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Given the current worldwide status of tuberculosis as the second leading cause of mortality attributed 
to an infectious disease, it is evident that this condition is a large-scale threat to achieving the Millennium 
Development Goals, more recently the Sustainable Development Goals, in the years to come. South 
Africa, given its high prevalence of both communicable and non-communicable diseases, has 
unfortunately not escaped its impact or undesirable consequences. Exploration of the bi-directional 
relationship between tuberculosis and diabetes has been gaining recognition in recent years, albeit more 
from a ‘diabetes resulting in tuberculosis’ angle.  
 
Insulin resistance is a common occurrence in a multitude of conditions, of which diabetes and metabolic 
syndrome are but a few.14,15,150,151 Insulin resistance unfortunately has far-reaching and detrimental 
health outcomes for susceptible individuals, specifically relating to cardiovascular and diabetes-related 
incidents.9 Given the recent description in the literature of impaired glucose tolerance, distortions in 
carbohydrate metabolism and altered insulin action among newly diagnosed TB patients257-259 it was 
considered prudent to investigate if there was an association between TB and the development of IR in 
newly diagnosed adults with pulmonary tuberculosis (PTB) in the Western Sub-District of the Cape 
Metropole region of South Africa.  
 
 
4.1       STUDY POPULATION  
 
Of the total number of TB patients admitted to the recruitment site during the period of data collection, 
313 individuals met the criteria for further screening by way of appropriate age, being newly registered 
individuals, as well as presenting with PTB. These participants were further whittled down to those who 
presented with an HIV-negative status. This equated to the majority of screened participants in this 
particular group being HIV-positive (61.3%), which is in line with current statistics reporting a 62.0% 
prevalence rate of HIV-positive TB patients in South Africa.18 Statistics from Albow Gardens clinic (2014) 
tend to support the national findings, with an HIV-positive rate of 52.5% among all TB patients.36 
Although these prevalence rates differ slightly, they confirm the overwhelming burden of the HIV/TB 
pandemic currently seen in Sub-Saharan Africa.  
 
Of the remaining HIV-negative persons, 20.7% were not contactable (n=17) or did not honour the initial 
appointment with the researcher (n=8). If one considers that approximately one-third of patients do not 
complete their recommended anti-tuberculosis treatment, this rate of non-contactable or defaulting 
patients is to be expected.58 
Stellenbosch University  https://scholar.sun.ac.za







Of the potential participants, seven were classified as obese (having a BMI ≥30 kg/m2), which equates 
to a 5.8% prevalence rate. Despite this figure being lower than the national obesity prevalence among 
females (39.2%) and males (10.6%) in the general population,301 this is of concern because although 
TB patients are often viewed as being malnourished, undernutrition is more often than not the norm.50,53 
The presence of overweight/obesity in this population could be symbolic of the double burden of disease 
often seen in developing countries such as South Africa.  Obesity is also often considered to be a slight 
protective factor against TB disease.271 
 
Estimates published in 2012 by the Society for Endocrinology, Metabolism and Diabetes in South Africa 
(SEMSDA), regarding diabetes prevalence in South Africa, show figures of approximately 6.5% in 
persons aged 20 - 79 years, although this could be as high as 13% in urban populations.3 In 2013, the 
South African National Health and Nutrition Examination Survey (SANHANES-1) diagnosed diabetes in 
9.5% of participants, which is in agreement with the above SEMSDA data.301 Only 3.3% (n=4) of the 
potential candidates in this study (with PTB, HIV-negative and newly registered) had confirmed diabetes 
before commencing with TB treatment. Although in the lower range, this prevalence rate is in agreement 
with findings by Jeon et al. in 2010 that showed the TB prevalence rate of current diabetic patients to 
be between 1.7% and 36%.251 The prevalence rate of diagnosed DM in this particular study was, 
however, noticeably lower when compared with other recent studies in both developing and developed 
countries, ranging between 14.8% and 44% (albeit with a range of diagnostic tools).254,261-264 It is 
important to bear in mind that the latter studies included patients who were diagnosed with DM after 
beginning treatment for TB, whilst the prevalence rate mentioned here refers to participants diagnosed 
prior to treatment commencement and thus excluded from participation. Since the 3.3% of participants 
with confirmed diabetes were newly registered PTB patients and were HIV-negative, this could have 
played a role in the lower prevalence rate of diabetes among TB patients. A study conducted in Africa 
documented a two-fold increase in the prevalence of diabetes in TB vs. non-TB patients,302 which is 
considerably higher than that of the current study population.  The low rates of diagnosed diabetes found 
in the current study could also be attributed to inadequate DM screening procedures by health care staff 
during TB testing. Assessing patients for both TB and DM is a growing need in combating the problem 
at hand.38 Participants who were excluded on the basis of obesity could also have presented with DM, 
although this was not verified. 
 
The present study population showed a 13.6% loss to follow-up. This relatively low rate could be 
advantageous, especially since the majority of the data from these defaulting participants could still be 
used in the baseline component of the study. Upon consideration of attrition rates commonly seen in 
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survey/questionnaire-based research, a response rate of 50% is often considered adequate, whilst 70% 
is deemed very good.303 Other authors have suggested that researchers strive to limit maximum loss to 
follow-up to less than 20%.304 Although the follow-up aspect of the present study follows a cohort study 
design, loss to follow-up rates of more than 20% in randomized controlled trials (RCT’s) have also been 
shown to affect the validity of trial results.305 Data published in 2013 shows that almost one-quarter of 
patients presenting with smear-positive sputum results are lost to follow-up before starting with their TB 
treatment.306 Factors identified as having an impact on patients once treatment has commenced include 
socio-economic issues, patient specific factors, treatment-related issues and factors relating to the 
specific function of the health system in the country.5  
 
With regard to demographic data, the majority of participants in the present study were males, which is 
in agreement with global data and data from the Western Cape Province.18,23,24,36 This phenomenon has 
been widely documented in literature, and proposed theories include a mixture of socio-economic and 
cultural factors, including inequality on various platforms, thus affecting access to health care services 
and adherence to pharmacological treatment.24,307,308 Other hypotheses for the disproportional gender 
findings include greater exposure of men to M tuberculosis as a result of increased opportunity for social 
interaction309,310 and inter-gender variations in immunological processes and sexual hormones.311,312 
The impact of gender on treatment outcomes is also of interest but is unfortunately beyond the scope 
of this study.  
 
The mean age of the study participants agreed with global data indicating that the majority of TB cases 
occur in the 15 to 59-year-old age group.18 A further sub-analysis also showed that the majority of 
participants fell into the 18 to 30-year-old age group (young adults),23 a vital segment of the national 
work force, which could have crippling effects on the functioning of the nation’s economy.   
 
The majority of participants were black African, followed by the coloured group and then the white 
participants. This is largely in agreement with the national demographic profile of South Africa, with 
black African’s being in the majority (80.2%) and coloured and white participants being similarly 
distributed as 8.8% and 8.4% respectively.313 However, given the strong coloured representation in the 
Western Cape Province, this group is very often in the majority, followed by black African’s and then 
whites.313 Possible reasons for the disparity in racial distribution could be clinic-specific because the 
area of data collection is known to be home to citizens of neighbouring African countries such as 
Zimbabwe, and these persons would be classified as black African.  
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4.2    ANTHROPOMETRY RESULTS  
 
Group 1 and 2 were selected on the basis of consecutive sampling, and no significant differences were 
expected between the groups. If any differences did occur, it could probably be explained by chance.  
 
Upon consideration of the significant mean anthropometrical measurements at baseline according to 
gender, males had both a higher body weight and height (stature). This occurrence is generally accepted 
since males have a higher body weight than females due to a larger stature and increased muscle (or 
fat-free) mass.2 Conversely, a national survey in 2013, (SANHANES-1), conducted among the general 
population showed that whilst males tended to be significantly taller than females, the latter had a far 
higher body weight than the males.301 Although this is not true for the present TB-specific study 
population, it is, however, evidence of the growing obesity epidemic in the country, especially among 
females because a larger body weight is often culturally linked to greater wealth and prosperity. Although 
the mean BMI of the female participants in this study was slightly higher than their male counterparts, 
this difference was not significant. Although TB-infected individuals do not typically present with an 
increased BMI, current evidence in South Africa shows that far more women fall into either the 
‘overweight’ or ‘obese’ BMI category than do males.301 It is, however, important to realise that the 
SANHANES-1 data was obtained from the general South African population, which differs vastly from 
the specific TB population under investigation.  
 
Although the mean BMI at baseline was classified in the normal range for both males and females, there 
was an overall prevalence of 33.9% of undernutrition (classified as a BMI <18.5 kg/m2) among the study 
population. These rates of undernutrition are in agreement with previously described rates of between 
20% and 71.6%, albeit on the lower end of the spectrum.59 A low BMI at diagnosis has been linked to 
an increased risk of relapse61 and demonstrates an indirectly proportional relationship existing between 
BMI and mortality risk.68 These at-risk patients should, therefore, be noted at diagnosis and followed-up 
throughout the treatment process.  
 
Although the basic anthropometrical measurements are performed upon diagnosis (weight, height and 
BMI) in accordance with the Department of Health (DoH) guidelines, and the patient is placed on the 
Nutritional Therapeutic Programme (NTP) if need be, in South Africa, there are often many problems 
relating to the successful implementation thereof. In the personal experience of the researcher, these 
problems often equate to issues such as high patient default rates, unavailability of supplementation 
stock at facilities and general abuse of the programme such as sharing and substitution of products 
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between family members. Ultimately, these have a detrimental impact on the nutritional status of the 
individual. Of interest to this particular study is the fact that a small number of participants were entered 
onto the NTP by the clinic staff because they met the qualifying criteria mentioned previously. The 
provision of supplementation could, therefore, be seen as a contributing factor to the weight gain seen 
over time, although it is uncertain if these products were issued on a regular basis or used correctly by 
the patient.  
 
Previous studies have also indicated that the occurrence of undernutrition among TB patients cannot 
be solely attributed to the disease itself but rather to a multitude of contributing factors, such as extreme 
poverty, food insecurity and reduced health-seeking behaviours.67,69 Although South Africa is still viewed 
as a developing country, levels of socio-economic depletion may not be as crippling as in other African 
countries. The high rates of overweight and obesity found among the general population in South Africa 
could also have a spin-off effect of increasing the mean BMI of the average TB patient from 
undernourished to normal (as seen in the current study) when compared with other African countries 
where overnutrition is not as prevalent.  
 
It was unfortunately beyond the scope of this study to assess TB-related weight loss before diagnosis 
and treatment commencement, and results would very likely be inaccurate if reliant on patient reporting 
alone. It would, however, be of interest to determine which patients were underweight for a time before 
their diagnosis, as well as track their progress whilst on treatment, since some studies have shown 
underweight to be an independent risk factor for TB disease.61,62 The weight loss experienced in patients 
with TB is postulated to be part of the APR, resulting in the release of cytokines, leading to an overall 
anorexic effect.114  
 
There were no significant differences in the measures of abdominal obesity between genders. According 
to the recent SANHANES-1 findings,301 one might have expected to see the females with larger 
measurements. Since all participants were excluded on the basis of having an increased waist 
circumference measurement (>88 cm in females and >102 cm in males), it is, therefore, logical that all 
of the patients would fall into the ‘not at risk’ group. This is in contrast to the increased prevalence of 
augmented measurements in the general South African population, with approximately half of the female 
population having an enlarged waist circumference.301 Given the fact that this TB study population was 
somewhat more prone to undernutrition than the general population and differed from the normal 
population profile, the results were, therefore, as expected. 
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More females than males were classified as having an increased waist:hip ratio (although the waist:hip 
ratio measurements showed no significant inter-gender differences), which was congruent with findings 
in the SANHANES-1 study. Waist circumference seems to be the more reliable indicator of visceral fat 
distribution.2,161 Both the IDF and ATP III definitions are relying more on this measurement than the 
previous waist:hip ratio, which is postulated not to be as absolute a measurement.180 Current thinking 
also regards fat distribution (i.e. android vs. gynoid) to be a more valuable risk factor for mortality and 
morbidity than obesity (i.e. measured by BMI).2  
 
The female participants also presented with significantly higher measurements of skinfolds, fat mass 
and percentage body fat. These findings are in agreement with the literature in which the ranges of cut-
off for body fat for women are significantly higher than those for males.2 The higher fat mass in females 
also indicates why conversely, males have a higher fat-free mass. 
 
Upon consideration of the percentage body fat of the participants, the majority fell into the groups of 
‘underweight’ (33.9%) and ‘slim’ (50.8%). This links to the concept of TB wasting in which a loss of both 
fat mass and lean body mass (LBM) has been described in similar patients.55 Although the current study 
excluded HIV-infected persons, previous studies investigating wasting in HIV-infected and uninfected 
TB patients have postulated that TB, not HIV, seems to be the main driving force behind the wasting 
occurrence.55 
 
Previous studies have documented the seemingly greater loss of LBM in the limbs compared with the 
FM loss in the trunk area due to the TB wasting syndrome.55 Regarding this study, if one considered the 
triceps skinfold (peripheral fat) as well as the subscapular skinfold (truncal fat), it was noted that whilst 
the triceps values for both genders were interpreted as being below average, the subscapular skinfold 
in the female group was defined as average, thereby not reflecting a decreased FM in this area. This 
occurrence should ideally be repeated among a larger study population to assess the accuracy of 
findings in the current study. This also highlights the possibility of gender-specific differences in body 
composition in TB patients, as previously reported by Mupere et al.81  
 
Because the participants were not stratified according to demographics (gender, race or age), possible 
conclusions were interpreted with caution. 
 
Markers of abdominal obesity performed in accordance with the literature since both waist 
circumference and waist:hip ratio increased with age, as was documented in the SANHANES-1 
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study.301 Although the oldest participant in the current study was only 62 years old, it was noted that 
body weight,314 total body fat and intra-abdominal fat generally increase with age, very often at the 
expense of subcutaneous peripheral fat.2  
 
The mean weight of the participants in the follow-up group increased by 7.4% overall between baseline 
and five months. The greatest weight gain occurred during the intensive phase of treatment, which was 
synonymous with the majority of the findings in this study showing significance during that specific time 
period. The intensive phase is described as the initial two months after treatment commencement, when 
a more aggressive regimen of TB drugs was prescribed, namely isoniazid, rifampicin, ethambutol and 
pyrazinamide.5 This regimen was largely followed in order to reduce the possibility of developing drug 
resistance and to target the various strains of bacteria.21 Once this period was completed, a less 
antagonistic protocol was followed in which fewer drugs were administered.  
 
This finding regarding the period of weight gain is interesting since one could expect a catabolic effect 
accompanying infectious conditions, which may have an inhibitory effect on weight gain. Evidence of 
the catabolic effect was seen in a study conducted in Cape Town, South Africa that documented an 
initial weight loss amongst hospitalised (severely ill) HIV-negative TB patients shortly after treatment 
commencement.315  
 
It could also be postulated that this catabolic stage could occur pre-diagnosis when the patient is still 
largely symptomatic. Therefore, after TB treatment commencement and symptom resolution, patients 
could undergo an improvement in clinical symptoms, such as an increase in appetite, which could 
partially be responsible for the weight gain seen during this time.  Of the ten patients that experienced 
a weight loss during the current study, the minority (30%) underwent the loss during the first two months. 
This could perhaps be equated to the patients in this study being ambulatory who were well enough to 
attend the health facility, versus those who were more severely ill.   
 
Overall weight gain of TB patients whilst on treatment is also a common phenomenon 54-56,71,73-76 
although some researchers are hesitant to use weight gain as a marker of successful response to 
treatment.66,316 Although the majority of patients gained weight over the duration of treatment, there were 
some that lost weight at two or five months. All participants, bar one, had surpassed their baseline 
weights by the end of the follow-up period.  
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It has been reported that patients with a low BMI at diagnosis and those failing to gain more than 5% 
weight between diagnosis and completion of treatment were at greater risk of relapse.61 In the current 
study population, 31.0% of participants did not achieve more than 5% overall weight gain. The majority 
of these patients all had normal BMI’s at the end of treatment, which may cause them to be overlooked 
if BMI is used as the sole anthropometric predictor of treatment outcome. These patients should, 
therefore, be observed closely and routinely followed-up at the health facility, even after successful anti-
tuberculosis treatment.    
 
Of the patients who were classified as underweight according to BMI at baseline, there were several 
that remained in this category at the five-month follow-up despite having gained weight. This is 
unfortunately also a common occurrence in this particular patient group66,71 and once again highlights 
the need for follow-up and support post-treatment. There were three patients who fell into the upper 
range of normal BMI at baseline but were subsequently classified as overweight at two and five months 
due to weight gain. Therefore, attention should also be given to these patients because they are 
considered malnourished and could be overlooked in light of their leaner counterparts.  
 
There was a significant increase in measures of abdominal adiposity over the five-month period. There 
was only one participant who exceeded the previously mentioned cut-off points for waist circumference 
at two and five months, thus placing him at a higher risk of developing chronic diseases. However, the 
overall increase seen in the study population should still be monitored given the excessive visceral 
obesity rates seen in South Africa and the propensity of gains in fat mass whilst on TB treatment.55   
 
Because the BMI and body weight alone are often insufficient means for documenting changes in body 
composition,81 skinfolds were also performed in the current study. Previous research conducted by 
Paton et al. in 2004 reported that the majority of later weight gain in TB patients on treatment was due 
to an increase in fat mass (FM).57 Results of the current study, however, show a significant increase in 
fat free mass (FFM) in all follow-up periods, which is in contrast with the increase in fat mass seen only 
during the intensive phase of treatment and between baseline and five months. This might indicate that 
patients in this study gained FFM beyond the intensive two-month period, which is promising because 
LBM or protein mass is associated with improved functionality, quality of life and longevity.57,66,84  
 
With regard to the sum of skinfolds measurement, findings largely echoed that of the fat mass and 
percentage body fat measurement, with the noticeable differences occurring during the intensive phase 
of treatment. The peripheral skinfold measurements (biceps and triceps) either showed no differences 
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over time or the increases occurred after the two-month period. The trunk/central measurements, 
namely the suprailiac skinfold, mimicked the sum of skinfolds outcome, whilst the subscapular values 
showed an increase only at the five-month mark. Gains in FM, therefore, seemed to occur in both the 
peripheral and trunk area of these patients (albeit slightly more in the trunk area), resulting in a more 
proportional fat distribution. Although there are individual variations in each of the four skinfolds 
measured, participants in this study experienced an overall significant increase in fat mass whilst on TB 
treatment, which is in line with the literature.  
 
The secondary objective of assessing any changes in anthropometrics and body composition between 
baseline and the follow-up periods was thus achieved since significant differences were noted.  
 
 
4.3    BIOCHEMISTRY RESULTS  
 
The results obtained from study participants were all compared with standardised values used by the 
laboratory tasked in the analysis of the specimens (NHLS).289 
 
Albumin and CRP are both markers of the inflammatory response, the former a negative acute phase 
protein, whilst the latter is a positive acute phase protein. If considering the baseline albumin levels of 
the study population, the mean albumin level was within normal reference ranges. Contrary to this 
finding, the mean CRP level at baseline was noticeably raised. Findings verifying low levels of albumin 
and high CRP levels in TB patients have been well documented in literature. 52,114,120,122-124 However, it 
is perhaps the raised CRP level that is more indicative of active TB disease because it has been 
described as a non-specific measure of systemic inflammation in the body.114 The degree of CRP 
escalation has also been linked to the presence of weight loss and to disease severity, and this may 
increase levels even further.114  
 
No hospitalised, drug-resistant or HIV-infected patients were included in this study. Therefore, the 
albumin levels were possibly not as severely affected due to the patients being relatively ‘well’ TB 
patients (i.e. with predominantly normal BMI’s). This could perhaps also be equated to a form of ‘adult 
marasmus’, a form of PEM, whereby the albumin level remains normal.317 One could postulate that in 
more stressed, hospitalised patients, the albumin level may be significantly lower; a study in South 
America associated on-admission hypoalbuminaemic levels in TB patients with an increased risk of in-
hospital mortality.120 Hypoalbuminaemia is also linked to the inhibitory action of cytokines on albumin 
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production (due to albumin being a negative acute phase protein), ultimately lowering levels of the 
protein and resulting in alterations in plasma concentrations of other essential micronutrients.111 
 
Despite the mean white cell count (WCC), also referred to as the leukocyte count, falling into the normal 
reference range, about one-third of the study participants presented with increased values. This 
occurrence is relatively common because increased white cells (leukocytosis) often indicate the 
presence of an infection in the body, which is the case in TB. Incidences of leukocytosis in the setting 
of TB compared with healthy controls have also been described in the literature.72,114  
 
According to the SEMSDA 2012 guidelines for the management of type 2 diabetes, a fasting plasma 
glucose level of between 6.1 mmol/L and 6.9 mmol/L classifies an individual with impaired fasting 
glucose (IFG) and any value ≥7.0 mmol/L to be indicative of a diabetes diagnosis.3 Taking this into 
account, only one individual in the current study was classified with IFG (1.7%) and two with diabetes 
(3.4%). The two patients who were classified as having diabetes on the basis of their baseline fasting 
glucose result were, however, not excluded from participating in the study because they were not 
diagnosed diabetics at the time of recruitment (See Chapter 2.5). A systematic review published by Jeon 
et al. in 2010 showed total DM prevalence in TB patients to fall between the range of 1.9% and 35%,251 
but some of these were diagnosed only after development of TB. Given South Africa’s high prevalence 
rates of TB, its status as one of 22 HBCs and its high rate of non-communicable diseases, this study 
may have been expected to exhibit a far higher number of DM patients.243 However, it is important to 
remember that participants recruited for this study excluded any persons already diagnosed with 
diabetes, which resulted in a lower prevalence rate.  
 
Upon consideration of the minority of patients that were classified as having either IFG or diabetes on 
the basis of their fasting glucose levels at baseline, it is prudent to make comparisons with similar 
studies. In a cross-sectional study conducted in West Africa, participants displayed a 5% IFG and a 
1.9% DM rate (in accordance with SEMSDA cut-off points above), which is comparable with the current 
study despite differing inclusion criteria (inclusion of pre-existing diabetics, HIV-positive and/or obese 
patients in the West-African study sample).318 A retrospective study performed in Sri Lanka found 7.1% 
pre-existing DM among their study sample, as well as 20% IFG and 2% DM rates. The high rate of IFG 
found in this study could perhaps be attributed to the lower fasting glucose cut-off points used in the 
diagnosis of this condition (5.6 – 6.9 mmol/L).319 
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Therefore, it would be advised to repeat the fasting plasma glucose in those patients with either IFG or 
suspected DM and to perform another corroborative test, such as an OGTT or HbA1C, before 
diagnosing diabetes. This stress/transient hyperglycaemia experienced in TB patients is a well-
described phenomenon in the literature since the raised glucose levels at diagnosis246,251,254 often 
subside with the progression of treatment.248,249 Certain anti-TB medications (such as Rifampicin) have 
also been documented to result in higher than normal levels of glucose in the beginning stages of 
treatment.260 In addition, the effect of pro-inflammatory cytokines is possibly related to IR increase and 
concomitant reduced insulin production.244 Counter-regulatory stress hormones (e.g. cortisol, glucagon 
and epinephrine) are often released during periods of inflammation in the body, and these have been 
shown to inhibit insulin action, which could also result in the hyperglycaemic response.245 These 
phenomena highlight the importance of confirmatory DM tests at diagnosis, during treatment and post-
treatment.243   
 
The preliminary stages of IR often present with normal fasting glucose levels (contrary to the TB 
medication-induced hyperglycaemia), which will progress to impaired fasting glucose and ultimately DM 
as the condition develops. This could indicate that patients with a normal glucose at baseline have 
already suffered β-cell damage and could have IR.320  
 
Although an isolated fasting insulin measurement was previously credited with being a relatively good 
indicator of IR,214 given the pathophysiology of IR and hyperinsulinaemia, current opinion suggests that 
due to the variability of the marker, formulae encompassing more than one fasting value are preferred, 
such as the HOMA-IR or QUICKI.194 Although normal reference values for fasting insulin do exist, there 
are no standardised cut-off values specifically identifying IR. The current study showed a very small 
proportion of patients having raised insulin levels at baseline, thereby confirming the suggestion that 
fasting insulin alone is insufficient to classify IR.   
 
A study conducted in the Eastern Cape Province of South Africa found higher levels of both glucose 
and insulin in TB patients compared with controls.257 Once again, due to the unavailability of a control 
group in this particular study, it is difficult to make comparisons. It could be postulated that although the 
TB patients in this study did not show abnormally high levels of glucose or insulin (according to the cut-
off values used), the levels could perhaps be higher than in those who did not have active TB disease. 
The findings from the Eastern Cape study also suggested that there was an alteration in insulin/glucose 
metabolism in the patients with TB, which is in agreement with the suggestion of Karachunskii et al. that 
carbohydrate metabolism was altered.258  
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With regard to the lipogram performed at baseline, the most noticeable abnormality was the reduced 
HDL-cholesterol values, which occurred in the majority of patients. A lowered total cholesterol level has 
previously been described in the literature,45,113,114 in which it was hypothesised that prolonged 
persistence of the TB bacterium may result in cholesterol breakdown, especially in persons who had 
been infected latently for a period of time. Interestingly, many of the conditions that are believed to result 
in higher TB risk, often present with concomitant hypercholesterolaemia.117 
 
Reduced HDL levels have been reported in numerous studies with various infectious or inflammatory 
conditions.321-323 A study by Deniz et al. in 2007 showed lowered levels of HDL-cholesterol in their PTB-
specific study population.113 The authors hypothesised that this finding could be linked to the activated 
APR often seen in TB disease and, more specifically, to acute phase proteins, secretory phospholipase 
A2 (sPLA2) and serum amyloid A (SAA).324-327 Other compounds such as ATP-binding cassette 
transporter (ABC)-1 and decreased lecithin cholesterol acyltransferase have also been implicated in 
reduced HDL-cholesterol during periods of infection or inflammation, albeit some in animal studies. 328,329 
The Deniz et al. study also showed that the HDL-cholesterol concentrations were negatively correlated 
with the degree of smear positivity as well as the radiological extent of the disease, therefore, identifying 
the ‘sicker’ patients with lowered levels of HDL-cholesterol.113 In addition, low HDL levels have also been 
linked to an increased cardiovascular disease risk.301  
 
Previously, LDL-cholesterol levels have also shown to be diminished in times of infection or 
inflammation,113 largely as a result of activated host response and LDL oxidation.322 If one had to 
speculate and compare findings from this study to the general population, as found in the SANHANES-
1 study in 2013, levels of total cholesterol, LDL-and HDL-cholesterol as well as triglycerides for both 
genders were all lower than the mean values in the larger national cohort.301 Once more, this finding 
could be expected because this was a very specific study population (obese and metabolic syndrome 
patients excluded). In a population consisting of chronic diseases of lifestyle participants (obesity and 
metabolic syndrome included), one might expect to see higher levels of blood lipids.  
 
The current study found a significant difference between inter-gender total cholesterol levels, with 
females showing a higher value. This is in line with findings from the SANHANES-1 study that found 
higher levels of total and LDL-cholesterol when compared with males.301 Literature has also documented 
findings of lower triglycerides and higher HDL-cholesterol in women330-334 although no significance was 
found in this study. On the contrary, other studies have found males to have a more atherogenic profile 
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than their female counterparts.335 It should be noted, however, that since the study was not stratified 
according to demographics, this data should be interpreted with caution.  
 
With regard to racial distribution, the current study found that the white participants had the highest 
levels of total and LDL-cholesterol, whereas the black African group displayed the lowest levels. This 
finding is in line with SANHANES-1 data, which also placed the black African race in the more ‘beneficial’ 
group.301 This can be further extrapolated because epidemiologically, black African males tend to have 
a greater prevalence of cardiovascular risk factors, yet their lipograms reflect a more positive 
HDL,331,332,336-339 LDL336,337and triglyceride331-333,336-339 picture when compared with white males.340 Whilst 
literature has reported black or African American males to have higher HDL-levels due to possible 
reduced activity of hepatic lipase,341 the current study shows the HDL levels to be lower among the black 
African population.   
 
The baseline fasting insulin level was shown to be significantly higher among younger participants. See 
Chapter 4.5 for further discussion on this phenomenon.  
 
Upon consideration of follow-up biochemisry results, the majority of changes  occurred during the 
intensive phase of treatment (i.e. from baseline to two months after commencement of treatment). 
During this time, a heightened response to the treatment is often noticed, depending on the patient’s 
adherence to the medication. This reduction in mycobacterial load has also been documented in 
previous years by the WHO, which noticed an improvement over the first three months of treatment.342 
Although the majority of significant results are seen in this time period, it remains vital to complete the 
full course of treatment because the intensive phase cannot singularly resolve TB.107 In the current study, 
albumin, CRP, white cell count, total, LDL-and HDL-cholesterol all experienced significant changes 
during this specific time period.  
 
Although there were two participants who could be classified as having ‘diabetes’ according to their 
fasting glucose levels at baseline, there were no patients with significantly increased levels at either two 
or five months. Mean glucose levels were reduced (although not significantly) between baseline and 
five months, and this could perhaps be seen as a resolution of the hyperglycaemic response seen in 
the beginning stages of treatment. This has been previously described in a few studies.246,248 The 
reduced blood glucose levels could also be attributed to the diminishing infection over time.254 This 
phenomenon could possibly be explained by the diminished effect of the anti-TB treatment, notably 
rifampicin, because this pharmaceutical aid has been shown to induce a maximum hyperglycaemic 
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effect approximately seven days after commencement of treatment, which resolves two weeks after 
ceasing treatment.343  
 
As previously mentioned, albumin and CRP are both synonymous with the APR, and TB can be seen 
to elicit a similar response in the body. The current study saw an increase in albumin levels, as well as 
a decrease in CRP. This would suggest a ‘resolution’ of the APR or a suppression of the inflammatory 
response,122 which is a phenomenon well reported in literature, both for albumin107 and CRP.46,107,122-126 
The white cell count performed similarly to the CRP, with a significant decrease between baseline and 
two months. This could also be indicative of an improved response to infection or inflammation although 
mean values remained normal throughout the five month period, which could indicate that CRP is the 
more sensitive marker.  
 
In the follow-up group, the majority of patients had a raised CRP level at baseline although this 
decreased over two and five months. There were, however, some patients who still presented with a 
raised CRP at the five-month mark, which could perhaps indicate a sub-optimal treatment response123 
or the presence of other infections, especially if the CRP did not show an overall downward trend. The 
elevated CRP together with an overall clinical picture of the patient should, therefore, be considered, 
and these patients should be monitored closely for treatment failure or possible relapse risk.  
 
The mean albumin level of the follow-up group remained within the normal range throughout, and there 
was only one patient who had a reduced albumin level at the five-month mark. This is in contrast with 
the raised CRP levels, which remained high even at five months, as well as there being eleven 
participants with raised levels at this time period. This could perhaps suggest that CRP could be a better 
marker of treatment response when compared with albumin.  
 
The phenomenon of reduced total and HDL-cholesterol levels at baseline has already been discussed 
in Chapter 4.3. Total cholesterol, as well as LDL-and HDL-cholesterol all experienced a significant 
increase in the intensive treatment phase, with no significant differences occurring between the two-and 
five-month periods. This is an unusual finding because one might expect the values to increase even 
more at the end of the follow-up period. This finding could be the result of a small sample size and 
definitely warrants more investigation given the important role of adequate cholesterol levels in 
protection against the mycobacteria.  
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A very controversial recommendation based on the hypothesis that an increased dietary intake of 
cholesterol or cholesterol supplementation, could perhaps fast-track the smear-conversion rate in PTB 
patients, has been made.344,345 If future findings show that cholesterol levels experience a tapering off 
after the intensive phase, these researchers suggest the possibility of exploring the option of exogenous 
cholesterol provision as a prophylactic measure to improve treatment response and relapse risk.344,345 
This is still, however, in a very exploratory stage and should not be recommended as standard practice 
since more evidence is needed.  
 
The secondary objective of assessing changes in the biochemistry values between baseline and the 
follow-up periods was also achieved, and significant differences were noted.  
 
 
4.4  BLOOD PRESSURE RESULTS  
 
Given the importance of hypertension as a risk factor for the development of cardiovascular disease 
(including stroke and ischemic heart disease), it was of interest to consider the prevalence in this 
particular population because South Africa suffers from a high burden of non-communicable diseases. 
The presence of hypertension (raised levels and/or on medication) is a category in assessing the 
metabolic syndrome, in which the presence of IR is strongly associated.  
 
The minority of participants had a blood pressure value that classified them as hypertensive at baseline 
(13.6%), and 18.7% were defined as pre-hypertensive. The majority of participants fell into the normal 
blood pressure category. These results should, however, be interpreted with caution because 
hypertension is not traditionally diagnosed during the first visit (as was done in the current study) but 
rather over a period of time.346 
 
The prevalence rate found in this study is noticeably lower than global data published in 2001, which 
showed a worldwide hypertension prevalence of 26.4%,347 and specific South African data generated 
from a survey performed in 1998 by Steyn et al. indicated South Africa had a minimally lower prevalence 
rate of 23.9%.348 Results from the Lancet study also make mention of the increased risk of hypertension 
in developing countries, of which South Africa is one.347 More recently, blood pressure values in South 
Africa were clinically assessed by the SANHANES-1 group on a small sub-sample of participants and 
showed pre-hypertensive rates of 10.4% in persons aged 15 and older, whilst hypertensive rates 
depicted a 10.2% nationwide prevalence.301 These results should, however, be interpreted with caution 
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because a large proportion of the blood pressure data in the SANHANES-1 study was self-reported. 
Once more, it is challenging to apply the available hypertension prevalence rates to the study population 
because it differs considerably from the general population from which the majority of data was gathered.  
 
There were no significant differences noted between baseline and the follow-up periods for blood 
pressure specifically, which addresses another of the secondary objectives (See Chapter 2.1). 
 
 
4.5   DIAGNOSTIC INSULIN RESISTANCE TEST RESULTS  
 
As was mentioned in Chapter 1.5, a multitude of different methods exist for the measurement and 
diagnosis of an IR state. Although the hyperinsulinaemic-euglycaemic clamp (HEC) has largely been 
recognised as the ‘gold standard’,6,13,187,188 it is not without its disadvantages (often pertaining to 
excessive cost and labour constraints), and less invasive indices are, therefore, often utilised.  
 
The HOMA-IR is one of the so-called ‘fasting indices’, which utilises fasting measurements of both 
glucose and insulin in its formula calculation. The HOMA-IR has been used extensively in 
epidemiological research and as a routine measurement in clinical practice187  and together with the 
QUICKI20 has proved to be a very popular fasting index.7 It has shown positive correlations with the gold 
standard measurement (HEC),13,187,196,216 been validated by the Insulin Resistance and Atherosclerosis 
study (IRAS)221 and has also been recommended as one of the methods for IR testing by the IDF.180 
The HOMA-IR is simple to perform, not labour intensive for staff, minimally invasive for the patient, cost-
effective and useful in follow-up studies.6,10,13,142,189 This made it an appropriate choice for the current 
study although it is definitely not without criticism due to several limitations of fasting indices in general, 
such as measuring hepatic and not peripheral IR.  
 
Newer versions of the HOMA-IR are mentioned in literature such as the HOMA2, which was released 
in 2004 and details the β-cell function and insulin sensitivity of an individual.13 This version has, however, 
not been validated196 and according to the literature is not used widely for the classification of IR. It was 
thus not used in the current study. The majority of other studies using the HOMA as a reference value 
have used the HOMA-IR, which makes inter-study comparison more feasible.  
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Although no significant results emerged from this sub-section (apart from IR tests and age), it was noted 
that the mean baseline value for HOMA-IR was above the cut-off point used to classify IR in this study. 
Similarly, the calculated QUICKI cut-off was below the mean value, thus also classifying IR. There were 
no significant differences for either gender or race but again, caution should be exercised given the lack 
of stratification, which fell outside the scope of this study. Various sources have identified age, gender 
and race or ethnicity-specific differences in HOMA-IR and QUICKI levels, and specifically in South 
Africa, greater levels of IR have been found among obese black Africans and Asian Indians when 
compared with white persons.349-350 This would be useful to pursue in a follow-up study seeking to 
document these specific occurrences.  
 
The incidence of IR decreased (lower HOMA-IR and higher QUICKI) with age, as was seen previously 
with a significantly higher baseline fasting insulin value among the younger participants. This 
phenomenon is discussed in more detail in Chapter 4.8. 
 
The EPIRCE study conducted in Spain also showed HOMA-IR levels to be influenced by physical 
activity, alcohol intake and smoking.351 Whilst physical activity had a protective action by reducing 
HOMA-IR levels, abstaining from substances such as alcohol and nicotine did not since abstainers were 
shown to have higher HOMA-IR levels for both substances.351 Substance abuse, namely alcohol intake 
of >40 g per day and smoking, are responsible for increasing TB risk by a relative risk of 2.9 and 2.0 
respectively.352  
 
Recent research has also indicated the possibility of genetic influences on the development of IR, 
although at the present moment, minimal variants have been associated with IR development. An 
example of this has been identified as a variant of the N-acetyltransferase 2 (NAT2) gene which has 
been linked to decreased insulin sensitivity irrespective of BMI.353 These genetic studies are, however, 
still in the preliminary stages of investigation but could potentially explain some of the current study 
participant’s having IR despite the absence of the typical chronic disease phenotype.  
 
The follow-up profiles of both HOMA-IR and QUICKI seemed to indicate an improvement in IR over 
time. Although there were no significant differences noted between any of the time frames, there was 
an overall downward pattern with the HOMA-IR and an upward curve for the QUICKI, both signifying a 
‘lessening’ of the IR state. The lack of significance could perhaps be due to the relatively small sample 
size. However, this ties in closely with an improved and diminishing inflammatory response, as 
demonstrated with the improved CRP, albumin and white cell count discussed previously. This could 
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also be due to the well-described ‘stress or transient’ hyperglycaemia seen to occur in the early stages 
after TB  diagnosis and which often resolves with progression of treatment.242,248,249 A state of 
hyperglycaemia would either increase the HOMA-IR value, or decrease the QUICKI reading, thus 
indicating an increased risk for IR.  
 
Despite the largely improved IR status over the five-month follow-up period and the majority of patients 
at the beginning stages of the study having resolved their IR status (albeit two participants), the following 
was noted. Two participants who had normal HOMA-IR and QUICKI values at baseline subsequently 
developed IR at two and five months, and two patients redeveloped IR at five months after originally 
presenting with it at baseline. This contests the stress hyperglyacemia hypothesis, as well as the 
improvement of an inflammatory state, and is an interesting phenomenon to be pursued. It would 
perhaps be prudent to follow-up such participants at a later stage to re-determine the IR status once the 
TB has resolved.  
 
An assessment of changes seen in IR status (using the HOMA-IR and QUICKI) was, therefore, 




4.6   METABOLIC SYNDROME INVESTIGATION 
 
Due to the lack of consensus regarding current guidelines for the diagnosis of metabolic syndrome, 
several studies have made use of multiple criteria to classify their particular study populations.354-356 
Some of the most popular include the IDF and ATP III guidelines, which were the two tools used in the 
current study.  
 
Considering the prevalence of individual components of the syndrome among the total study population 
at baseline, the following was shown: increased waist circumference (5.1% for IDF and 0.0% for ATP 
III); raised triglycerides (1.7% for both IDF and ATP III); reduced HDL-cholesterol (69.5% for both IDF 
and ATP III); increased blood pressure (13.6% for both IDF and ATP III); and raised fasting plasma 
glucose (6.8% for both IDF and ATP III). Apart from the reduced HDL-cholesterol, which has previously 
been discussed within the context of TB (Chapter 4.3), this corroborates the relatively low prevalence 
of individual metabolic syndrome findings, which is to be expected among this study population.  
 
Stellenbosch University  https://scholar.sun.ac.za







Two participants were classified by the IDF criteria at baseline (3.4%), whereas only one was classified 
by the ATP III criteria (1.7%). This seems to indicate that the IDF is a more specific indicator for IR. 
However, in the group of patients that were followed up, the ATP III criteria identified one person with 
the syndrome at two months, which the IDF did not. This is contrary to the baseline findings and 
highlights the disparity between the two methods. This disparity has also been shown in large studies 
such as the AusDiab and DECODE studies, in which the former found that less than 10% of patients 
met the criteria for each of the IDF, ATP III and WHO guidelines. 357,358 This also makes inter-study 
comparison challenging because data is not standardised according to a single definition.  
 
The major difference between the IDF and ATP III guidelines is the classification of the waist 
circumference because different cut-offs are employed. In addition, an increased measurement is a 
prerequisite for the IDF criteria. The ATP III criteria do not require pre-requisite factors in the 
classification of metabolic syndrome and have been reported to have a higher sensitivity than the IDF 
classification.359 Although IR is recognised as an important facet of the metabolic syndrome, both the 
IDF and ATP III guidelines do not take IR into account when classifying an individual with the syndrome, 
which is in contrast to previous definitions (e.g. WHO). This is mainly due to the lack of standardised 
reference values for IR and problems with inter-study measurements of insulin.360 The above-mentioned 
disparity between the different criteria highlights the need to develop a standardised set of guidelines 
that are country and ethnicity specific and are able to identify all individuals correctly. Until this time, the 
most suitable tool (or combination of tools) and cut-off values should be utilised. 
 
When compared with the suggested global prevalence of metabolic syndrome that ranges between 15% 
and 40%,9,147,148 the prevalence rates found at baseline in this study (3.4%) are much lower, which could 
be viewed positively. This could be expected, given the exclusion of patients presenting with typical 
‘metabolic syndrome’ during the recruitment process. The low prevalence rates in this population can 
also be viewed in the light of findings from other studies that indicate a much lower prevalence of the 
syndrome among normal weight or overweight subjects when compared with obese individuals,356,361,362 
of which the current study had none. One could also expect a lower prevalence of the syndrome among 
underweight individuals, of which there were several in this study.  
 
Of the patients classified as having IR according to an increased HOMA-IR level (>2.477), only one was 
identified as having the metabolic syndrome according to both the IDF and ATP III criteria at baseline. 
One IR participant identified by the ATP III criteria presented with the syndrome at two months, whereas 
no IR patients met either the IDF or ATP III criteria at the five-month follow-up. Given the increased 
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prevalence of IR at baseline, according to the specific HOMA-IR cut-off used (25.4%), it appears that IR 
is present before the development of the other components of the metabolic syndrome, and is a result 
of a longstanding IR state in the body.172,363 The HOMA-IR may possibly have preventatively identified 
at-risk persons who may have been overlooked by the IDF and ATP III criteria.354 In a study assessing 
the relationship between IR diagnosis and the ATP III criteria, it was found that the ATP III guidelines 
do not show good sensitivity in identifying individuals with IR.219 The SuRFNCD-2007 study also found 
the presence of IR in approximately one-third of participants who were not identified by either the ATP 
III or IDF criteria.364 It would be ideal if one could target patients with suspected IR before the onset of 
the metabolic syndrome via lifestyle changes (diet and exercise) and thus prevent the cascade of 
complications from being triggered, although some researchers argue to the contrary.219  
 
It has previously been mentioned that due to the limitations of the fasting indices (such as HOMA-IR or 
QUICKI), it is often preferable to combine additional parameters when assessing IR status. These 
parameters include classic risk factors such as waist circumference, blood pressure and lipid profile and 
should be viewed in light of an abnormal fasting index result.13,187 Although this is the approach often 
taken by many researchers and certain laboratories in South Africa, it may be prudent to consider the 
fasting index alone in a non-typical metabolic syndrome population (i.e. TB), given the disparity in 
identification of at-risk persons.  
 
When comparing the HOMA-IR with all of the individual criteria for metabolic syndrome, only the fasting 
glucose was found to show a significant positive correlation. This is logical because the fasting glucose 
is a factor used in the calculation formula of the HOMA-IR (see Chapter 2.6.3.4 for the specific formula). 
Although there were no other significant results found, an increasing HOMA-IR was found with increased 
triglycerides and blood pressure, whilst HDL was lower with increasing HOMA-IR. This would seem to 
be in line with the metabolic syndrome criteria discussed above and is definitely an avenue worth 
investigating with repeated research and a larger sample size.  
 
The primary objective of the study was to determine whether IR was present in PTB patients, through 
the use of the HOMA-IR and QUICKI, as well as through anthropometrical and biochemical markers. 
Since anthropometry (waist circumference), biochemistry (HDL-cholesterol, triglycerides and fasting 
glucose) and blood pressure measurements formed part of the assessment for metabolic syndrome, 
this objective (together with diagnostic IR tools) has been achieved.  
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4.7   DETERMINATION OF HOMA-IR CUT-OFF POINT  
 
As mentioned in Chapter 1, there is currently no consensus as to the HOMA-IR cut-off points used to 
classify IR, which makes comparison between studies challenging.364 Previous researchers have made 
use of ROC curves to estimate HOMA-IR cut-offs,296,365 whilst others have used the Youden index and 
distance from the top left-hand corner of the ROC curve to quantify cut-offs.364 Another method 
employed is to calculate the value of either the median,366-370 75th percentile,293-296 90th percentile,371-374 
lower limit of the top quintile (80th percentile)146,365 or tertile (66th percentile)219,375,376 in non-obese 
subjects with no apparent metabolic disorders. Table 4.1 documents previous studies and their HOMA-
IR cut-offs, as well as the comparison between those cut-offs and that of the current study.  
 
Due to the disparity in defining a suitable HOMA-IR cut-off point, the current study employed the HOMA-
IR cut-off value as the lower limit of the upper quartile (75th percentile) in this study population of TB 
patients (see Table 4.1). Previous studies have quantified IR to occur between the HOMA-IR levels of 
2.1 and 3.8,7,193 which is a vast range but in which the value of 2.477 calculated in this study fits 
comfortably. The median for this study was 1.394, which is noticeably lower than the proposed range of 
2.1 – 3.8 mentioned above.  
 
A South African laboratory practising outside of the Western Cape Province (Lancet Laboratories) 
performs the HOMA-IR index and states that a normal range for this variable is between 0.08 and 2.0.377 
They do, however, mention the uncertainty of the HOMA measurement in routine clinical practice and 
utilise the additional cut-off points provided by Stern et al. 171 (Table 4.1) as further diagnostic IR 
information. They also mention that the HOMA-IR and the QUICKI can be unreliable in cases of raised 
fasting glucose (>6.0 mmol/L).171 
 
The variability seen in the HOMA-IR cut-off values seen in Table 4.1 could be due to the lack of 
standardised insulin assay and the variability in the types of population studied, thus making comparison 
between studies difficult. The current study is, to the knowledge of the author, the first of its kind to 
assess IR prevalence using a calculated HOMA-IR and QUICKI value in a population of TB patients. 
 
The current study yielded an IR prevalence rate at baseline of 25.4% (Males=25.0%; females=27.3%), 
which is in line with findings in the general population of between 20% and 40%,145,146 although some 
studies have placed the IR prevalence slightly lower (10 - 25%).320 Although this finding may seem 
unexpectedly high, given the somewhat opposing clinical picture of TB and metabolic syndrome, recent 
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studies have reported high levels of hyperglycaemia, impaired glucose tolerance and DM in TB 
patients.242,244,246-249,251,254,257-259,261-264 Glucose intolerance was also recently found to occur at rates of 
34.2% and 18.3% for males and females respectively,259 which indicates the increasing prevalence of 
this phenomenon and as such, formed the basis for this exploratory research study. The prevalence 
rate of IR according to the HOMA-IR levels in this study also showed a decreasing pattern (i.e. 
diminishing IR status with treatment progression), which was explained in Chapter 4.5.  
 
The primary objective of the study was to assess if IR was present in patients with PTB by means of 
various tests, of which the main diagnostic tool was the HOMA-IR, with the QUICKI used as a 
confirmatory measurement. The current study has thus achieved this objective because a total 
prevalence of 25.4% according to both tools was found.
Stellenbosch University  https://scholar.sun.ac.za
Stellenbosch University  https://scholar.sun.ac.za
 154 
Table 4.1: Comparison of previous studies investigating HOMA-IR levels 
Study Population investigated HOMA-IR cut-off value Comparison with current study 
Matthews et al. (1985)7 General population Normal subjects = 1.21 – 1.45 
IR diabetic subjects = 2.61 – 2.89 
Lower than current study 
Haffner et al.  
[San-Antonio study 
(1997)]378 
General population 9.5 in NIDDM 
2.7 in normal glucose tolerance  
Slightly higher than current 
study  
Matsumoto et al. (1997)374 15 – 70 years (Japan) 
Non-diabetic and BMI <25 kg/m2  
90th percentile = 1.9 Lower than current study 
Bonora et al.  
[Bruneck study (1998)]146 
40 - 79 years (Italy) 
No metabolic abnormalities (BMI <25 kg/m2) 
Diabetic and non-diabetic 
80th percentile = 2.77 
50th percentile = 2.5 and 
75th percentile = 3.7  
Slightly higher than current 
study  
Yeni-Komshian et al. 
(2000)367 
Healthy non-diabetic volunteers 2.7 Slightly higher than current 
study 
Hedblad et al. (2000)293 45 – 64 years (Sweden) 
Non-diabetic individuals 
75th percentile = 2.0 Lower than current study 
Ascaso et al. (2001)373 20 – 65 years (Spain)  
No metabolic abnormalities 
90th percentile = 3.8 Higher than current study 
Marques-Vidal et al. 
(2002)294 
35 – 64 years (France)  
Diabetic and non-diabetic 
75th percentile = 3.8 Higher than current study 
Nakai et al. (2002)372 Japan 
No metabolic abnormalities (BMI <25 kg/m2) 
90th percentile = 1.8 Lower than current study 
Ascaso et al. (2003)295 30 – 60 years 
Hospital personnel (healthy subjects) 
75th percentile = 2.6 Slightly higher than current 
study  
Gokcel et al. (2003)379 15 – 87 years (Turkey) 
Healthy subjects   
2.24 (SD 1.26) Slightly lower than current 
study  
Stern et al. (2005)171 General population HOMA >4.65 or 
HOMA >3.60 and BMI >27.5 kg/m2 or 
BMI >28.9 kg/m2 
Higher (but these cut-offs do 
not make allowance for non-
overweight/obese subjects) 
Geloneze et al. (2006)371 Brazil  
No metabolic abnormalities (BMI <2 5kg/m2) 
90th percentile = 2.7 Slightly higher than current 
study 
Lee et al. (2006)296 30 – 79 years (Korea)  
Non-diabetic individuals 
75th percentile = 3.04  
Cut-off for increasing metabolic syndrome: 
HOMA-IR = 2.34 (ATP III criteria) 
HOMA-IR = 2.38 (IDF criteria) 
Higher than current study (75th 
percentile) 
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*BMI = body mass index; HOMA-IR = homeostasis model assessment – insulin resistance; NIDDM = non-insulin dependent diabetes mellitus; IDF = International Diabetes Federation; ATP =
Adult Treatment Panel
Study Population investigated HOMA-IR cut-off value Comparison with current study 
Radikova et al. (2006)380 White rural population  
No previous history of diabetes or dysglycaemia 
75th percentile = 2.29 Lower than current study 
Bertoni et al. (2007)368 45 – 84 years (United States) 
Non-diabetic; multi-ethnicity  
50th percentile = 1.2 Lower than current study 
Sumner et al. NHANES 
(2008)375 
≥20 years 
Non-diabetic adults in the United States 
Multi-ethnic study population  
66th percentile = 2.73 
75th percentile = 3.23 
Slightly lower than 66th and 
lower than the 75th percentile 
De Luis et al. (2009)368 Non-diabetic (Spain) 
Obese (BMI >30 kg/m2) 
50th percentile = 4.4 (SD 4.1) Lower (population differed) 
Esteghamati et al. 
(2009)365 
20 – 77 years (Iran) 
No metabolic abnormalities (BMI <25 kg/m2) 
Non-diabetic and non-hypertensive 
50th percentile = 1.4 (SD 0.9) 
75th percentile = 1.6 
80th percentile = 1.8 
90th percentile = 2.3 
50th percentile = 1.8 (SD 1.2) 
75th percentile = 2.3 
80th percentile = 2.6 
90th percentile = 3.3 
Lower than current study (80th 
percentile) 
Similar to 75th and 80th 
percentiles 
Esteghamati et al. (2010) – 
SuRFNCD-2007364 
25 – 64 years Optimal HOMA-IR cut-off for diagnosis of 
metabolic syndrome (IDF and ATPIII) = 1.775 
Lower than current study 
Do et al. (2010)381 Non-diabetic hospital personnel 
Thailand  
BMI <25 kg/m2 
50th percentile = 0.9 
75th percentile = 1.4 
90th percentile = 1.6 
Lower than current study 
Tomè et al. (2010)370 18 – 104 years  
Diabetic and non-diabetic 
50th percentile = 1.7 Lower than current study 
Gayoso - Diz et al. 
[EPIRCE study (2011)]351 
20 – 92 years 
Spain  
Non-diabetic  
50th percentile = 1.7 
66th percentile = 2.2 
75th percentile = 2.5 
80th percentile = 2.7 
90th percentile = 3.5 
Similar to 75th and 80th 
percentiles 
Simarro et al. (2011)382 General population in Spain 
>18 years of age  
90th percentile = 1.24 Lower than current study 
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The QUICKI was performed in this study as a confirmatory measurement to the HOMA-IR because 
it has also been relatively well validated with the HEC method in a vast array of populations, such 
as non-obese, obese and type 2 diabetic patients.20,218,226,229,232,233 Katz et al. has credited the 
QUICKI with a greater predictive value of IR than the HOMA-IR, which has been said to perform 
better than its predecessor when compared with the HEC and minimal model.20 It has been 
mentioned that it is often useful to make use of more than one IR index in a study to corroborate 
findings and to prevent incorrect conclusions from being drawn.194 
 
As with the HOMA-IR, there is no consensus regarding a standardised QUICKI cut-off point. This 
would seem logical since both of these fasting indices rely on the same underlying physiological 
standard13 and appear to be similar when comparing all aspects.196 Whilst the increasing values of 
HOMA-IR indicate IR, decreased values of QUICKI are indicative of an IR state. Proposed cut-offs 
for IR have also been suggested for the QUICKI and are shown below in Table 4.2. 
 
Table 4.2: Proposed QUICKI cut-off points 
 
Source  Population/rationale  QUICKI   
cut-off 
value 
Katz et al.20 Mean values:  
 Non-obese 
 Obese 





Ascaso et al. (2003)295 Healthy subjects (hospital personnel) 0.33 
Gokcel et al.379 Healthy subjects 0.347 
Hrebicek et al.235 Lower limit of 95% confidence level in healthy 
individuals (in which metabolic syndrome may 
typically manifest) 
0.357 
Pathcare Laboratories (South 
Africa)383 
Accompanied by relevant clinical markers of 
metabolic syndrome  
<0.357 







QUICKI = quantitative insulin sensitivity check index  
 
This equates to a range for QUICKI cut-offs of between 0.304 and 0.382, into which the calculated 
QUICKI for this particular study (0.336) falls comfortably. The QUICKI cut-off identified the same 
participants as the HOMA-IR in this particular study, which equates to an overall IR prevalence at 











In an attempt to improve reporting rates of IR in this study, a sub-analysis was performed by 
excluding the participants classified as having metabolic syndrome (IDF and ATP III criteria) from 
the total baseline study population. This was done because IR is often seen as being synonymous 
with the syndrome, and it was interesting to investigate if the inclusion of any of these participants 
would affect the prevalence of IR. The previously-explained principle of calculating HOMA-IR as the 
75th percentile was applied with the respective participants excluded, and this had little impact on the 
overall IR prevalence rate at baseline (24.6% with IDF and 25.9% with ATP III). The two participants 
who presented with raised fasting glucose levels were excluded for interest sake in an additional 
sub-analysis, which produced the same HOMA-IR cut-off point as the IDF exclusions.  
 
Since the HOMA-IR cut-offs decreased slightly with the excluded participants, this signified slightly 
more participants being identified with IR at two months, but the same six participants were identified 
with all three HOMA-IR cut-off points. This would suggest congruence among the cut-off points and 
relatively minimal impact on the overall prevalence of the excluded participants.   
 
 
4.8   INSULIN RESISTANT vs. NON-INSULIN RESISTANT GROUP 
 
Insulin resistance is a condition typically found in those who are overweight/obese and/or have an 
increased amount of visceral body fat, as well as in those individuals who suffer from a range of IR-
associated conditions, such as DM, PCOS or metabolic syndrome.14,15,150,151,314 It is, therefore, 
interesting to assess which factors (either demographic, anthropometrical or biochemical) were 
related to possible IR development in this particular TB population. This is of importance, given that 
the participants recruited for this study were not suffering from obesity or any other IR-related 
condition and did not fit the ‘typical’ profile of an IR patient.  
 
The development of IR has often been linked to the process of aging,20,191 since age progression is 
generally associated with greater gains in body weight and/or fat mass, especially in the central area 
of the body,314 as well as with an increased prevalence of chronic diseases of the lifestyle, including 
metabolic syndrome.147,384 As previously mentioned, the presence of abdominal adipose tissue is 
linked to both hyperinsulinaemia and IR.314  In this study population, there was a significant difference 
in age between the IR and non-IR groups, with the younger patients displaying a greater prevalence 
of IR. It is, however, important to note that the majority of participants (54.2%) in the study fell into 
the youngest age group (18 - 30 years).This is corroborated by the biochemical results in the present 
study in which younger participants showed a higher fasting insulin measurement. The systematic 
review conducted by the Jeon et al. group in 2008 also documented a more prominent relationship 







between DM and TB among the younger group269 although this may be due to the type of diabetes 
concerned (type 1 vs. type 2).   
 
A study by Esteghamati et al. found that HOMA-IR levels underwent a slight decrease after the age 
of 50 years, signifying a lower prevalence of IR in this older age group,365 whilst a study performed 
by Simarro et al. in 2011 found an increasing trend with age, except for subjects older than 65 years 
in which IR levels decreased.382 In another study (EGIR in healthy Europeans), age was not deemed 
to be a significant cause of IR,320 whilst the EPIRCE study was in agreement with the current study 
by showing slightly decreasing HOMA-IR levels with aging.351 This could signal the need for 
increased awareness of greater disease potential among the more youthful TB population, despite 
contrasting results to date.  
 
Another theory that has come to the fore involves the evolutionary debate encompassing the ‘thrifty 
hypothesis’.385 This hypothesis was generated to provide some explanation, however speculatory, 
regarding the escalation of global obesity rates and its postulated relationship with the tuberculosis 
epidemic seen much earlier in history. This hypothesis postulates that persons who had sufficient 
body fat stores were more likely to survive famine-like conditions and starvation (or TB) and, thereby 
had an immediate advantage over their leaner counterparts in the short term. Whilst this may be 
plausible, the undesirable side-effects of this thrifty hypothesis would lead to unfavourable 
consequences such as the development of chronic conditions (i.e. metabolic syndrome) during times 
when dietary intake was plentiful and starvation was not commonplace.386,387 This could apply in 
South Africa because although largely still a developing country, many geographical areas do not 
suffer from food insecurity such as the Western Cape, which was recently shown to have the lowest 
hunger rate (16.4%) in the country.301 This could subsequently trigger excessive dietary intake, 
leading to the rise in obesity and non-communicable disease rates. It could also be postulated that 
the specific fat content in the body could act as a ‘set point’ for triggering the metabolic and immune 
responses (or IR) whereby each individual varies.14,387-389 This, however, only provides grounds for 
speculation at present.  
 
There is generally a greater risk of IR with increasing anthropometrical measurements,382 and 
positive correlations have been documented between IR and BMI,367,390 waist and hip circumference, 
body fat content and weight gain.168,214,351 There was a significant difference between the IR and 
non-IR groups at baseline with regard to the interpretations of percentage body fat, subscapular 
skinfold and the sum of subscapular and triceps skinfolds. In addition,  measurements of BMI and 
fat mass (not documented in Chapter 3) were all slightly higher in the IR group (although not 
significantly). This could perhaps be indicative of the phenomenon of increasing anthropometric 
measurements with IR, although this should be repeated in future studies.  







A study conducted in 2012 by Addo et al. amongst adolescents in the United States showed that 
skinfolds (tricep and subscapular) were able to identify individuals at risk of developing IR.391 The 
study also showed that amongst the male study population, the subscapular skinfold had a 
stronger association with HOMA-IR than with the tricep measurement, suggesting the greater 
likelihood of developing IR with increased central adiposity compared to peripheral distribution.391   
 
In the current study, only the interpretation of subscapular skinfold and sum of subscapular and tricep 
skinfolds showed a significant difference between the IR and non-IR groups. The mean skinfold 
values were higher among the IR group (although not significantly so), which would seem to agree 
with the Addo et al. study. However, results of a multiple regression analysis showed that IR can be 
explained by waist circumference, sum of skinfolds and fat mass (although only yielding a 20.4% 
variation). Individual skinfolds (subscapular or tricep) did not contribute to IR at all. The sum of 
skinfolds could therefore perhaps be used as a marker to identify those at risk of developing IR, 
given the link between increased subcutaneous fat and IR.  Although no significant differences were 
seen in this study regarding the waist circumference classification, an increased waist circumference 
measurement, largely identifying individuals at risk of excess VAT, has long since been associated 
with IR.12,15,153,392 The greater the amount of intra-abdominal fat present, the higher the risk for the 
development of glucose intolerance393 and the greater severity of IR.394 This easily-performed 
measure of central adiposity has also been linked to the chronic, often low-grade inflammation 
commonly found in patients with IR.17,156 Although it is possible for IR to develop in individuals 
presenting with a normal body weight, as seen in the current study population, IR is more commonly 
associated with obesity, be it visceral or total BMI.12,15,153 Obese patients are more likely to present 
with the majority of their fat tissue as visceral fat, which by nature is more pro-inflammatory, whilst 
non-obese individuals (as was seen in the current study) store a greater proportion of their fat as 
subcutaneous tissue, consisting of less pro-inflammatory markers.388,395,396  
 
An increased waist circumference would thus seem to indicate a greater likelihood of developing, or 
having, active IR because it may result in the excessive secretion of inflammatory components such 
as TNF-α, IL-6, MCP-1 and resistin.166 Visceral adipose tissue, or adipose tissue in general, has 
been theorised to play host to a vast number of mycobacteria, thus potentiating the risk for active 
disease development.267 Insulin resistance pathogenesis typically occurs as a result of free fatty acid 
release from the visceral tissue, resulting in an influx of various hormones and cytokines, giving rise 
to an inflammatory response.164 In addition, excessive amounts MCP-1 (an adipokine) have 
specifically been linked to the development of IR, largely through the inhibitory action on insulin.267 
Although there were no significant differences in waist circumference classification seen in this study, 
an increased waist circumference, apart from increasing IR prevalence, has also been linked to a 
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concomitant reduction in HDL-cholesterol,397 another risk factor for the development of metabolic 
syndrome.  
Because IR is largely termed an ‘inflammatory’ condition, levels of CRP (a positive acute phase 
protein) are often raised,144 although not as much as in a more acute condition. The inflammation 
typically found in IR is more of a ‘low-grade’ inflammatory state, which is often the result of the 
production of cytokines from VAT.398 The CRP levels are often produced as a response to the release 
of various cytokines designed to enable the inflammatory response.399 A similar reaction is seen with 
the concomitant positive association between IR and the metabolic syndrome, and other markers of 
the acute phase response.17,400-403
One might thus have expected the CRP levels of the IR participants to be higher than the non-IR 
group, given the inflammatory nature of IR itself, its relationship with the APR and the fact that TB 
patients generally have increased CRP levels. However, the converse was seen. Given the fact that 
patients included in this study did not fit the conventional ‘metabolic syndrome’ or obesity profile, it 
could be speculated that they may have slightly higher levels of subcutaneous fat, compared with 
visceral tissue, which would, therefore, render a slightly less inflammatory profile, and this could 
have an inhibitory effect on CRP levels in the blood. Although the IR group seemed to display a 
lesser inflammatory response when compared with the non-IR group, the sample size was relatively 
small, and this finding should definitely be repeated in future studies.  
The chronic inflammation often seen in IR and metabolic syndrome has been postulated to be due 
to the following factors: (1) IR may be set-off by the chronic inflammation seen in obesity; (2) the 
metabolic syndrome is strongly associated with increased cardiovascular risk, and CRP may, 
therefore, be increased due to a pre-existing atherosclerotic state; (3) reduced insulin sensitivity may 
be linked to an enhanced expression of CRP; and (4) there is a strong association between chronic 
inflammation and body fat content.17  
Literature has also documented the correlation between IR occurrence and biochemical measures, 
namely raised triglycerides, reduced HDL-cholesterol, increased glucose and insulin, as well as 
hepatic enzymes.169 In a large study conducted in Spain (EPIRCE), HOMA-IR levels showed a non-
linear association with blood pressure (systolic), HDL-cholesterol and triglycerides.351 Other factors 
shown to correlate well with IR include blood pressure (although hypertension is strongly associated 
with obesity),214 as well as a family history of diabetes, 171-174 although the latter was not taken into 
account in the present study.
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Although there was no significance regarding any of the metabolic syndrome markers between the 
IR and non-IR groups, the IR participants displayed slightly higher levels of blood pressure (both 
systolic and diastolic), fasting glucose and triglycerides. Despite there being no significant 
differences between the classifications of HDL-cholesterol and waist circumference between the 
groups, this may indicate IR being a pre-cursor for the development of certain clinical conditions 
associated with metabolic syndrome and could highlight the need for more preventative action prior 
to development of the syndrome.  
Although the above discussion primarily concerns the IR and non-IR groups at baseline, it was 
observed that the IR participants at the follow-up periods displayed a similar trend with regard to the 
behaviour of the variables (both anthropometric and biochemical). There were also no differences 
between the sputum conversion rates (AFB) in the IR and non-IR groups in this study, despite all of 
the IR participants having converted by the two-month mark. Considering the evidence available for 
sputum conversion among diabetic patients (which encompasses the condition of IR), the results are 
inconclusive,243 although some studies have found a longer conversion time in DM.264,404-406 It is 
unclear whether diabetes has an advantageous or disadvantageous effect on the smear results.   
Therefore, the objectives entailing the assessment of differences between IR and non-IR participants 
as well as demonstrating no relationship between IR status and sputum results at any of the 
measured time frames were also achieved.  
4.9   SPUTUM RESULTS 
The majority of participants in the current study presented with a smear-positive sputum result at 
baseline, which indicated a more ‘severe’ or infectious form of TB compared with their smear-
negative counterparts. Although there were no significant differences between any of the 
anthropometrical and biochemical markers (excepting fasting glucose), one could perhaps have 
expected the smear-positive group to have presented with slightly more derangements of these 
parameters given their propensity to be more ‘unwell’ than those in the negative group. It is important 
to note that the patients recruited for this study, although presenting with infectious TB, were still 
relatively well and able to attend the health facility, and as such, disease severity may not have such 
a prominent effect when compared with a hospital-type setting.  
Literature has reported the relationship between a decreased BMI and the increased radiological 
extent of TB (i.e. degree of sputum positivity).407 Given the supposed bi-directional relationship 







between TB and malnutrition, it might be speculated that the more severe form of TB would result in 
a greater degree of weight loss (albeit both fat and lean body mass) and ultimately, an impaired 
nutritional status. Although there was no significance reported, the smear-positive group did present 
with lower mean values for weight, BMI, waist circumference, sum of skinfolds, fat mass, fat free 
mass and percentage body fat. This lack of significance could perhaps be caused by the small 
sample size because groups were not stratified into statistically representative groups according to 
sputum results.  
 
Similarly, regarding the biochemical values, the only variable to show a significant difference 
between the positive- and negative-smear groups was the fasting glucose, which was lower in the 
sputum-positive group. This is an unexpected finding because it may be postulated that the smear-
positive group was subjected to a greater form of inflammation than the negative patients, and this 
heightened inflammatory response may have given rise to greater IR, which may lead to a reduction 
in insulin production and a concomitant hyperglycaemic response.244 Diabetes also seems to have 
a strong causative link to the more infectious type of TB,261  as well as a greater prevalence in the 
smear-positive group in this study. Although fasting insulin was lower in the positive group (although 
not significantly so), there was no sign of hyperglycaemia in these patients, which is a converse 
finding and definitely warrants further investigation. Due to the decreased mean fasting glucose 
value, this resulted in a lower HOMA-IR and higher QUICKI value in the positive group, which 
correlates with the converse finding of a seemingly decreased IR status in the more ‘unwell’ patients.  
 
The finding of raised CRP levels in TB patients was documented in Chapter 4.3: Biochemistry 
Results. Literature has also reported significantly higher levels of CRP among smear-positive 
patients,107,404 given the nature of CRP to act as an indicator of inflammation intensity. Since the 
smear-positive patients present with a more severe and radiologically advanced disease, they 
generally have an increased inflammatory load,113 which often leads to a poorer prognosis.408 A 
higher CRP level has also been linked with the severity of lung dysfunction.126 There seemed to be 
higher mean CRP levels and lower albumin levels in the smear-positive group in this study and 
although not significant, could perhaps be in agreement with the above literature.  
 
Differences in lipid profile (namely total cholesterol, HDL-cholesterol and triglycerides) have been 
documented by researchers, who stated that lower levels of these markers were found in patients 
with more advanced stages of infection.114 This is again explained by the increased inflammatory 
response seen in patients with the more severe form of the disease.114 Although there was no 
significance, results generated by this study showed a lower mean value for total and HDL-
cholesterol, but a higher mean triglyceride level, and this should also be followed up.   
 







The secondary objective of assessing changes between smear-positive and smear-negative 
participants was also achieved, and although minimal significant differences were seen, these could 
be pursued in subsequent studies.  
 
One of the main reasons why participants in the current study were chosen to be followed up at two 
and five months was to allow for the coinciding with fixed sputum follow-up dates as implemented 
by the South African DoH. Participants had their sputum re-tested at both periods if they presented 
with a positive or unclear sputum at baseline. The anticipated sputum conversion is of vital 
importance to allow for assessment of treatment efficacy because a smear that remains positive at 
the five-month mark would indicate a treatment failure.5 Researchers have suggested possible 
causative factors of treatment failure, which include a higher prevalence of localised disease with 
chest radiography, little radiological improvement over time, greater drug resistance and high default 
rates.409 
 
Those individuals who are able to convert from smear-positive to smear-negative within a certain 
period of time are deemed ‘fast’ responders, whilst those that present with a persistent positive 
smear are termed ‘slow’ responders.410 Smear results and their subsequent conversion are often a 
very useful tool in determining a patient’s response to TB treatment.316 The WHO is currently aiming 
for a treatment success rate of a minimum of 85% of cases, which will hopefully bring South Africa 
closer to achieving the MDGs or SDGs, in terms of lowering TB incidence and mortality rates.24  
 
The current study population showed promising signs of sputum conversion because the majority of 
smear-positive patients at baseline had converted by two months (the intensive phase), and all but 
one participant had converted at the five-month mark, thus indicative of treatment success and well 
above the WHO cut-off of 85%. However, one of the patients in the follow-up group who had sputum 
converted relapsed a few months after treatment completion and was placed on a new course of 
therapy. This indicates the need for at-risk patients to be followed-up even after treatment completion 
due to confounding relapse risks such as poor nutritional status, default history and known household 
contact with TB suspects. This may, however, be somewhat of a challenge given the overburdening, 
understaffing and resource depletion of the public health system in South Africa.  
 
Because significant differences were seen in sputum TB results between baseline and two months, 












4.10      STUDY STRENGTHS AND LIMITATIONS  
 
This study was the first to investigate the prevalence of IR in a population of adult patients newly 
diagnosed with PTB, by means of the HOMA-IR and QUICKI indices. Many studies have explored 
the phenomena of increased rates of diabetes occurring in TB patients, but this study exclusively 
considered IR status and excluded all previously diagnosed diabetic patients. In addition to the novel 
data presented, the study was further strengthened by the principal researcher performing all 
administrative, anthropometrical and transport functions, thereby reducing the risk of inter-observer 
variability or bias. Only one laboratory was used for the analysis of biochemical measures, which 
allowed for comparison between samples in this particular study, especially regarding the evaluation 
of the fasting insulin marker.  
 
The HOMA-IR and QUICKI, despite their shortcomings, are two of the most prominent fasting indices 
used in clinical research and have shown good correlation with the gold standard method of testing 
and diagnosing IR. Because these indices have been linked to defining hepatic IR, which often 
occurs before peripheral IR sets in, it may be possible to intervene in a timely manner with patients 
presenting with early onset IR. The analytical component of the study added strength to the baseline 
component since participants were followed-up over time, and inferences were made from generated 
data. The follow-up period also extended beyond the two-month intensive phase, in which the 
majority of significant results were seen. In addition to these strengths, the researcher was also able 
to achieve an excellent recruitment rate (98.3% of the target study population). Patients were 
enrolled in the study shortly after treatment commencement, thus reducing the confounding effect of 
the TB medication on the IR status. A subgroup analysis was also performed to re-evaluate the 
HOMA-IR and QUICKI cut-off points if patients were found to have any pre-disposing IR conditions 
post-study recruitment, thus reducing bias.  
 
Due to the novel nature of the study, a few limitations arose that were largely beyond the control of 
the researcher.  
 
The nature of the HOMA-IR and QUICKI indices is such that it makes inter-study comparison very 
challenging, given the paucity of standardised reference values, the reliability in the quality of glucose 
and insulin measurements, the lower accuracy in normal or near-normal weight individuals and the 
lesser relevance in certain ethnic groups. The fasting insulin measurement also presents with 
countless problems, given its short half-life, pulsatile action and variability between assays. Although 
it is recommended to perform three insulin measurements, many studies have used one basal insulin 
measurement, as was done in this study. It has also been reported that IR is often higher in the 
morning due to the combined action of cortisol and FFA.6 This unfortunately co-incided with the time 







of data collection, although this was beyond the researcher’s control given logistical issues with 
phlebotomy samples and patient compliance with fasting requirements.  
 
In addition, there is currently no consensus as to which metabolic syndrome guidelines (IDF, ATP 
III, WHO, etc.) should be used because this is an ever-changing concept. Furthermore, it was unclear 
if patients presented with hyperglycaemia before recruitment into the study since the researcher 
recruited individuals purely on the absence of any pre-diagnosis diabetic conditions in the medical 
folder at the facility. In the patients who presented with hyperglycaemia, this could be due to 
previously undiagnosed DM, newly diagnosed IR or to transient hyperglycaemia, often found in TB 
patients. Due to logistical and ethical issues, the researcher was also only able to access the patients 
once they had started treatment and, therefore, all patients seen were receiving anti-TB medication. 
Given the complexities in working with human subjects, exact compliance with the TB medication 
and fasting on the day of sample collection were reliant upon the patient’s confirmation thereof.  
 
Other limitations included inherent facets of the study design, such as the cross-sectional nature of 
the baseline aspect of the study, which resulted in no conclusions of causality being drawn. As the 
study was primarily planned and executed by the principal researcher, logistics only allowed one 
study site to be used for recruitment, which could impact on the generalisability of results. Although 
not a primary objective of the study because no stratification was done, caution needed to be applied 
in the assessment of the demographic findings because this could limit the reliability of any 
associations drawn from a heterogeneous study population. In closing, the groups that were 
compared in the sub-analyses (IR vs. non-IR; sputum-positive vs. sputum-negative) were not known 
before data analysis was completed, and these groups were not always of an equal sample size, 


































































5.1    CONCLUSION 
 
This study aimed to assess if there was an association between TB and the development of IR in 
newly diagnosed ambulatory adults between the ages of 18 and 65 years with PTB in the Cape Town 
area of South Africa. This was measured via an assortment of methods, and certain patients were 
followed-up whilst on TB treatment. The current study is, to the knowledge of the author, the first to 
assess IR prevalence using the HOMA-IR and QUICKI indices in a population of PTB patients. The 
results generated from this study show an association between TB and the development of IR and 
fulfill the overarching aim of investigating this relationship, shedding light on this novel research 
avenue, providing scope for possible future research ventures.  
 
A number of important findings were made and are outlined below in accordance with the objectives 
of the study. These findings, as well as recommendations for future research and clinical practice, 
will hopefully contribute to the available knowledge of the subject at hand.  
 
5.1.1 To Assess if IR was Present in Participants with PTB via the Testing of 
Anthropometrical and Biochemical Measures, as well as Diagnostic IR Tests 
 
 Using the calculated cut-off point for HOMA-IR (2.477), the IR prevalence at baseline was 
25.4%, which equates to 1 in 4 persons with newly diagnosed PTB having IR. These findings 
were echoed by the QUICKI.  
 This prevalence rate falls within the proposed range of 20 - 40% IR in the general population, 
of whom the majority are healthy persons (i.e. do not have TB).145,146 The rates among this 
study population are, therefore, found to be quite high.  
 The metabolic syndrome criteria used (IDF and ATP III) failed to classify the majority of 
patients who presented with IR according to HOMA-IR and QUICKI calculated cut-offs. 
 Adjusting for patients with the metabolic syndrome according to both IDF and ATP III criteria 
had little effect on the total IR prevalence at baseline.  
 
5.1.2 To Assess Changes in Anthropometrics and Body Composition at Baseline and 
Follow-up Periods 
 
 The majority of participants in the study had a normal BMI. However, some were classified 
as overweight (BMI>25 kg/m2). Being underweight (BMI<18.5 kg/m2) is often viewed as a risk 
factor in the development of TB disease, and the prevalence of normal or over-nourished 
patients in this study might be due to the significant overweight/obesity epidemic that South 
Africa is currently facing.  







 It is, however, pertinent that the majority of studies evaluating the nutritional status of TB 
patients at baseline have found these persons to be more underweight than their healthy 
counterparts. Many of these studies, however, were conducted among hospitalised patients, 
perhaps for ease of access to participant data. The current study investigated facility-based 
ambulatory patients, which could also signify a less severe or less undernourished patient 
population, linking to the largely ‘normal’ nutritional status mentioned above.  
 Despite the majority of patients having a BMI within the normal range, the total body fat was 
still relatively low, and most patients were classified as being either ‘underweight’ or ‘slim’ 
when assessed. The phenomenon of fat mass loss (as well as lean body mass loss) has 
been well documented in literature, but should be monitored, especially given the significant 
gains in fat mass commonly seen whilst on treatment that could later prove to be detrimental.  
 The majority of anthropometrical measurements showed a significant increase whilst the 
patients were on treatment, with the greatest changes taking place during the intensive phase 
(first two months of treatment). However, some patients failed to gain more than 5% weight 
over the five-month period and/or remained in the underweight BMI category, thereby placing 
them at greater risk of treatment failure and/or relapse at a later stage. 
 There was a significant increase in both fat and fat free mass over time. Whilst the increase 
in fat mass has been previously described, the increase in fat free mass is encouraging, given 
its association with improved functionality, quality of life and longevity.  
 The increase in fat mass seemed to be associated with gains in both the peripheral and trunk 
area (albeit slightly more in the trunk area). 
 
5.1.3 To Assess Changes in Biochemistry and Blood Pressure at Baseline and Follow-up 
Periods 
 
 The most noticeable derangements in baseline biochemical values showed the majority of 
patients having an increased CRP level and a decreased HDL-cholesterol level, both of which 
could be indicative of the inflammatory state noted in TB patients.  
 There were relatively few presentations of hyperglycaemia and/or abnormal insulin levels in 
the study although IR rates were found to be high. This raises the question as to what caused 
the IR in these patients. Possibilities include either chronic infection or medication although 
this concept needs to be explored further.  
 With regard to the changes in biochemical markers over time, the CRP, albumin and white 
cell count all showed an improvement (especially in the intensive treatment phase), which 
would seem to indicate an improvement in the inflammatory state or infectious state of the 
body. Although the cholesterol levels (total, LDL and HDL) increased in the first two months 







of treatment, indicating a possible improved response to infection, there were no differences 
noted over the last few months, which is an interesting concept to revisit.  
 
5.1.4 To Assess Changes in IR Status at Baseline and Follow-up Periods 
 
The HOMA-IR and QUICKI levels also improved with time, although not significantly, which may 
indicate a seeming reduction in IR. Some patients who had IR at baseline presented with normal 
levels at two months but then redeveloped IR at five months. In addition, some patients were non-
IR at baseline, but developed it at two and five months. These two occurrences possibly question 
the stress hyperglycaemia or reduction in inflammation theories presented in the literature.  
 
5.1.5 To Assess Changes in Sputum TB Results at Baseline and Follow-up Periods 
 
There were significant differences in sputum results between baseline and two months, as well as 
baseline and five months. This is indicative of the majority of patients having converted to sputum 
smear-negative by the five-month mark, signifying an improved clinical state.  
 
5.1.6 To Determine the Relationship between IR Status and Sputum TB results at Baseline 
and Follow-up Periods 
 
No significant differences were found in this category.  
 
5.1.7 To Assess Differences between IR and non-IR Participants 
 
 Differences noted in IR patients compared with their non-IR counterparts included the 
following: IR patients were younger, had a significantly higher interpretation of skinfolds and 
percentage body fat (signifying a ‘greater’ fat mass) and higher fasting insulin values. 
Although no other significant results were noted, IR patients generally showed a pattern with 
markers of the metabolic syndrome (increased fasting glucose, triglycerides and blood 
pressure).  
 Mean CRP levels were lower in patients with IR compared with their non-IR counterparts 















5.1.8 To Assess Differences between Sputum-Negative and-Positive Participants 
  
When comparing differences between the sputum smear-positive and negative groups, only the 
fasting glucose measurement was significant; the sputum-positive group had a lower fasting glucose 
level than the negative group and ultimately ‘less’ IR according to HOMA-IR and QUICKI.  
 
 
The diagnosis of TB has previously been linked to consumption of harmful substances (nicotine and 
alcohol), as well as a low BMI, poorer educational level, unemployment and inferior household 
wealth.411 If one considers these factors, it can be seen that all either affect or are affected by nutrition 
at some point, be it lowering dietary intake or influencing access to food, or in the case of a low BMI, 
rendering the immune system defenseless against infection. This, therefore, equates to a ‘vicious 
cycle’, which could perhaps be broken through the preventative provision of appropriate nutritional 
care and far-reaching education. Similarly, nutrition therapy induced action could also be utilised in 
the prevention and management of IR in TB patients, via dietary adaptations and physical activity, 
before the disease manifests.  
 
If one considers the dire TB statistics facing South Africa at the current time, which include the 
country being labelled as having the highest incidence and prevalence rates and having a large 
proportion of multi-drug resistant TB and TB-HIV co-infected cases,48 there is definitely a need for 
action in this arena. The compounding factor of diabetes, given the high level of non-communicable 
diseases in South Africa, is also reason for concern because diabetes has been found to increase 
the rate of mortality and treatment failure, as well as the relapse rate in those with TB.280 Appropriate 
preventative screening methods, glucose control and monitoring of patients presenting with 
diabetes, impaired glucose tolerance or IR should be implemented at all stages of treatment. If 
patients are found to have IR, these individuals should be earmarked as at-risk patients, given the 
propensity of IR to result in chronic illnesses such as cardiovascular disease and diabetes. It would, 
therefore, be beneficial to identify these individuals at an early stage to prevent these probable 
complications from occurring.  
 
Given the current nutrition transition experienced in South Africa, coupled with crippling rates of both 
communicable and non-communicable diseases, this will need to be executed within a multi-












5.2       RECOMMENDATIONS 
 
5.2.1    Clinical Practice  
 
 Integrative bi-directional screening (i.e. screening for DM in newly diagnosed TB patients and 
screening for TB in diabetic patients) should ideally be implemented in health facilities 
nationwide, which will address both communicable and non-communicable forms of disease.  
 Because screening for DM in active TB patients is generally a more cost-effective alternative, 
this should be done with a simple measurement (such as a fasting or random blood glucose 
measurement) that does not infringe on the vast workload of staff members. Although testing 
of baseline urinary glucose and ketones in all TB patients is currently part of the national DoH 
TB management guidelines, ideally blood glucose should also be measured in all patients, 
not only in those who display symptoms. Those patients who are found to have increased 
glycaemic values should be retested soon after by means of a confirmatory method such as 
an OGTT or HbA1C, of which the latter is probably more practical. Screening should also 
encompass an enquiry into the patient’s family history of DM or other hyperglycaemia-related 
conditions or symptoms.  
 Patients presenting with hyperglycaemia should be monitored throughout the treatment 
period in order to dispel the transient hyperglycaemia effects or the side-effects of medication 
before actively being diagnosed with DM. Despite normalisation of glucose levels, the 
previously increased glucose levels may still pose a future risk for an individual.   
 Patients found to be more susceptible (retreatments or previous defaulters, known diabetics, 
newly diagnosed IR/DM patients, patients with impaired nutritional status, HIV-TB co-infected 
patients, etc.) should be referred for appropriate nutritional intervention, either via dietary 
counselling or supplementation. 
 Patients with undesirable markers (such as low BMI, inadequate weight gain, raised CRP 
levels, lack of sputum conversion, poor clinical presentation, etc.) should be continually 
assessed in terms of nutritional status, regardless of whether they have successfully 
completed their course of treatment or not.  
 Patients identified with IR should be closely monitored and appropriate counselling given to 
prevent the onset of any of the conditions associated with the metabolic syndrome. One could 
also monitor and evaluate an excessive waist circumference with regard to increasing IR risk 
or inflammatory profile.  
 Since the intensive phase of treatment seemed to yield the most significant changes, it would 
be prudent to interact with the patient at an early stage in order to improve the outcome and 
lessen the negative effects of TB disease. Patients with possible IR and those with an 







impaired nutritional status upon commencement of treatment could be counselled in terms 
of dietary improvements and physical activity levels.  
 Although a recent Cochrane review86 could not find sufficient evidence to support the blanket 
issuing of nutritional interventions for undernourished TB patients, one must not discount this 
option entirely. The Nutritional Therapeutic Programme of the DoH should, therefore, be 
correctly implemented in combination with adequate dietary monitoring by a nutritional 
professional such as a registered dietician or nutritionist, or in their absence, a registered 
nurse.  
 Physical activity (as tolerated) should also be emphasised, in conjunction with support from 
a suitable health care professional in the multi-disciplinary team (such as a physiotherapist, 
biokineticist or occupational therapist). Increased physical activity will be beneficial to all TB 
patients because it is able to reduce total and visceral fat and build lean body mass, which is 
crucial. Increased activity also has a diminishing effect on the IR status in the body.  
 Constant re-evaluation of strategies to prevent high default rates should be carried out, 
especially in patients who never begin treatment despite a positive diagnostic TB test, 
although this remains challenging.  
 
5.2.2    Future Research   
 
 Given the high prevalence of IR in this particular study population, it may prove prudent to 
investigate the prevalence of IR in other TB-specific patient populations. Because the current 
study focused largely on the uncomplicated, drug-susceptible form of TB, assessing IR status 
in multi-drug resistant (MDR) and extensively drug-resistant (XDR) patients might yield 
interesting results.  
 One could also perhaps target vulnerable TB patient populations, such as miners, prisoners, 
children or the elderly to determine if they display a greater propensity for IR compared with 
the current population. The children/adolescent population might be extremely valuable to 
assess, given the current trend of earlier development of previously adult-onset diseases 
such as diabetes and cardiovascular disease.  
 It may also be of value to include a comparison of HIV-negative with co-infected TB patients 
to assess the impact of the ‘double burdened’ patients on the IR status, since HIV alone has 
previously been linked to development of IR.  
 A greater number of recruitment sites could be introduced in future studies. This would allow 
for a faster data-collection process, as well as for inter-site comparisons to be made in terms 
of demographic profile (providing the sample size was sufficient).  
 Although the current sample size was adequate, a larger sample size would perhaps 
corroborate findings shown in the current study.  







 It would be prudent to re-assess the patients who displayed IR at the five-month period after 
completion of their TB treatment. They could be investigated for worsening IR status or 
possible development of the metabolic syndrome. Due to time limitations and logistical 
issues, this was unfortunately not part of the scope of the current study. 
 Additional tools could be utilised in the assessment of IR status (i.e. HEC method) as a 
comparison with the results found in this study.   
 An intervention study could possibly be conducted at a later stage that could assess the 
impact of dietary and lifestyle counselling on IR progression in TB patients. Alternatively, 
different forms of TB (drug susceptible, MDR, XDR, HIV co-infected, etc.) could be compared 
with one another to assess IR severity.  
 Although it was not possible in the current study, a desired outcome of a future study could 
be to determine a specific biomarker cut-off (e.g. CRP) that would be able to identify IR in TB 
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Additional metabolic measurements for metabolic syndrome research devised by the IDF9 
 
Abnormal body fat distribution   General body fat distribution (DEXA) 
 Central fat distribution (CT/MRI) 
 Adipose tissue biomarkers: leptin, adiponectin 
 Liver fat content  
Atherogenic dyslipidaemia (beyond 
elevated triglycerides and low HDL) 
 ApoB (or non-HDL-cholesterol) 
 Small Low Density Lipoprotein (LDL) particles  
Dysglycaemia   Oral Glucose Tolerance Test (OGTT) 
IR (other than elevated fasting glucose)  Fasting insulin/pro-insulin levels  
 Homeostasis Model Assessment-IR (HOMA-IR) 
 IR by Bergman Minimal Model 
 Elevated free fatty acids (fasting and during 
OGTT) 
 M value from clamp  
Vascular dysregulation (beyond elevated 
blood pressure)  
 Measurement of endothelial dysfunction  
 Microalbuminuria  
Pro-inflammatory state  Elevated high sensitivity C-reactive protein 
 Elevated inflammatory cytokines (e.g. TNF-α, IL-
6) 
 Decrease in adiponectin plasma levels  
Pro-thrombic state   Fibrinolytic factors (PAI-1, etc.) 
 Clotting factors (fibrinogen, etc.) 
Hormonal factors   Pituitary-adrenal axis 
 
HDL = high density lipoprotein; IR = insulin resistance; DEXA = dual energy x-ray absorptiometry; CT = computerised tomography; MRI 
= magnetic resonance imaging; ApoB = apolipoprotein B; LDL = low density lipoprotein; TNF-α = tumour necrosis factor- α; IL-6 = 
interleukin-6; PAI-1 = plasminogen activator inhibitor-1 
 























Oral glucose tolerance test derived indices13 
 
Index  Formula  
Avignon Index204 {0.137 x [108 / (fasting insulinµIU/mL x fasting glucosemg/dL x VD)]) + [108 / 
(120 min insulinµIU/mL x 120 min glucosemg/dL   x VD)]} /2 
Belfiore Index205 2/ [(INSpµIU/mL) x (GLYp mg/dL) +1]  
INSp = AUC of insulin (µIU/mL) during OGTT divided by mean values of 
non-diabetic subjects as a unit, and GLYp =AUC of glucose (mg/dL) during 
OGTT divided by mean values of non-diabetic subjects as a unit 
Cederholm Index412 [75 000 + (fasting glucose – 120 minutes glucosemmol/L) x 1.15 x 180 x 
0.19 x body weightkg] / [120 x (log mean insulinµIU/mL) x mean 
glucosemmol/L] 
Gutt Index413 [{75 000 + (fasting glucose – 120 minutes glucosemmol/L) x 0.19 x body 
weightkg}} / 120 / [fasting glucose + 2 h glucosemg/dL] / 2] / log [fasting 
insulin + 120 min insulinµIU/mL]/2]  
Matsuda Index145 104 / (fasting glucosemg/dL x fasting insulinµIU/mL x mean glucose OGTTmg/dL 
x mean insulinµIU/mL)0.5 
Stumvoll Index206 0.0226 – 0032 X BMIkg/m2 – 0.0000645 x 120 min insulinpmol/L – 0.00375 x 
90 min glucosemmol/L 
Oral Glucose Insulin Sensitivity 
(OGIS) Index414 
Available online at http://webmet.pd.cnr.it/ogis/index.php 
SIisOGTT218 1/{ log [sum glucose0+30+90+120 min (mmol/L) ] + log [ sum insulin0+30+90+120 min 
(µIU/mL])} 
 
OGTT = oral glucose tolerance test; VD = volume of distribution; AUC = area under curve; INS = insulin; GLY = glucose; BMI = body 





















Protocol for selecting the most appropriate technique for assessment of IR prior to 
commencement of a study5 
  
OGTT =      oral glucose tolerance test 
HOMA =    homeostasis model assessment  
QUICKI =   quantitative insulin sensitivity  
                   check index  
IGFBP-1 = insulin-like growth factor binding  
                   protein-1 
SHBG =      sex hormone binding globulin;  
 
FSIVGTT = frequently sampled intravenous  
                   glucose tolerance test;  
ITT =          insulin tolerance test;  
CIGMA =   continuous infusion of glucose with  
                   model assessment;  
HEC =        hyperinsulinaemic euglycaemic  
                   clamp 









Data collection sheet (principal researcher) 
 
 
Unique ID number of participant   
Participant Allocation:  Baseline (1) 







AGE   YEARS   















    
 









    
 









    
 









    
 
 



















7. Elbow width and frame size (at baseline) 
 
mm SMALL  MEDIUM  LARGE  
 









    
 









    
 









    
 













NB! The following measurements are only to be completed if the participant is selected to 




12. Weight (at f/up) 
 







2/12     















13. Waist circumference (at f/up) 
 







2/12     
5/12     
 
 
14. Hip circumference (at f/up) 
 







2/12     
5/12     
 
 
15. BMI (at f/up)   
 
2/12 kg/m2 










17. Biceps skinfold (at f/up) 
 
F/up  Measurement 1 
(mm) 






2/12     
5/12     
 
18. Triceps skinfold (at f/up) 
 
F/up  Measurement 1 
(mm) 






2/12     
5/12     
 
19. Subscapular skinfold (at f/up) 
 
F/up  Measurement 1 
(mm) 






2/12     












20. Suprailiac skinfold (at f/up) 
 
F/up  Measurement 1 
(mm) 






2/12     





















BLOOD PRESSURE:  
 
 































Master of Nutrition Study 
Tuberculosis and Insulin Resistance 



























For laboratory use 
Instructions  
Clinical Information/Sample Information  




NHLS Tygerberg Laboratory Request Form 
Patient Information  
N/A 
NHLS Location:  









notes:  Serum albumin; CRP; Fasting insulin; Fasting glucose;  
Markers to be taken 
Lipid profile; WCC 
Sample Taken  /         /  20         
Time:   
Specimen Yellow: Serum albumin; 
CRP; fasting insulin; lipid 
profile (4-5ml) 
Purple: WCC (4-5ml) 
Grey: Fasting glucose (1ml) 
 
Phlebotomist:    Signature:     
Please email results through to: 











ADDENDUM F  
 
Health Research Ethics Committee approval 
 



















City of Cape Town approval 
 













25th February 2013  
Dear Madam/Sir  
 
RE: Masters in Nutrition Research Project                                                                             
 
I would hereby like to approach you for permission to conduct a study for Postgraduate Masters research 
purposes. The study is entitled ‘The association between tuberculosis and the development of insulin 
resistance in adults with pulmonary tuberculosis in the Western Sub-District of the Cape Metropole region.’  
 
The aim of the proposed study is thus to determine whether there is an association between tuberculosis 
and the development of insulin resistance in adults with pulmonary tuberculosis in the Western Sub-
District, with the aim of recording possible emerging trends and improved future care for persons with TB.   
 
As principal investigator of the study, myself (or an appointed research assistant), will visit the Albow 
Gardens clinic, situated in the Western sub-district of the Cape Metropole region. This will be done with the 
sole purpose of recruiting patients for the study. All further measurements will not be done on site at the 
clinic (done at Brooklyn Chest Hospital), as not to increase the staff workload or create a shortage of space 
in the facility. The period of data collection is aimed to extend from June 2013 – March 2014.  Various 
measurements will be performed on the selected participants (anthropometrics, biochemistry, etc.) under 
the supervision of the investigator and nursing sister of the research facility.  
 
I would like to reassure you that during the hours of duty, I will refrain from any invasive interaction with 
the patients, without their informed consent.  Consent will be obtained prior to the collecting of data, by 
means of individualised consent forms. The data will be kept anonymous and confidentiality of participants 




Request for permission letter:  
Albow Gardens Clinic 
 







The investigator will also behave in a professional manner at all times and act in accordance with the 
stipulations set aside by the facility. 
 
A transcript of the study protocol and final results can be forwarded to you, if you so wish. 
 
If there are any further queries, please feel free to contact my study supervisors:  
 
Mrs. Janicke Visser  
 
 021 938 9259 (work) 
 jconrad@sun.ac.za (email) 
Professor Renee Blaauw  
 
 021 938 9259 (work) 
 rb@sun.ac.za (email) 
 
Thank you for your favourable consideration and I look forward to hearing from you soon.  
 
Kind regards,  
Miss Lauren Philips  
Principal Investigator 
 
Cell: 072 658 7623 
Work: 021 938 9258 
Email: laurenp@sun.ac.za 
Fakulteit Gesondheidswetenskappe  Faculty of Health Sciences  
 
 
Verbind tot Optimale Gesondheid  Committed to Optimal Health 
Division of Human Nutrition  Department of Interdisciplinary Health Sciences 
Posbus/PO Box 19063  Tygerberg 7505  Suid-Afrika/South Africa 
Tel.:  +27 21 938 9259  Faks/Fax: +27 21 933 2991 
              Webblad / Web page: www.sun.ac.za/nutrition; www.sun.ac.za/nicus  
 
 









Participant information leaflet and consent form 
 
TITLE OF THE RESEARCH PROJECT: 
 
The association between tuberculosis and the development of insulin resistance in adults with 




PRINCIPAL INVESTIGATOR:  Lauren Philips, Registered Dietician (SA) 
 
ADDRESS: Division of Human Nutrition, Faculty of Medicine and Health Sciences, Stellenbosch 
University  
 
CONTACT DETAILS:  Principal Investigator: 072 658 7623 
 
You are being invited to take part in a research project.  Please take some time to read the 
information presented here, which will explain the details of this project.  Please ask the investigator, 
doctor or nursing sister any questions about any part of this project that you do not fully understand.  
It is very important that you are fully satisfied that you clearly understand what this research entails 
and how you could be involved.  Also, your participation is entirely voluntary and you are free to 
decline to participate.  If you say no, this will not affect you negatively in any way whatsoever.  You 
are also free to withdraw from the study at any point, even if you do agree to take part. 
 
This study has been approved by the Health Research Ethics Committee at Stellenbosch 
University and will be conducted according to the ethical guidelines and principles of the 
international Declaration of Helsinki, South African Guidelines for Good Clinical Practice and the 
Medical Research Council (MRC) Ethical Guidelines for Research. 
 
WHAT IS THIS RESEARCH STUDY ALL ABOUT? 
 
Participants will be recruited from the Albow Gardens clinic and data collection performed on site at 
the Brooklyn Chest Hospital, both in the Western Sub-District of the Cape Metropole region. The aim 
is to include at least 60 participants in the study, of which 30 persons will be chosen to come back 







for two (2) follow-up visits. Participants will be signed up for the study over a period of five (5) months 
and the maximum amount of time you will be involved in the study is five (5) months.  
 
Tuberculosis (TB) is currently a big concern, and is the 2nd leading cause of death worldwide, after 
HIV/AIDS. The number of TB cases in South Africa, and especially in the Western Cape, is also 
growing. The aim of the study is to gather valuable information regarding the nature of infection in 
persons with TB. This aim also includes investigating whether persons with TB have insulin 
resistance, which occurs when the body doesn’t respond normally to insulin (a substance 
responsible for controlling your body’s blood sugar levels).  
 
Basic non-harmful measurements such as weight, height, skinfolds, waist and hip circumference will 
be performed by the investigator. Other measurements, such as blood samples and blood pressure, 
will be taken and recorded by the staff at the facility according to a specific schedule. These 
measurements will not interfere with your normal care at the facility, and you will not be exposed to 
harmful techniques.  
 
Your confidentiality will be guaranteed at all times, and no personal information (such as names, 
gender, age, address etc.) will be shared. Unique identification numbers will be used for each 
participant (based on your folder number at the facility).   
 
WHY HAVE YOU BEEN INVITED TO PARTICIPATE IN THIS STUDY? 
 
A need has been identified for a study to be performed based on the fact that there is relatively little 
information available at present on the possible relationship between TB and insulin resistance. You 
have been invited because you are newly diagnosed with TB and are HIV-negative. Your 
involvement in the study will ensure knowledge is gained on this subject, resulting in improved care 
and treatment of persons with TB.  
 
WHAT WILL YOUR RESPONSIBILITIES BE? 
 
 It will be expected of you to answer some questions, have some body measurements (weight, 
height, waist and hip measurements, blood pressure etc.) taken and provide a small amount of 
blood (1 – 3 teaspoons) 
o Blood samples that will be taken include: glucose, insulin, albumin, CRP, white cell count 
and lipogram 
 It will also be your responsibility to ensure that you return to the facility for follow-ups on the days 
given to you by the investigator  







 Certain selected study participants that are part of the follow-up portion of the study (and are, 
therefore, required to come back to the clinic) will be compensated for their time and transport 
costs at each visit to the clinic. 
 
WILL YOU BENEFIT DIRECTLY FROM TAKING PART IN THIS RESEARCH? 
 
No immediate benefits exist for participants, but findings of the study will indirectly contribute to an 
improved understanding of the course of TB and whether insulin resistance occurs in this group of 
people. This will hopefully lead to an improved level of patient care, as doctors and other health care 
workers may be able to provide better levels of treatment to people with TB in the future.   
 
ARE THERE RISKS INVOLVED IN YOUR TAKING PART IN THIS RESEARCH? 
 
There are no risks involved in this study, as methods used by the investigator and study staff are not 
harmful and shouldn’t cause pain. Your privacy and confidentiality will also be strictly protected at all 
times.  
 
IF YOU DO NOT AGREE TO TAKE PART, WHAT ALTERNATIVES DO YOU HAVE? 
  
If you decide not to take part in the study, it will not affect your treatment at the health facility in any 
way and it will not be held against you.  
 
WHO WILL HAVE ACCESS TO YOUR MEDICAL RECORDS? 
 
The investigator will have access to the information available in the medical records, and to the 
results of all measurements performed (weight, height, blood samples etc.). The investigator will only 
be able to gain access to your medical file and perform measurements once you have given your 
informed consent and signed this form. If the results of this study are published or used in a thesis 
(final project), your identity will still remain unknown.  
 
WHAT WILL HAPPEN IN THE UNLIKELY EVENT OF SOME FORM OF INJURY OCCURING AS 
A DIRECT RESULT OF YOUR TAKING PART IN THIS RESEARCH STUDY?  
 
It is very unlikely that you will suffer any form of injury due to this study, but you may experience 
some discomfort after providing a blood sample.  
 
 







WILL YOU BE PAID TO TAKE PART IN THIS STUDY AND ARE THERE ANY COSTS 
INVOLVED? 
 
You will not be paid directly for your involvement in the study, but will be rewarded for your time and 
transport costs at scheduled visits to the clinic. No additional costs are expected for the participant. 
  
IS THERE ANYTHING ELSE THAT YOU SHOULD KNOW OR DO? 
 
 You may choose to inform your doctor that you are taking part in a research study 
 You may contact the principal investigator, Ms. Philips, at 072 658 7623, if there are any further 
queries or if any problems/injuries are experienced 
 You may contact the Health Research Ethics Committee (HREC) at 021 938 9207 (during 
working hours) if there are any concerns or complaints that have not been adequately addressed 
by the study investigator or facility staff 
 A need may arise for either sponsors of the study, study monitors/auditors or HREC members to 
inspect the research records – your confidentiality will still be ensured 
 You will be informed if there are any significant changes made to the study and will be asked to 
sign another consent form  
 You will receive a copy of this information and consent form for your own record-keeping 
 
DECLARATION BY PARTICIPANT 
 
By signing below, I …………………………………..…………. agree to take part in a research study 
entitled ‘The association between tuberculosis and the development of insulin resistance in adults 
with pulmonary tuberculosis in the Western Sub-District of the Cape Metropole region’  
 
I declare that: 
 
 I have read or had read to me this information and consent form and it is written in a language 
with which I am fluent and comfortable 
 I have had a chance to ask questions and all my questions have been adequately answered 
 I understand that taking part in this study is voluntary and I have not been pressurised to take 
part 
 I shall receive no direct payment for participating in this study (other than that of transport costs 
and refreshments on follow-up days) 
 I may choose to leave the study at any time and will not be penalised or prejudiced in any way 







 I may be asked to leave the study before it has finished, if the investigator feels it is in my best 
interests, or if I do not follow the study plan, as agreed to 
 
 
Signed at (place) ......................…........…………….. on (date) …………....……….. 20......... 
 
 ...................................................................  ................................................................. 







DECLARATION BY INVESTIGATOR 
 
I (name) ……………………………………………..……… declare that: 
 
 I explained the information in this document to ………………………………….. 
 I encouraged him/her to ask questions and took adequate time to answer them. 
 I am satisfied that he/she adequately understands all aspects of the research, as discussed 
above 
 I did/did not use an interpreter.  (If an interpreter is used then the interpreter must sign the 
declaration below. 
Signed at (place) ......................…........…………….. on (date) …………....……….. 20.......... 
 
 ...................................................................  ................................................................. 
Signature of investigator Signature of witness 
 
 
DECLARATION BY INTERPRETER 
 
I (name) ……………………………………………..……… declare that: 
 I assisted the investigator (name) ………………………………………. to explain the 
information in this document to (name of participant) ……………..…………………………….. 
using the language medium of Afrikaans/isiXhosa. 
 We encouraged him/her to ask questions and took adequate time to answer them. 
 Thumbprint of participant (if illiterate) 







 I conveyed a factually correct version of what was related to me. 
 I am satisfied that the participant fully understands the content of this informed consent 
document and has had all his/her question satisfactorily answered. 
 
Signed at (place) ......................…........…………….. on (date) …………....……………….. 
 
 ...................................................................  ................................................................. 
Signature of interpreter                                                                Signature of witness
Stellenbosch University  https://scholar.sun.ac.za
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Deelnemerinligtingsblad en Toestemmingsvorm 
 
TITEL VAN DIE NAVORSINGSPROJEK: 
 
Die verband tussen tuberkulose en die ontwikkeling van insulien weerstandigheid in 





HOOFNAVORSER: Lauren Philips, Geregistreerde Dieetkundige (SA) 
 
ADRES: Afdeling Menslike Voeding, Fakulteit Geneeskunde en Gesondheidswetenskappe, 
Universiteit Stellenbosch  
 
KONTAKNOMMER: Hoofnavorser: 072 658 7623 
 
U word genooi om deel te neem aan ’n navorsingsprojek.  Lees asseblief hierdie inligtingsblad op 
u tyd deur aangesien die ‘detail’ van die navorsingsprojek daarin verduidelik word.  Indien daar 
enige deel van die navorsingsprojek is wat u nie ten volle verstaan nie, is u welkom om die 
navorsingspersoneel of dokter daaroor uit te vra.  Dit is baie belangrik dat u ten volle moet 
verstaan wat die navorsingsprojek behels en hoe u daarby betrokke kan wees.  U deelname is 
ook volkome vrywillig en dit staan u vry om deelname te weier.  U sal op geen wyse 
hoegenaamd negatief beïnvloed word indien u sou weier om deel te neem nie.  U mag ook te 
eniger tyd aan die navorsingsprojek onttrek, selfs al het u ingestem om deel te neem. 
 
Hierdie navorsingsprojek is deur die Gesondheidsnavorsingsetiekkomitee (GNEK) van die 
Universiteit Stellenbosch goedgekeur en sal uitgevoer word volgens die etiese riglyne en 
beginsels van die Internasionale Verklaring van Helsinki en die Etiese Riglyne vir 
Navorsing van die Mediese Navorsingsraad (MNR). 
 
WAT BEHELS HIERDIE NAVORSINGSPROJEK? 
 
Die studie sal by die Albow Gardens kliniek, asook op die perseel van die Brooklyn Chest 
Hospitaal plaasvind. Die bogenoemde is albei in die Westelike Sub-Distrik van die Kaapse 
Metropool area. Daar word beoog om ten minste 60 deelnemers in die studie in te sluit, waarvan 
30 individue gekies sal word om terug te kom vir twee (2) opvolg besoeke. Deelnemers sal deel 







vorm van die studie vir ’n periode van vyf (5) maande en die maksimum tydsduur wat u deel sal 
hê aan die studie is vyf (5) maande.  
 
Tuberkulose (TB) is tans ’n groot bron van kommer aangesien dit wêreldwyd die 2de grootste 
oorsaak van sterfte, naas MIV/VIGS, is. Die hoeveelheid TB gevalle  in Suid-Afrika en veral in die 
Wes-Kaap, is ook aan die toeneem. Die doel van die studie is om waardevolle inligting met 
betrekking tot die aard van die infeksie in individue met TB in te win. Die doel is ook om vas te 
stel of mense met TB insulien weerstandig [’n toestand waartydens die liggaam nie normaal 
teenoor insulien  (’n substans wat verantwoordelik is om die liggaam se bloedsuikervlakke te 
beheer) reageer nie] is?  
 
Basiese nie-skadelike meetings soos gewig, lengte, velvoue en middel- en heup-omtrek  sal deur 
die navorser uitgevoer word. Ander meetings soos die neem van bloedmonsters en bloeddruk  
sal  volgens ’n spesifieke skedule deur die kliniek personeel geneem en aangeteken word. Die 
meetings sal nie met u gewone sorg by die kliniek inmeng nie en u sal ook nie aan enige skadelike 
prosedures blood gestel word nie.  
 
Vertroulikheid van u inligting sal te alle tye verseker word en geen persoonlike inligting (soos u 
naam en van, geslag, ouderdom, adres ens.) sal aan ander uitgegee word nie. Unieke 
identifikasie nommers (gebaseer op u kliniek lêer nommer) sal vir elke deelnemer gebruik word. 
 
WAAROM IS U GENOOI OM DEEL TE NEEM? 
 
’n Behoefte is geïdentifiseer om ’n studie te loots aangesien daar tans relatief min inligting 
rakende die moontlike verband tussen TB en insulien weerstandigheid bestaan. U word uitgenooi 
om deel te neem aan die studie aangesien u nuut gediagnoseer is met TB en MIV-negatief is. U 
deelname aan die studie sal bydra tot die vermeerdering van kennis rakende die onderwerp, wat 
in die toekoms sal help met beter sorg en behandeling van mense met TB.  
 
WAT SAL U VERANTWOORDELIKHEDE WEES? 
 
 Daar sal van u verwag word om ’n paar vrae te beantwoord, beskikbaar te wees vir sekere 
liggaamsmetings (gewig, lengte, middel- en heupomtrek, bloeddruk ens.) asook om ’n klein 
hoeveelheid bloed (1 – 3 teelepels) te verskaf 
o Bloedmonsters wat geneem gaan word sluit in: glukose, insulien, albumien, CRP, wit 
sel telling en lipogram 







 Dit sal ook u verantwoordelikheid wees om na die kliniek terug te keer (op die spesifieke dae 
soos deur die navorser versoek) vir u opvolgsessies 
 Sekere geselekteerde deelnemers wat ook deel is van die opvolg fase van die projek (en weer 
na die kliniek toe moet kom) sal weereens vergoed word vir hul tyd en vervoer onkostes 
tydens elke kliniek besoek.  
 
SAL U VOORDEEL TREK DEUR DEEL TE NEEM AAN HIERDIE NAVORSINGSPROJEK? 
 
Daar is nie enige onmiddellike voordele vir deelnemers nie, maar die studie resultate sal indirek 
bydra tot ’n beter begrip van die verloop van TB , tesame met die antwoord op of insulien 
weerstandigheid in die groep mense voorkom of nie. Dit sal hopelik bydra tot ’n beter vlak van 
pasiëntsorg, aangesien dokters en ander gesondheidswerkers in staat sal wees om beter 
behandeling aan mense met TB in die toekoms te verskaf.  
 
IS DAAR ENIGE RISIKO'S VERBONDE AAN U DEELNAME AAN HIERDIE 
NAVORSINGSPROJEK? 
 
Daar is geen risiko’s  vir u tydens u deelname aan die studie nie. Alle prosedure wat deur die 
navorser en kliniek personeel uitgevoer gaan word, is skadeloos en sal nie enige pyn veroorsaak 
nie. U privaatheid en vertroulikheid van u inligting sal te alle tye verseker word. 
 
WATTER ALTERNATIEWE IS DAAR INDIEN U NIE INSTEM OM DEEL TE NEEM NIE? 
 
Sou u besluit om nie aan die studie deel te neem nie, sal dit nie u sorg by die kliniek enigsins 
beïnvloed nie. Dit sal ook nie teen u gehou word nie. 
 
WIE SAL TOEGANG HÊ TOT U MEDIESE REKORDS? 
 
Die navorser sal toegang hê tot alle beskikbare inligting in u mediese lêer, asook tot die resultate 
van alle metings wat op u uitgevoer (gewig, lengte, bloedmonsters ens.) is. Die navorser sal egter 
slegs toegang tot u mediese rekords ontvang, en meetings op u uitvoer, wanneer u u ingeligte 
toestemming gee en die vorm teken. Sou die resultate van die projek gepubliseer of gebruik word 
in ’n tesis (finale projek), sal u identiteit steeds onbekend bly. 
 







WAT SAL GEBEUR IN DIE ONWAARSKYNLIKE GEVAL VAN ’N BESERING WAT MAG 
VOORKOM AS GEVOLG VAN U DEELNAME AAN HIERDIE NAVORSINGSPROJEK? 
 
Dit is onwaarskynlik dat u enige besering tydens die studie sal opdoen, u mag egter ’n mate van 
ongemak na afloop van die neem van die bloedmonster ervaar. 
 
SAL U BETAAL WORD VIR DEELNAME AAN DIE NAVORSINGSPROJEK EN IS DAAR 
ENIGE KOSTE VERBONDE AAN DEELNAME? 
 
U sal nie direkte betaling  vir u deelname aan die studie ontvang nie, maar sal vergoed word vir 
u tyd en vervoer onkostes tydens gereelde kliniek besoeke. Geen verdere onkoste word van u 
verwag nie. 
 
IS DAAR ENIGIETS ANDERS WAT U MOET WEET OF DOEN? 
 
 U is welkom om u dokter in kennis te stel van u deelname aan die navorsingstudie  
 U mag die hoof-navorser, Me. Philips, by 072 658 7623, kontak indien u enige verdere vrae 
het of indien daar enige probleme/beserings is 
 U mag die Gesondheidsnavorsingsetiekkomitee (GNEK) by 021 938 9207 (tydens kantoor 
ure) kontak sou  u enige bekommernis of probleem beleef wat nie toepaslik deur die navorser 
of kliniek personeel aangespreek word nie 
 Dit kan gebeur dat die borge van die studie, studie monitors/ouditeure of GNEK-lede die 
navorsing rekords moet inspekteur – vertroulikheid van u inligting sal steeds verseker word 
 U sal in kennis gestel word indien daar enige beduidende veranderinge aan die studie in die 
toekoms aangebring word; u sal dan gevra word om nog ’n toestemmingsvorm te teken 
 U sal ’n kopie van die toestemmingsvorm vir u eie rekords ontvang 
 
VERKLARING DEUR DEELNEMER 
 
Met die ondertekening van hierdie dokument onderneem ek, 
…….....................……….....……...……….., om deel te neem aan ’n navorsingsprojek getiteld  
‘Die verband tussen tuberkulose en die ontwikkeling van insulien weerstandigheid in 
volwassenes met pulmonêre tuberkulose in die Westelike Sub-Distrik van die Kaapse Metropool 
area’. 
 
Ek verklaar dat: 








 Ek hierdie inligtings- en toestemmingsvorm gelees het of aan my laat voorlees het    en 
dat dit in ’n taal geskryf is waarin ek vaardig en gemaklik mee is. 
 Ek geleentheid gehad het om vrae te stel en dat al my vrae bevredigend beantwoord 
is. 
 Ek verstaan dat deelname aan hierdie navorsingsprojek vrywillig is en dat daar geen 
druk op my geplaas is om deel te neem nie. 
 Ek te eniger tyd aan die navorsingsprojek mag onttrek en dat ek nie op enige wyse 
daardeur benadeel sal word nie. 
 Ek gevra mag word om van die navorsingsprojek te onttrek voordat dit afgehandel is 
indien die studiedokter of navorser van oordeel is dat dit in my beste belang is, of indien 
ek nie die ooreengekome navorsingsplan volg nie. 
 
 
Geteken te (plek) ..............................…………….. op (datum) …………....……….. 20.......... 
 
 
 ...................................................................   .................................................................  
Handtekening van deelnemer Handtekening van getuie 
 
 
VERKLARING DEUR NAVORSER 
 
Ek (naam) …………………………………...……………… verklaar dat: 
 
 Ek die inligting in hierdie dokument verduidelik het aan 
…………………….............................................……….. 
 Ek hom/haar aangemoedig het om vrae te vra en voldoende tyd gebruik het om dit te 
beantwoord. 
 Ek tevrede is dat hy/sy al die aspekte van die navorsingsprojek soos hierbo bespreek, 
voldoende verstaan. 
 Ek ’n tolk gebruik het/nie ’n tolk gebruik het nie.  (Indien ’n tolk gebruik is, moet die tolk 
die onderstaande verklaring teken.) 
 
 
Geteken te (plek) ..............................…………….. op (datum) …………....……….. 20........... 









 ...................................................................   .................................................................  
Handtekening van navorser Handtekening van getuie 
 
 
VERKLARING DEUR TOLK 
 
Ek (naam) …………………………………...……………… verklaar dat: 
 
 Ek die navorser (naam) ……….............................…………………. bygestaan het om die 
inligting in hierdie dokument in Afrikaans/Xhosa aan (naam van deelnemer) 
……………………………......................... te verduidelik. 
 Ons hom/haar aangemoedig het om vrae te vra en voldoende tyd gebruik het om dit te 
beantwoord. 
 Ek ’n feitelik korrekte weergawe oorgedra het van wat aan my vertel is. 
 Ek tevrede is dat die deelnemer die inhoud van hierdie dokument ten volle verstaan en 
dat al sy/haar vrae bevredigend beantwoord is. 
 
 
Geteken te (plek) ..............................…………….. op (datum) …………....……….. 20……. 
 
 
 ...................................................................   .................................................................  



















Incwadana Engolwazi Ngomthathi Nxaxheba Kunye Nefomu Yemvumelwano  
 
ISIHLOKO SEPROJEKTHI YOPHANDO: 
 
Unxulumano phakathi kwesifo sephepha kunye nokuvela kongquzulwano ne-insulini kubantu 
abadala abanesifo sephepha semiphunga kwiNgingqana yeNtshona yengingqi yeKapa 




UMPHANDI OYINTLOKO: Lauren Philips, Incutshe kwisondlo ebhalisiweyo (eMzantsi Afrika) 
 
IDILESI: Icandelo leSondlo saBantu, iFakhalthi yezoNyango neeNzululwazi zeMpilo, 
eYunivesithi yaseStellenbosch  
 
IINKCUKACHA ZOQHAGAMSHELWANO:  Umphandi oyiNtloko: 072 658 7623 
 
Uyamenywa ukuba athathe inxaxheba kwiprojekthi yophando. You are being invited to take part 
in a research project.  Nceda thatha ixesha lokufunda ulwazi oluvezwe apha, oluzakuthi luchaze 
iinkcukacha zale projekthi.  Nceda buza nayiphina imibuzo emalunga nayiphina indawo 
ongayiqondiyo ngokupheleleyo kubasebenzi besi sifundo okanye kugqirha.  Kubaluleke kakhulu 
ukuba waniliseke ngokupheleleyo yinto yokuba ucacelwe kakuhle ukuba yintoni ebangwa sesi 
sifundo kwaye ungabandakanyeka njani.  Kwakhona, ukuthatha kwakho inxaxheba 
kungentando yakho ngokupheleleyo kwaye ukhululekile ukuba ungarhoxa ekuthatheni 
inxaxheba.  Ukuba uthi hayi, oku akusayi kuchaphazela ukungavumi kwakho nangayiphina 
indlela.  Ukwakhululekile ukuba uyeke kwesi sifundo naninina, nkqu nokokuba uyavuma 
ukuthatha inxaxheba ekuqaleni. 
 
Olu phando luvunywe ziinqobo ezisesikweni zeKomiti yoPhando Lomntu kwiYunivesithi 
yaseStellenbosch kwaye luzakwenziwa ngokwemigaqo esesikweni lophando 
elamkelekileyo kwiSaziso sehlabathi sika-Helsinki, iMigaqo eLungileyo yoMzantsi Afrika 
yokuSebenza eKliniki kunye neBhunga lezoPhando ngamaYeza (MRC) iMigaqo yeNqobo 
yezoPhando. 
 









SIMALUNGA NANTONI ESI SIFUNDO SOPHANDO? 
 
Abathathi-nxaxheba baza kufunwa eKlinikhi yase-Albow Gardens,  luze uqokelelo 
lweenkcukacha lwenziwe esiBhedlele sesiFuba iBrooklyn, zombini ezi klinikhi zikwiNgingqana 
eseNtshona yengingqi yeKapa eliMbaxa. Injongo kukuba kuqukwe ubuncinane abathathi-
nxaxheba abangama-60 kolu phando, apho kulo abantu abangama-30 baza kukhethwa ukuze 
babuye beze kutyelelo lokulandelela lweentsuku ezimbini (2). Abathathi-nxaxheba baza kuba 
kolu phando ngapha kwexesha leenyanga ezintlanu (5) kwaye elona xesha lininzi eliza kuthathwa 
kolu phando ziinyanga ezintlanu (5).  
 
Isifo sephepha (i-TB) sixhalabisa kakhulu, kwaye sisizathu sesibini sokufa kwihlabathi liphela, 
emva kwentsholongwane kagawulayo nogawulayo buqu. Inani labantu abanesifo sephepha 
eMzantsi Afrika, nangakumbi eNtshona Koloni nalo liyakhula. Injongo yolu phando kukuqokelela 
ulwazi olululo olumalunga nohlobo lolosuleleko kubantu abanesifo sephepha. Injongo ikwaquka 
nokuphanda ukuba ingaba abantu abanesifo sephepha banongquzulwano lwe-insulini na, 
olwenzeka xa umzimba ungaphenduli ngendlela eqhelekileyo kwi-insulini (into enoxanduva 
lokulawula amanqanaba akho eswekile yegazi lomzimba).   
 
Imilinganiselo esisiseko engenangozi enje ngobunzima, ubude, ukusongana kolusu,kunye  
nesazinge sesinqe nesenyonga iza kwenziwa ngumphandi. Eminye imilinganiselo enje 
ngamasampula egazi kunye noxinzelelo lwegazi iza kuthathwa ize ibhalwe ngabasebenzi 
abaseklinikhi ngokwesicwangciso esithile. Le milinganiselo ayisayi kuphazamisana nonakekelo 
lwakho lwesiqhelo eklinikhi, kwaye akusayi kuvezeka kwizenzo eziyingozi.    
 
Ukuba yimfihlo kwakho kuza kuqinisekiswa ngamaxesha onke, kwaye akukho lwazi lwakho 
(olunje ngamagama, isini, ubudala, idilesi, njalo njalo) kuza kwabelwana ngalo. Kuza 
kusetyenziswa iinombolo zesazisi ezifana zodwa kumthathi-nxaxheba ngamnye (ezisekelwe 
kwinombolo yakho yefowulda yaseklinikhi).  
  
KUTHENI UMENYIWE UKUBA UTHATHE INXAXHEBA? 
 
Kuye kwabonwa imfuneko yokuba kwenziwe uphando kusukelwa kwinto yokuba kukho ulwazana 
oluncinane olukhoyo olumalunga nonxulumano olunokuba khona phakathi kwesifo sephepha 
(TB) kunye nongquzulwano lwe-insulini. Umenywe kuba kusanda kufunyaniswa ukuba unesifo 
sephepha, kwaye ukuthatha kwakho inxaxheba kolu phando kuza kuqinisekisa ukuba 







kufunyanwa ulwazi kwesi sifundo, loo nto ikhokelele kunakekelo nonyango oluphuculweyo 
lwabantu abanesifo sephepha.   
 
LUYAKUBA YINTONI UXANDUVA LWAKHO? 
 
 Kuza kulindelwa ukuba uphendule eminye imibuzo, kuthathwe imilinganiselo yomzimba 
(ubunzima, ubude, nemilinganiselo yesinqe neyenyonga, uxinzelelo lwegazi, njalo njalo) uze 
unikeze nentwanana yegazi ( 1 –3 amatispuni) 
o Amagazi azotsalwa ngala: iSwekile, insulini, iAlbumin, iCPR, iWhite cell count, iLipogram 
 Iza kuba luxanduva lwakho ukuqinisekisa ukuba ubuyela eklinikhi ukuza kutyelelo lolandelelo 
ngeentsuku ozinikwe ngumphandi  
 Abantu abakhethiweyo abazothatha uxanduva kuyanyanzeleka babuyele eklinikhi 
bazobonelelwa ngexesha kabo nange mali yokhwela quo xabe vakashela eklinikhi 
 
INGABA UZA KUZUZA EKUTHATHENI INXAXHEBA KOLU PHANDO? 
 
Akukho zibonelelo zikhawulezileyo kubathathi-nxaxheba, kodwa imiba efunyenwe kolu phando 
iza kuba negalelo elingathanga ngqo ekuqondeni kakuhle inkqubo yesifo sephepha,  kwanokuba 
ingaba ungquzulwano lwe-insulini luyenzeka na kweli qela labantu. Kuthenjwa ukuba le nto iza 
kukhokelela kwinqanaba eliphuculweyo lonakekelo lwesigulana, njengoko oogqirha kunye 
nabanye abasebenzi bonakekelo lwempilo benokwazi ukunikeza amanqanaba angcono onyango 
kubantu abanesifo sephepha kwixa elizayo.    
 
INGABA ZIKHO IINGOZI EZIBANDAKANYEKAYO EKUTHATHENI KWAKHO INXAXHEBA 
KOLU PHANDO? 
 
Akukho mingcipheko ikhoyo kolu phando, njengoko izenzo ezisetyenziswa ngumphandi kunye 
nabasebenzi bolu phando zingenangozi kwaye zingasayi kwenza iintlungu uzothi ke ubonelelwe 
rhoqo xa uze eklinikhi koluphando. Ukuba bucala kunye nokuba yimfihlo kwakho kuza 
kukhuselwa ngendlela engqongqo amaxesha onke.  
 
UKUBA AWUVUMI UKUTHATHA INXAXHEBA, LOLUPHI OLUNYE UNYANGO ONALO? 
  
Ukuba ugqiba kwelokuba ungathathi nxaxheba kolu phando, loo nto ayisayi kuchaphazela 
unyango lwakho eklinikhi nangaluphina uhlobo, kwaye loo nto ayisayi kukubalela.   
 







NGUBANI UZA KUFUMANA INGXELO YAKHO YAMAYEZA? 
 
Umphandi uza kufikelela kulwazi olukhoyo kwiingxelo zonyango, kunye nakwiziphumo zayo 
yonke imilinganiselo eyenziweyo (ubunzima, ubude, amasampula egazi, njalo njalo). Umphandi 
uza kufikelela kuphela kwifayile yakho yonyango aze enze imilinganiselo xa unike imvume eyiyo 
waze watyikitya le fomu. Ukuba iziphumo zolu phando ziyashicilelwa okanye zisetyenziswa 
kwithisisi (umsebenzi wokugqibela), ukwaziwa kwakho kuza kuhlala kungaziwa.   
 
KUZA KWENZEKA NTONI KWIMEKO YESIGANEKO ESINGALINDEKANGA 
SOKWENZAKALA NGENXA YOKUTHATHA KWAKHO INXAXHEBA KWESI SIFUNDO 
SOPHANDO? 
 
Kuthandabuzeka kakhulu ukuba uza kufumana naluphina uhlobo lomonzakalo ngenxa yolu 
phando, kodwa usenokufumana ukungonwabi emva kokunikezela ngesampula legazi. .  
 
INGABA UZA KUHLAWULWA NGOKUTHATHA INXAXHEBA KWESI SIFUNDO KWAYE 
INGABA KUKHO IINDLEKO EZIBANDAKANYEKAYO? 
 
Akusayi kuhlawulwa ngokuthe ngqo ngokuthatha kwakho inxaxheba kolu phando, kodwa uza 
kubonelelwa ngexesha lakho nangeendleko zesithuthi. Akulindelwanga ezinye iindleko 
ngokuthatha inxaxheba. 
  
INGABA IKHO ENYE INTO EKUMELE UYAZI OKANYE UYENZE? 
 
 Ungakhetha ukuxelela ugqirha wakho ukuba uthatha inxaxheba kwisifundo sophando. 
 Ungaqhgamshelana noGqr kule inombolo yomnxeba ukuba unemibuzo engaphaya 
okanye uhlangabezana neengxaki. 
 Ungaqhagamshelana neKomiti yoPhando Lomntu kwa-021-938 9207 ukuba 
unenkxalabo okanye izikhalazo ezingasonjululwanga kakuhle ngugqirha wakho 
wesifundo. 
 Kusenokubakho imfuneko yokuba abaxhasi bolu phando, abalawuli/abaphicothi bolu phando 
okanye amalungu e-HREC ahlole iingxelo zolu phando – nalapho ukuba yimfihlo kwakho 
kuza kuqinisekiswa 
 Uza kwaziswa ukuba kukho utshintsho olukhulu olwenziwayo kolu phando kwaye uza 
kucelwa ukuba utyikitye enye ifomu yemvume  
 Uza kufumana ikopi yolu lwazi kunye neyefomu yemvume ukuze uzigcinele zona 










Ngokuytyikitya ngezantsi, Mna …………………………………..…………. ndiyavuma ukuthatha 




 Ndilufundile okanye ndalufunda olu lwazi kunye nefomu yemvumelwano kwaye ibhalwe 
ngolwimi endiliciko nendikhululekileyo kulo  
 Bendinalo ithuba lokuba ndibuze imibuzo kwaye yonke imibuzo yam iphendulwe 
ngokwanelisayo. 
 Ndiyakuqonda ukuba ukuthatha inxaxheba kolu phando kube kukuzithandela kwam 
kwaye andikhange ndinyanzelwe ukuba ndithathe inxaxheba. 
 Ndingakhetha ukusishiya isifundo naninina kwaye andisayi kohlwaywa okanye uqal’ 
ugwetywe nangayiphi indlela. 
 Usenokucelwa ukuba usishiye isifundo phambi kokuba siphele, ukuba ugqirha wesifundo 
okanye umphandi ukubona kuyinzuzo kuwe, okanye ukuba andisilandeli isicwangciso 
sesifundo, ekuvunyelenwe ngaso. 
 
 
Kutyikitywe e-(indawo) .........…........…………….. ngo-(usuku) ………....……….. 20…….. 
 
 
 ...................................................................   .................................................................  




Mna (igama) ………………………………………………… ndiyafunga ukuba: 
 Ndilucacisile ulwazi olu kweli xwebhu ku-…………………..……………... 
 Ndimkhuthazile ukuba abuze imibuzo kwaye athathe ixesha elifanelekileyo ukuba 
ayiphendule. 
 Ndiyaneliseka kukuba uyakuqonda ngokwanelisayo konke okumalunga nophando 
okuxoxwe ngasentla. 











Kutyikitywe e-(indawo) .........…........…………….. ngo-(usuku) ………....……….. 20........... 
 
 
 ...................................................................   .................................................................  





Mna (igama) ………………………………………………… ndazisa ukuba: 
 Ndicende umphandi (igama) …………………………. Ekucaciseni ulwazi olu lapha kweli 
xwebhu ku-(igama lomthathi-nxaxheba) …………………………….. ndisebenzisa 
ulwimi lwesiAfrikaans/lwesiXhosa. 
 Simkhuthazile ukuba abuze imibuzo kwaye athathe ixesha elifanelekileyo ukuba 
ayiphendule. 
 Ndimxelele eyona nto iyiyo malunga nokunxulumene nam. 
 Ndiyaneliseka kukuba umthathinkxaxheba ukuqonda ngokupheleleyo okuqulathwe 




Kutyikitywe e-(indawo) .........…........…………….. ngo-(usuku) ………....……….. 20........... 
 
 
 ...................................................................   .................................................................  
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